{
  "letters": 661193,
  "pages": 205,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "DiaMedica Therapeutics Inc.",
    "major_industry": "Healthcare",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 27,
          "title": "Potential Effects of Proposed Articles Amendment",
          "data": [
            {
              "key": "Amendment Impact",
              "value": "The proposed amendment to the Articles is designed to enhance procedural mechanics and disclosure requirements regarding director nominations, potentially deterring shareholders from proposing nominee directors or pursuing a board replacement."
            },
            {
              "key": "Anti-Takeover Provisions",
              "value": "The document discloses several anti-takeover measures, including provisions that delay, defer or prevent a change in control, such as the availability of an unlimited number of common shares for future issuance, flexible alteration of Articles, special resolution requirements for shareholder meetings, and provisions for appointment and removal of directors."
            },
            {
              "key": "Regulatory Disclosure Requirement",
              "value": "SEC rules mandate the disclosure of governing document provisions that could have an anti-takeover effect, emphasizing the importance of these clauses in protecting current management."
            },
            {
              "key": "Defensive Strategy",
              "value": "These measures are intended to protect the continuity of management by making it more challenging for hostile takeovers or board changes, thereby acting as a defensive tool in corporate control."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 31,
          "title": "Potential Effects of Proposed Articles Amendment",
          "data": [
            {
              "key": "Proposed Amendment",
              "value": "Amendment to Articles that would vest the responsibility of setting the number of directors solely in the Board of Directors."
            },
            {
              "key": "Potential Effects",
              "value": "If approved, the amendment may make it more difficult or discourage a merger, tender offer, proxy contest, or change in control."
            },
            {
              "key": "Anti-Takeover Provisions",
              "value": "The document discloses SEC-required anti-takeover provisions, such as unlimited available common shares and provisions allowing the Board to issue shares to friendly parties."
            },
            {
              "key": "Governance and Control",
              "value": "Includes provisions related to altering the Articles/Notice of Articles, shareholder meeting calling requirements, appointment and removal of directors, and indemnification of directors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 73,
          "title": "Company Registration and Address Information",
          "data": [
            {
              "key": "location",
              "value": "British Columbia (State or other jurisdiction of incorporation or organization) 301 Carlson Suite 210"
            },
            {
              "key": "identifier",
              "value": "Not Applicable (LR.S. Employer Identification No.)"
            },
            {
              "key": "location",
              "value": "Parkway, Minneapolis, Minnesota (Address of principal executive offices)"
            },
            {
              "key": "zip_code",
              "value": "55305 (Zip Code)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 90,
          "title": "Competition and Current Treatments for Acute Ischemic Stroke and Chronic Kidney Disease",
          "data": [
            {
              "key": "DM199 Description",
              "value": "Novel therapy for CKD through protein replacement therapy activating the KKS."
            },
            {
              "key": "Supporting Data",
              "value": "Porcine KLK1 is used in Japan, China, and Korea for CKD treatment."
            },
            {
              "key": "Competition",
              "value": "The biopharmaceutical industry is highly competitive with rapid development of proprietary drugs."
            },
            {
              "key": "Challenges",
              "value": "Significant competition from better-resourced companies."
            },
            {
              "key": "Market Positioning",
              "value": "Competition for financial, technical, and human resources."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 164,
          "title": "Cash Flow Data",
          "data": [
            {
              "key": "Operating activities 2022",
              "value": "-11511"
            },
            {
              "key": "Operating activities 2021",
              "value": "-12252"
            },
            {
              "key": "Investing activities 2022",
              "value": "11538"
            },
            {
              "key": "Investing activities 2021",
              "value": "-20537"
            },
            {
              "key": "Financing activities 2022",
              "value": "-6"
            },
            {
              "key": "Financing activities 2021",
              "value": "30087"
            },
            {
              "key": "Net increase (decrease) in cash 2022",
              "value": "21"
            },
            {
              "key": "Net increase (decrease) in cash 2021",
              "value": "-2702"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 3,
          "title": "Leadership Changes at DiaMedica",
          "data": [
            {
              "key": "New Appointments",
              "value": "Kirsten Gruis, M.D. joined as Chief Medical Officer."
            },
            {
              "key": "Experience of New CMO",
              "value": "Over 20 years in clinical medicine and drug development."
            },
            {
              "key": "New Chief Commercial Officer",
              "value": "Dominic Cundari joined as Chief Commercial Officer."
            },
            {
              "key": "Experience of CCO",
              "value": "Over 30 years at Genentech, led product launch of ACTIVASE."
            },
            {
              "key": "New Senior Vice President",
              "value": "Julie Daves joined as Senior Vice President, Clinical Development Operations."
            },
            {
              "key": "Experience of SVP",
              "value": "Over two decades of clinical development operations experience."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 4,
          "title": "Board Leadership Update and Clinical Trial Insights",
          "data": [
            {
              "key": "New Board Member",
              "value": "Tanya Lewis"
            },
            {
              "key": "Appointment Date",
              "value": "March 2023"
            },
            {
              "key": "Expertise",
              "value": "Regulatory expertise and over 25 years in global drug development; key role in approval of multiple new drugs"
            },
            {
              "key": "Current Role",
              "value": "Chief Development Operations Officer at Replimune Group, Inc."
            },
            {
              "key": "Board Composition",
              "value": "Includes Rick Pauls (President and CEO) and Richard Pilnik (Chairman of the Board)"
            },
            {
              "key": "Clinical and Strategic Updates",
              "value": "Discussion on ReMEDy2 trial restart, DM199 dosing strategy to mitigate blood pressure drops, and enhancements in clinical protocols and investor materials"
            },
            {
              "key": "Financial Position",
              "value": "Strong cash position with $33.5 million as of December 31, 2022, expected to carry into Q4 2024"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "leadership_change",
          "page": 5,
          "title": "Notice of Annual General and Special Meeting of Shareholders",
          "data": [
            {
              "key": "Meeting Date",
              "value": "May 17, 2023"
            },
            {
              "key": "Location",
              "value": "301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305, USA"
            },
            {
              "key": "Agenda Item",
              "value": "To elect six directors"
            },
            {
              "key": "Reminder for Shareholders",
              "value": "Only those shareholders of record at the close of business on March 21, 2023, will be entitled to notice and to vote."
            },
            {
              "key": "Proxy Voting",
              "value": "Vote by the Internet or telephone, or request a paper proxy card."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 7,
          "title": "Corporate Proxy Statement Table of Contents",
          "data": [
            {
              "key": "Section Overview",
              "value": "The document is a proxy statement outlining corporate governance matters. It includes details on meeting information, voting procedures, election of directors, board and director information, proposals for independent auditor appointment, remuneration authorization, and shareholder nominations with proposed articles amendments."
            },
            {
              "key": "Table 1 - XY STATEMENT SUMMARY",
              "value": "Contains an overview of sections such as 'GENERAL INFORMATION ABOUT THE MEETING AND VOTING', voting instructions, board recommendations, and the first proposal on the election of directors."
            },
            {
              "key": "Table 2 - Board and Director Information Sections",
              "value": "Lists key topics like board size and structure, information about current directors and board nominees, additional details on directors, penalties/sanctions, and corporate compliance (e.g. cease trade orders or bankruptcies)."
            },
            {
              "key": "Table 3 - NOMINATIONS BY SHAREHOLDERS",
              "value": "Outlines sections covering background information, text of the proposed articles amendment, reasons for the amendment, potential effects, and timing and effect of the amendment in relation to shareholder nominations."
            },
            {
              "key": "Table 4 - AUTHORITY TO FIX NUMBER OF DIRECTORS",
              "value": "Provides a structured layout for proposed amendments to articles regarding board structure, including background, details of the amendment, reasons and potential effects, board recommendation, and security ownership information."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 9,
          "title": "PROXY STATEMENT SUMMARY and Voting Proposals",
          "data": [
            {
              "key": "Overview",
              "value": "This summary provides an overview of the information included in the proxy statement. Shareholders are advised to review the entire proxy statement and the Annual Report to Shareholders before voting."
            },
            {
              "key": "Meeting Details",
              "value": "2023 Annual General and Special Meeting of Shareholders. Date and Time details: Wednesday, May 17, 2023 at 1:00 p.m. (CDT)."
            },
            {
              "key": "Voting Proposals Table Summary",
              "value": "The table lists four voting proposals including: Election of Directors; Appointment of an Independent Registered Public Accounting Firm with authority to fix remuneration; Amendment to Articles regarding Director Nominations by Shareholders; and Amendment to Articles regarding Board Authority to Fix the Number of Directors. All proposals are recommended as 'FOR'."
            },
            {
              "key": "Additional Meeting Information",
              "value": "Location: DiaMedica Therapeutics Inc., 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305. Record Date: Holders of record at the close of business on March 21, 2023 are entitled to vote."
            },
            {
              "key": "Internet Availability",
              "value": "Proxy materials, including the Annual Report to Shareholders and Form 10-K, are available via the internet at www.proxyvote.com. Notice of Internet Availability was expected around April 4, 2023."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 10,
          "title": "Corporate Governance Highlights and Board Election",
          "data": [
            {
              "key": "Governance Highlights",
              "value": "Annual election of directors, regular executive sessions, majority of independent directors, independent Board Chairman, access to independent advisors, three fully independent Board committees, independent compensation consultant, corporate governance guidelines, absence of guaranteed bonuses, annual governance document review, and no perquisites."
            },
            {
              "key": "Board Nominees",
              "value": "Six director nominees for the 2023 Annual General and Special Meeting of Shareholders. All served during FY ended December 31, 2022, except Tanya Lewis, appointed effective March 1, 2023. The nominees feature an average age of 59.3 years (range 51 to 67) with five out of six being independent; Rick Pauls is the sole non-independent and the longest-serving (since 2005). Two directors hold medical credentials (M.D.)."
            },
            {
              "key": "Committee Assignments",
              "value": "The Board maintains three committees: Audit, Compensation, and Nominating & Corporate Governance. Chairs include James Parsons (Audit), Michael Giuffre (Compensation), and Richard Pilnik (Nominating). Rick Pauls, the only non-independent director, holds no committee positions, while 'e' indicates regular committee membership."
            },
            {
              "key": "Board Recommendation",
              "value": "The Board of Directors recommends a vote 'FOR' each of the six nominees."
            },
            {
              "key": "Key Qualifications",
              "value": "Leadership/Management, Financial Expertise, Business Development Experience, Prior Board Experience, Regulatory Expertise, Biopharmaceutical Industry Expertise."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 12,
          "title": "PROXY STATEMENT FOR ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS",
          "data": [
            {
              "key": "corporate_address",
              "value": "301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305, USA"
            },
            {
              "key": "meeting_date",
              "value": "May 17, 2023"
            },
            {
              "key": "meeting_time",
              "value": "1:00 p.m. CDT"
            },
            {
              "key": "meeting_type",
              "value": "Annual General and Special Meeting of Shareholders"
            },
            {
              "key": "notice_availability_date",
              "value": "On or about April 4, 2023"
            },
            {
              "key": "record_date",
              "value": "March 21, 2023"
            },
            {
              "key": "shares_outstanding",
              "value": "26,460,688 common shares"
            },
            {
              "key": "voting_instructions",
              "value": "Vote by proxy, Internet voting instructions available at http://www.proxyvote.com, or in person"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 13,
          "title": "Instructions for Proxy Voting and Election of Directors",
          "data": [
            {
              "key": "Telephone Voting",
              "value": "Dial 1-800-690-6903 and follow the instructions provided on the Notice of Internet Availability of Proxy Materials or on your proxy card."
            },
            {
              "key": "Proxy Card Voting",
              "value": "Complete, sign, date and mail the enclosed proxy card if you received a paper copy of the proxy materials. Do not mail if voting electronically."
            },
            {
              "key": "Electronic Voting",
              "value": "Vote using the Internet or telephone if eligible as per instructions provided by your broker, bank or nominee."
            },
            {
              "key": "Voting Deadline",
              "value": "Voting by telephone or Internet must be completed by 11:59 p.m. EDT (10:59 p.m. CDT) on May 16, 2023."
            },
            {
              "key": "Voting Proposal One",
              "value": "Election of Directors – Vote FOR all six nominees or WITHHOLD your vote from one or more nominees."
            },
            {
              "key": "Voting Proposal Two",
              "value": "Appointment of Baker Tilly US, LLP as Independent Registered Public Accounting Firm and Authorization to Fix Remuneration – Options to vote FOR, WITHHOLD, or ABSTAIN."
            },
            {
              "key": "Voting Proposal Three",
              "value": "Approval of Amendment to Articles Regarding Director Nominations by Shareholders – Options to vote FOR, AGAINST, or ABSTAIN."
            },
            {
              "key": "Voting Proposal Four",
              "value": "Approval of Amendment to Articles Regarding Board Authority to Fix Number of Directors – Options to vote FOR, AGAINST, or ABSTAIN."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 14,
          "title": "Proxy Voting Instructions and Recommendations",
          "data": [
            {
              "key": "Voting Proposal One",
              "value": "Election of Directors – vote FOR all six nominees for the Board of Directors."
            },
            {
              "key": "Voting Proposal Two",
              "value": "Appointment of Baker Tilly US, LLP as Independent Registered Public Accounting Firm and Authorization to Fix Remuneration – vote FOR."
            },
            {
              "key": "Voting Proposal Three",
              "value": "Approval of Amendment to Articles Regarding Director Nominations by Shareholders – vote FOR."
            },
            {
              "key": "Voting Proposal Four",
              "value": "Approval of Amendment to Articles Regarding Board Authority to Fix Number of Directors – vote FOR."
            },
            {
              "key": "Voting Recommendation Summary",
              "value": "The Board of Directors unanimously recommends voting FOR the proposals as described."
            },
            {
              "key": "Change or Revocation of Vote",
              "value": "Shareholders may revoke their proxy by submitting a new proxy with a later date, sending written revocation to the Corporate Secretary, or by voting in person at the meeting."
            },
            {
              "key": "Quorum Requirement",
              "value": "A quorum requires shareholders holding at least 33 1/3% of the issued common shares or 8,820,229 common shares."
            },
            {
              "key": "Broker Non-Vote Explanation",
              "value": "A broker non-vote applies when a broker returns a proxy without instructions, and such proxies are still counted toward the quorum."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 16,
          "title": "Voting Requirements and Effects Matrix & Proxy Voting Instructions",
          "data": [
            {
              "key": "table_title",
              "value": "Voting Requirements and Effects Matrix"
            },
            {
              "key": "table_summary",
              "value": "A template voting matrix outlining vote thresholds and effects (withheld/against, abstentions, broker non-votes) with no data rows provided."
            },
            {
              "key": "proxy_instructions",
              "value": "Directors Appointment of Proxyholders: The proxy card names specific officers of DiaMedica. Shareholders may replace the designated names by striking them out and inserting a person or company of their choice, not necessarily a shareholder, as their proxy."
            },
            {
              "key": "shareholder_eligibility",
              "value": "Only registered shareholders as of the close of business on March 21, 2023 are entitled to vote or grant proxies. Differentiates between registered shareholders and beneficial shareholders."
            },
            {
              "key": "meeting_procedures",
              "value": "The document outlines the process for voting at the meeting and the procedures to be followed, including that only matters brought in accordance with the Articles will be considered and the requirement for a natural person to make or second a motion."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 18,
          "title": "VOTING PROPOSAL ONE—ELECTION OF DIRECTORS and Board Structure",
          "data": [
            {
              "key": "Proposal",
              "value": "Voting Proposal One – Election of Directors; board composition and director nominations."
            },
            {
              "key": "Board Structure",
              "value": "Articles provide for at least three members, fixed at six directors; current board consists of six directors."
            },
            {
              "key": "Director Election Term",
              "value": "Each director is elected annually by the shareholders and serves until the next annual general meeting."
            },
            {
              "key": "Nominees and Roles",
              "value": "Nominees include Michael Giuffre, M.D. (Director), Tanya Lewis (Director), James Parsons (Director), Rick Pauls (President and Chief Executive Officer, Director), Richard Pilnik (Chairman of the Board), and Charles Semba, M.D. (Director)."
            },
            {
              "key": "Committee Memberships",
              "value": "Directors hold various roles such as Independent Director; Member of the Compensation Committee; Member of the Nominating and Corporate Governance Committee; and Member of the Audit Committee."
            },
            {
              "key": "Additional Information",
              "value": "Further paragraphs provide detailed backgrounds, principal occupations, employment history, and qualifications of each nominee."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 19,
          "title": "Board of Directors and Leadership Biographies",
          "data": [
            {
              "key": "Michael Giuffre - Board & Leadership History",
              "value": "Served as a member of the Board of Directors since August 2010. Since July 2009, he has been a Clinical Professor at the University of Calgary. From 2012 to October 2019, he served as Chief Scientific Officer and President of FoodChek Laboratory and was a board member of FoodChek Systems Inc., including serving as Chairman from November 2017 to October 2019. He has also served on several other boards (CMA, Unicef Canada, AMA, Can-Cal Resources Ltd, Vacci-Test Corporation, IC2E International Inc., MedMira Inc. and Brightsquid Dental, Inc.)."
            },
            {
              "key": "Tanya Lewis - Board & Executive Roles",
              "value": "Has served as a member of the Board of Directors since March 1, 2023. Currently the Chief Development Operations Officer at Replimune Group, Inc. since May 2021. Previously, she held senior leadership roles at Karyopharm Therapeutics Inc. as Executive Vice President, Chief Regulatory Officer and Quality Officer (November 2019 to May 2021) and served at Syros Pharmaceuticals, Idera Pharmaceuticals, Tesaro, Inc. and Millennium Pharmaceuticals in various regulatory and quality positions."
            },
            {
              "key": "James Parsons - Board & Financial Leadership",
              "value": "Has served as a member of the Board of Directors since October 2015. Previously served as Vice President of Finance (October 2010 - May 2014) and as Chief Financial Officer and Corporate Secretary of Trillium Therapeutics Inc. from August 2011 until its acquisition by Pfizer in November 2021."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 20,
          "title": "Board and Leadership Appointments Overview",
          "data": [
            {
              "key": "Pfizer Employment",
              "value": "He became employed by Pfizer Canada ULC until March 2022."
            },
            {
              "key": "Mr. Parsons",
              "value": "Serves as a member of the board of directors and audit committee chair of Sernova Corp., and is a board member of Oncolytics Biotech Inc. He has been a Chief Financial Officer in the life sciences industry since 2000, holds a Master of Accounting degree from the University of Waterloo, and is a Chartered Professional Accountant. He is a resident of Ontario, Canada."
            },
            {
              "key": "Rick Pauls",
              "value": "Appointed as President and Chief Executive Officer in January 2010. He has served as a board member since April 2005 and was Chairman from April 2008 to July 2014. Previously, he was the Co-Founder and Managing Director of CentreStone Ventures Inc., and worked as an analyst and in structured finance roles. He is a resident of Minnesota, USA."
            },
            {
              "key": "Richard Pilnik",
              "value": "Has served as a member of the Board of Directors since May 2009 and as Chairman since July 2014. He has held leadership roles such as President at Vigor Medical Services, Inc. and was involved with Chiltern International Limited. His career includes executive roles at Quintiles Commercial Solutions and a 25‐year tenure at Eli Lilly and Company, where he held several leadership positions. He has extensive board experience and is an Emeritus Board Member of Duke University Fuqua School of Business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 21,
          "title": "Board of Directors – Director Biographies and Disclosures",
          "data": [
            {
              "key": "Director Nominees",
              "value": "Mr. Pilnik and Dr. Charles Semba"
            },
            {
              "key": "Mr. Pilnik Background",
              "value": "Holds a BA in Economics from Duke University and an MBA from the Kellogg School of Management at Northwestern University; resident of Florida, USA; affiliated with International, the largest mid-size Clinical Research Organization, and Certara, L.P., a private biotech company focused on drug development modeling and biosimulation; expected to contribute valuable expertise to the Board of Directors."
            },
            {
              "key": "Dr. Semba Background",
              "value": "Served as a Board member since July 2021; has over 20 years of drug-development experience in public and venture-funded biotechnology companies; previously held CMO roles at Eluminex Biosciences, Graybug Vision, Inc., and ForSight VISION5 (acquired by Allergan); held senior positions at Genentech and Shire; adjunct professor at Stanford University School of Medicine; holds a BA in Chemistry from Carleton College and an MD from the University of Minnesota Medical School; resident of California, USA."
            },
            {
              "key": "Regulatory Disclosures",
              "value": "No penalties or sanctions imposed by courts or securities regulatory authorities; no history of corporate cease trade orders or bankruptcies reported for any director or director nominee within the relevant period."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 22,
          "title": "Nominee Eligibility and Board Recommendation",
          "data": [
            {
              "key": "Eligibility Conditions",
              "value": "The text outlines events impacting former directors, CEOs, or CFOs of DiaMedica. It specifies that if, after ceasing to hold these roles, a person became the subject of a cease trade or similar order (or was denied an exemption under securities legislation for over 30 consecutive days), or within a year experienced bankruptcy, insolvency proceedings, creditor arrangements, or had a receiver/trustee appointed, then certain adverse conditions apply."
            },
            {
              "key": "Board Recommendation",
              "value": "The Board of Directors unanimously recommends a vote FOR the election of all six director nominees."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 25,
          "title": "VOTING PROPOSAL THREE—APPROVAL OF AMENDMENT TO ARTICLES REGARDING DIRECTOR NOMINATIONS BY SHAREHOLDERS",
          "data": [
            {
              "key": "Background",
              "value": "The SEC approved new universal proxy rules mandating the use of a universal proxy card in contested director elections. This change is expected to lead to more proxy contests."
            },
            {
              "key": "Proposed Amendment",
              "value": "The Board of Directors, upon recommendation of the Nominating and Corporate Governance Committee, approved a proposal (subject to shareholder approval) to amend Article 10 by adding Article 10.10. This amendment aims to incorporate the universal proxy rules and additional advance notice provisions to ensure an orderly nomination and election process."
            },
            {
              "key": "Rationale",
              "value": "Due to changes in SEC rules, many U.S. public companies have revised their governing documents to incorporate advance notice requirements. The amendment will ensure that DiaMedica and its shareholders have sufficient information in case of contested nominations."
            },
            {
              "key": "Effective Timing",
              "value": "The universal proxy rules became effective for shareholder meetings held after August 31, 2022, with the amendment providing specific timing for notice submissions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 26,
          "title": "Proposed Articles Amendment for Enhanced Director Nomination Procedures",
          "data": [
            {
              "key": "Amendment Purpose",
              "value": "To enhance procedural mechanics and disclosure requirements for director nominations in accordance with the SEC’s universal proxy rules."
            },
            {
              "key": "Deadline Extension",
              "value": "Extends the 60-day deadline provided under the universal proxy rules to allow more time for review and action."
            },
            {
              "key": "Proxy Handling",
              "value": "Specifies that if a shareholder fails to follow applicable procedures, DiaMedica may disregard proxies or votes solicited for nominees other than its own."
            },
            {
              "key": "Advance Notice Procedures",
              "value": "Requires shareholders to submit nominations under strict timing (no later than the 90th day and no earlier than the 120th day before the annual meeting, with exceptions for special meetings) and include detailed information about the nominee and nominating party."
            },
            {
              "key": "Board and Committee Involvement",
              "value": "The Board of Directors, based on the recommendation of the Nominating and Corporate Governance Committee, approved the proposed amendment on March 9, 2023, subject to shareholder approval."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 28,
          "title": "Timing and Effect of Proposed Articles Amendment",
          "data": [
            {
              "key": "Voting Proposal",
              "value": "Three"
            },
            {
              "key": "Effectiveness",
              "value": "If approved, changes are effective immediately; if not approved, Article 10 remains unchanged"
            },
            {
              "key": "Interdependency",
              "value": "Approval of Voting Proposal Three is not conditioned upon Voting Proposal Four, and vice versa"
            },
            {
              "key": "Board Recommendation",
              "value": "The Board of Directors unanimously recommends a vote FOR the amendment to enhance procedural mechanics and disclosure requirements for director nominations"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 30,
          "title": "Election or Appointment of Directors & Articles Amendment",
          "data": [
            {
              "key": "Governance Change",
              "value": "Proposal that only the Board of Directors fixes the number of directors, replacing the current method under Articles 13.1(a)(i) and 13.1(b)(i)."
            },
            {
              "key": "Rationale",
              "value": "Aligns corporate governance practices with those of U.S. public companies and decreases the risk of unsolicited takeover attempts by hostile or activist shareholders."
            },
            {
              "key": "Approval Process",
              "value": "On March 9, 2023, the Board of Directors, upon recommendation of the Nominating and Corporate Governance Committee, approved the amendment subject to shareholder approval."
            },
            {
              "key": "Contingency Provision",
              "value": "If DiaMedica is no longer a public company, the number of directors would be determined either by the Board of Directors or under Article 14.4, removing the Nasdaq Listing Rules requirement for a minimum of three directors."
            },
            {
              "key": "Referenced Articles",
              "value": "Articles 13.1(a)(i), 13.1(b)(i), 14.8, and 14.4"
            },
            {
              "key": "Stakeholder Impact",
              "value": "Intended to safeguard DiaMedica’s strategic direction and shareholder interests by preventing unwanted board expansion and potential hostile takeover attempts."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 36,
          "title": "CORPORATE GOVERNANCE – Management by Board of Directors",
          "data": [
            {
              "key": "Board Responsibilities",
              "value": "The Board of Directors is responsible for overseeing DiaMedica's management and affairs, including approval of major acquisitions, dispositions, investments, and contracts outside the ordinary course of business."
            },
            {
              "key": "Director Election and Term",
              "value": "Each director is elected annually by shareholders and serves until the next annual meeting."
            },
            {
              "key": "Independent Oversight",
              "value": "A majority of independent directors provide independent supervision through formal meetings and informal discussions."
            },
            {
              "key": "Corporate Governance Guidelines",
              "value": "The Guidelines describe the board's approach to governance, covering topics such as board size, director qualifications, conflicts of interest, leadership structure, board committees, and evaluations."
            },
            {
              "key": "Leadership Structure",
              "value": "The Board may combine the roles of Chairman and CEO, but maintains flexibility to appoint an independent director for leadership if needed. The leadership structure is periodically reviewed by the Nominating and Corporate Governance Committee."
            },
            {
              "key": "Table Summary",
              "value": "A table lists governance topics like board size, conflicts of interest, director independence, board leadership, board committees, executive sessions, board compensation, stock ownership by directors, CEO evaluation, succession planning, and communications with directors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 37,
          "title": "Lead Director Responsibilities and Board Leadership Structure",
          "data": [
            {
              "key": "lead_director_duties",
              "value": "The lead director is responsible for chairing executive sessions of the independent directors, calling meetings, setting agendas, coordinating feedback with the CEO, retaining legal counsel or advisors, and other duties as determined by the Board."
            },
            {
              "key": "current_chairman",
              "value": "Mr. Pilnik"
            },
            {
              "key": "current_ceo",
              "value": "Rick Pauls"
            },
            {
              "key": "leadership_structure_comments",
              "value": "The company believes that the current leadership structure, which balances the CEO’s day-to-day management and strategic direction with the Chairman’s oversight and board governance, is in the best interests of DiaMedica and its shareholders. The Board may review and change this structure in the future."
            },
            {
              "key": "independent_directors",
              "value": "Independent directors include Michael Giuffre, M.D., Tanya Lewis, James Parsons, Richard Pilnik, Charles Semba, M.D., and former director Amy L. Burroughs, all determined to be independent under Nasdaq Listing Rules."
            },
            {
              "key": "board_meetings",
              "value": "The Board met in executive session six times during the fiscal year ended December 31, 2022."
            },
            {
              "key": "board_committees",
              "value": "The Board has an Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 38,
          "title": "Board Committees Membership and Audit Committee Responsibilities",
          "data": [
            {
              "key": "Committee Table Summary",
              "value": "The table presents the current assignments for the Board of Directors' committees. It includes three committees: Audit, Compensation, and Nominating and Corporate Governance. According to the table, Michael Giuffre, M.D. is the Chair of the Compensation Committee, Tanya Lewis and James Parsons serve on the Compensation Committee, Rick Pauls is marked as the Chair of the Audit Committee, and Richard Pilnik is indicated as the Chair of the Nominating and Corporate Governance Committee while also serving on the Audit Committee."
            },
            {
              "key": "Additional Audit Committee Details",
              "value": "The text further describes the responsibilities of the Audit Committee which covers oversight of financial reporting, internal controls, engagement of independent auditors, and legal/ethical compliance programs. It specifies that the current Audit Committee members are Mr. Parsons, Mr. Pilnik, and Dr. Semba, with Mr. Parsons identified as the Chair. This indicates a discrepancy with the table regarding the Audit Committee leadership, suggesting updates or differing reporting information."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 42,
          "title": "Orientation and Continuing Education of Directors & Board Nomination Process",
          "data": [
            {
              "key": "Orientation Process",
              "value": "New directors receive an orientation including access to public filings, technical reports, internal financial information, minutes, and corporate governance materials."
            },
            {
              "key": "Continuing Education",
              "value": "Continuing education is emphasized as a compliance requirement with participation in education programs by regulatory bodies."
            },
            {
              "key": "Committee Responsibilities",
              "value": "The Nominating and Corporate Governance Committee develops and oversees the orientation process for new Board directors."
            },
            {
              "key": "Committee Composition",
              "value": "Current members include Dr. Giuffre and Mr. Pilnik (Chair); Ms. Burroughs served as a member in 2022. All are considered independent directors under Nasdaq Listing Rules."
            },
            {
              "key": "Nomination Process",
              "value": "New directors are approved by the Board after evaluation and recommendation by the Committee. Criteria include expertise, diversity, independence, and potential conflicts of interest."
            },
            {
              "key": "Recent Appointment",
              "value": "Ms. Lewis was appointed to the Board effective March 1, 2023, identified by a member of management."
            },
            {
              "key": "Shareholder Nominations",
              "value": "The Committee will also consider director candidates recommended by shareholders, following specified advance notice requirements per British Columbia’s Business Corporations Act."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 64,
          "title": "SHAREHOLDER PROPOSALS FOR 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS",
          "data": [
            {
              "key": "SEC Rule 14a-8 Submission Deadline",
              "value": "December 6, 2023 (close of business)"
            },
            {
              "key": "Director Nomination Submission Deadline",
              "value": "No later than 5:00 p.m. (CDT) on February 17, 2024 (with earliest submission on January 18, 2024)"
            },
            {
              "key": "Universal Proxy Notice Deadline",
              "value": "March 18, 2024"
            },
            {
              "key": "Nomination Notice Delivery",
              "value": "Delivered to Corporate Secretary at the registered office or principal executive offices at 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305"
            },
            {
              "key": "Additional Conditions",
              "value": "Proposals and nominations must comply with SEC Rule 14a-8, the BCBCA requirements, and the company's amended Articles. Timeliness and compliance are required for consideration."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 66,
          "title": "Proposed Amendment Regarding Director Nominations by Shareholders",
          "data": [
            {
              "key": "Article",
              "value": "10.10"
            },
            {
              "key": "Description",
              "value": "Amendment setting advance notice provisions and procedures for nominating directors to the board of the Company. It outlines eligibility criteria and the nomination process in accordance with the Business Corporations Act and the U.S. Securities Exchange Act of 1934."
            },
            {
              "key": "Governing Laws",
              "value": "Business Corporations Act; United States Securities Exchange Act of 1934 (as amended)"
            },
            {
              "key": "Nomination Process",
              "value": "Directors can be nominated at annual or special general meetings of shareholders either by the board, an authorized officer, or by a Nominating Shareholder who meets ownership and notice requirements."
            },
            {
              "key": "Timely Notice Requirements",
              "value": "Nominations must be submitted in proper written form to the CEO at the designated office within specific timeframes – not later than 5:00 p.m. (CDT) on the 90th day and not earlier than 5:00 p.m. (CDT) on the 120th day prior to relevant meeting dates."
            },
            {
              "key": "Exclusive Submission",
              "value": "Article 10.10 is established as the sole method for submitting director nominations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 67,
          "title": "Nominating Shareholder’s Notice Requirements – Article 10.10",
          "data": [
            {
              "key": "meeting_notice_period",
              "value": "ninetieth (90th) day prior to an annual meeting or the tenth (10th) day following the initial public announcement of the meeting date"
            },
            {
              "key": "postponement_notice",
              "value": "Public announcement of an adjournment or postponement of an annual general meeting does not start a new or extend the existing time period for submitting a Nominating Shareholder’s notice"
            },
            {
              "key": "special_meeting_deadline",
              "value": "For a special general meeting (not an annual meeting) that includes director elections, the notice must be received by 5:00 p.m. (CDT) on the tenth (10th) day following the first public announcement of the meeting date"
            },
            {
              "key": "proper_notice_format",
              "value": "The notice must be in proper written form and comply with all provisions of Article 10.10"
            },
            {
              "key": "proposed_nominee_requirements",
              "value": "For each proposed nominee for director, all required information per Regulation 14A under the Exchange Act must be disclosed including written consent to serve, and a statement of compliance with corporate governance, conflict of interest, confidentiality, and stock policies"
            },
            {
              "key": "shareholder_information",
              "value": "Each Nominating Shareholder (and any beneficial owner represented) must disclose their name, address, share class/series and number of shares held, and any related agreements or arrangements affecting share value or risk management"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 69,
          "title": "Director Nomination and Proxy Solicitation Disclosure Requirements",
          "data": [
            {
              "key": "Disclosure Scope",
              "value": "Includes detailed disclosure requirements for nominating shareholders, including disclosures about current or former officers, directors, affiliates, and associated parties, and identification of other shareholders supporting a nomination."
            },
            {
              "key": "Schedule 13D Reference",
              "value": "Specifies that all information required in a Schedule 13D under Rule 13d-1(a) or its amendment under Rule 13d-2(a) should be provided if applicable."
            },
            {
              "key": "Proxy Statement and Solicitation",
              "value": "Details the information necessary for proxy statements or filings related to solicitation of proxies for director elections, including representations on voting commitments and the intention to appear personally or by proxy."
            },
            {
              "key": "Nominee Eligibility",
              "value": "Outlines that to be eligible as a director nominee, the proposed nominee must comply with the procedures, submit a completed questionnaire regarding background, qualifications, stock ownership, independence, and provide assurances regarding conflicts and Voting Commitments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 70,
          "title": "Nomination and Proxy Solicitation Guidelines for Proposed Nominees",
          "data": [
            {
              "key": "Trading Policies & Guidelines",
              "value": "The Company’s trading policies and guidelines are available to any Proposed Nominee upon request."
            },
            {
              "key": "Eligibility Information",
              "value": "Proposed Nominees must furnish any additional information reasonably required by the Company to assess their eligibility to serve as an independent director."
            },
            {
              "key": "Timeliness Requirement",
              "value": "Information must be provided promptly upon request, and in any event within five (5) business days."
            },
            {
              "key": "Interview Provision",
              "value": "The Board of Directors may require Proposed Nominees to participate in interviews within ten (10) days of a request."
            },
            {
              "key": "Proxy Solicitation Compliance",
              "value": "Shareholders nominating directors must comply with Rule 14a-19 under the Exchange Act; failure to do so may result in disregarded nominations and proxies."
            },
            {
              "key": "Currency and Update of Information",
              "value": "All information provided in a Timely Notice must reflect the date of the notice and be updated to remain accurate at least 10 business days before the meeting."
            },
            {
              "key": "Delivery Method",
              "value": "Notices or documents must be delivered personally or by courier (not by fax or email) to the Company's principal executive offices or registered office."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 71,
          "title": "Defective Nomination Determination",
          "data": [
            {
              "key": "Article",
              "value": "10.10"
            },
            {
              "key": "Power of Chair",
              "value": "Determine compliance of proposed nominations"
            },
            {
              "key": "Waiver",
              "value": "Board may waive requirements"
            },
            {
              "key": "Definitions",
              "value": "Definitions under the United States Securities Act of 1933 and the Exchange Act"
            },
            {
              "key": "Public Announcement",
              "value": "Disclosure requirements for public announcements"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 106,
          "title": "Executive Leadership and Confidentiality Policies",
          "data": [
            {
              "key": "Confidentiality & IP Assignment",
              "value": "The document details the use of confidentiality agreements and invention assignment agreements with employees, consultants, scientific advisors, contractors, and partners. These agreements require that all confidential information and relevant inventions developed during any relationship must remain confidential and be assigned exclusively to the company."
            },
            {
              "key": "Employee Count & Relations",
              "value": "As of December 31, 2022, the company employed 16 full-time employees. There has never been a work stoppage and none of the employees are covered by collective bargaining agreements, reflecting positive employee relations."
            },
            {
              "key": "Executive Leadership Team",
              "value": "The document provides a table (as of March 15, 2023) listing key executive officers: Rick Pauls (President and CEO, Director), Scott Kellen (CFO and Secretary), Kirsten Gruis, M.D. (Chief Medical Officer), Dominic Cundari (Chief Commercial Officer), and Julie VanOrsdel Daves (Senior VP, Clinical Development Operation)."
            },
            {
              "key": "Leadership Background",
              "value": "Biographical summaries include Rick Pauls' longstanding tenure and leadership history since 2010, including previous roles in venture capital and financial services, as well as Scott Kellen's career progression through significant financial roles prior to his appointment as CFO and Secretary."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 107,
          "title": "Leadership Changes at DiaMedica",
          "data": [
            {
              "key": "New Chief Medical Officer",
              "value": "Kirsten Gruis, M.D. joined DiaMedica in January 2022."
            },
            {
              "key": "Previous Roles of Kirsten Gruis",
              "value": "Chief Medical Officer for Edgewise Therapeutics; Franchise Head at Roche; various roles at Wave Life Sciences, Idera Pharmaceuticals, Alynylam Pharmaceuticals, Pfizer."
            },
            {
              "key": "New Chief Commercial Officer",
              "value": "Dominic Cundari joined DiaMedica in February 2022."
            },
            {
              "key": "Previous Roles of Dominic Cundari",
              "value": "Independent consultant for Genentech; senior director at Genentech."
            },
            {
              "key": "New Senior Vice President, Clinical Development Operations",
              "value": "Julie VanOrsdel Daves, MSHS, CCRP joined DiaMedica in September 2022."
            },
            {
              "key": "Previous Roles of Julie Daves",
              "value": "Vice President at Sanifit Therapeutics; consulting at JVD Pharma Consulting; multiple roles at Edgewise."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 200,
          "title": "Corporate Officers and Directors Signatures",
          "data": [
            {
              "key": "Registrant",
              "value": "DIAMEDICA THERAPEUTICS INC."
            },
            {
              "key": "Rick Pauls",
              "value": "President and Chief Executive Officer; Signed on March 28, 2023 (date noted as '28,')"
            },
            {
              "key": "Scott Kellen",
              "value": "Chief Financial Officer and Secretary (principal financial and accounting officer); Signed on March 28, 2023"
            },
            {
              "key": "Richard Pilnik",
              "value": "Chairman of the Board; Signed on March 28, 2023"
            },
            {
              "key": "Michael Giuffre, M.D.",
              "value": "Director; Signed on March 28, 2023"
            },
            {
              "key": "Tanya N. Lewis",
              "value": "Director; Signed on March 28, 2023"
            },
            {
              "key": "James Parsons",
              "value": "Director; Signed on (date noted as '28,')"
            },
            {
              "key": "Charles P. Semba, M.D.",
              "value": "Director; Signed on March 28, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 203,
          "title": "Corporate Governance - Board of Directors and Executive Officers",
          "data": [
            {
              "key": "Board of Directors",
              "value": "Richard Pilnik (Chairman of the Board); Michael Giuffre, M.D. (Clinical Professor of Cardiac Sciences and Pediatrics, University of Calgary); Tanya Lewis (Chief Development Operations Officer, Replimune Group, Inc.); James Parsons (Former Chief Financial Officer and Corporate Secretary, Trillium Therapeutics Inc.); Rick Pauls (President and Chief Executive Officer, DiaMedica Therapeutics Inc.); Charles Semba, M.D. (Chief Medical Officer, Eluminex Biosciences)"
            },
            {
              "key": "Executive Officers",
              "value": "Rick Pauls (President and Chief Executive Officer); Kirsten Gruis, M.D. (Chief Medical Officer); Scott Kellen (Chief Financial Officer and Corporate Secretary); Dominic Cundari (Chief Commercial Officer); Julie VanOrsdel Daves (Senior Vice President, Clinical Development Operations)"
            },
            {
              "key": "Professional Service Providers",
              "value": "Independent Auditors: Baker Tilly US, LLP, 225 South Sixth Street Suite 2300, Minneapolis, MN 55402; Legal Counsel: Fox Rothschild LLP (City Center, 33 South Sixth Street Suite 3600, Minneapolis, MN 55402) and Pushor Mitchell LLP (301 – 1665 Ellis Street, Kelowna, BC V1Y 2B3, Canada); Patent Counsel: Cooley LLP (1700 Seventh Avenue Suite 1900, Seattle, WA 98101); Transfer Agent and Registrar: Computershare Investor Services (100 University Avenue, 8th Floor, Toronto, ON M5J 2Y1, Canada, +1 (514) 982 7555, service@computershare.com)"
            },
            {
              "key": "Share Information",
              "value": "Voting common shares traded on The Nasdaq Capital Market under the symbol 'DMAC'"
            },
            {
              "key": "Annual General and Special Meeting",
              "value": "Scheduled for Wednesday, May 17, 2023, beginning at 1:00 p.m. Central Daylight Savings Time at DiaMedica Therapeutics Inc., 301 Carlson Parkway Suite 210, Minneapolis, MN 55305"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": true,
      "elements": [
        {
          "type": "layoff",
          "page": 113,
          "title": "Operational Challenges Due to Layoffs and COVID-19 Impact",
          "data": [
            {
              "key": "layoff_reason",
              "value": "Layoffs and employee burnout causing workforce reduction"
            },
            {
              "key": "clinical_nurses_reallocation",
              "value": "Reallocation of clinical nurses to COVID-19 care during surges, particularly at the beginning of 2022"
            },
            {
              "key": "study_coordinator_loss",
              "value": "Loss of study coordinators due to budget constraints and COVID-19 vaccination requirements"
            },
            {
              "key": "trial_enrollment_impact",
              "value": "Slower than expected enrollments in the ReMEDy2 trial due to these staffing issues and patient concerns"
            },
            {
              "key": "mitigation_efforts",
              "value": "Brought site engagement responsibilities in-house and engaged a clinical services consulting firm to support study sites"
            },
            {
              "key": "trial_risk",
              "value": "Risk of increased patient enrollment numbers, extended timelines, additional costs, and potential adverse impact on trial outcomes"
            },
            {
              "key": "covid_continuation",
              "value": "Ongoing and potential future COVID-19 disruptions, including new variants, could further impact trial initiation and operations"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "layoff",
          "page": 166,
          "title": "Workforce Reduction and Obligations",
          "data": [
            {
              "key": "employee_reduction",
              "value": "Reducing the number of our employees or employee compensation."
            },
            {
              "key": "DM199_product_candidate",
              "value": "Modifying or delaying the development of our DM199 product candidate."
            },
            {
              "key": "licensing_rights",
              "value": "Licensing rights to third parties for DM199 product candidate."
            },
            {
              "key": "relinquishing_rights",
              "value": "Relinquishing significant rights to technologies and future revenue streams."
            },
            {
              "key": "potential_actions",
              "value": "Divesting assets or ceasing operations through merger or liquidation."
            },
            {
              "key": "outstanding_commitments",
              "value": "Approximately $4.0 million over the next 12 months and $3.0 million in the following 12 months."
            },
            {
              "key": "future_operating_lease_commitments",
              "value": "Approximately $459,000 total over the lease, $63,000 due next 12 months."
            },
            {
              "key": "license_agreement",
              "value": "Licensed gene expression technology from Catalent."
            },
            {
              "key": "milestone_payment",
              "value": "One milestone payment obligation tied to the first commercial sale."
            },
            {
              "key": "royalty_payment",
              "value": "Royalty of less than 1% on net sales after product launch."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 1,
          "title": "2022 Annual Report & 2023 Annual General and Special Meeting Proxy Statement",
          "data": [
            {
              "key": "Document Title",
              "value": "2022 Annual Report & 2023 Annual General and Special Meeting Proxy Statement"
            },
            {
              "key": "Document Type",
              "value": "Annual Report and Proxy Statement"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 8,
          "title": "Delinquent Section 16(a) Reports",
          "data": [
            {
              "key": "Delinquent Section 16(a) Reports",
              "value": ""
            },
            {
              "key": "CORPORATE GOVERNANCE",
              "value": ""
            },
            {
              "key": "Management by Board of Directors",
              "value": ""
            },
            {
              "key": "Board Leadership Structure...",
              "value": ""
            },
            {
              "key": "Director Independence",
              "value": ""
            },
            {
              "key": "Board Committees...",
              "value": ""
            },
            {
              "key": "Audit Committee",
              "value": ""
            },
            {
              "key": "Compensation Nominating and Corporate Governance Committee ...",
              "value": ""
            },
            {
              "key": "Board Diversity Matrix Board Diversity",
              "value": ""
            },
            {
              "key": "DIRECTOR COMPENSATION Non-Employee Director Compensation Program",
              "value": ""
            },
            {
              "key": "Director Compensation Table...",
              "value": ""
            },
            {
              "key": "EXECUTIVE COMPENSATION",
              "value": ""
            },
            {
              "key": "Executive Compensation Overview Summary Compensation Table ... Outstanding Equity Awards at Fiscal Year-End Employee Benefit and Stock Plans..",
              "value": ""
            },
            {
              "key": "Anti-Hedging and Pledging Policy..",
              "value": ""
            },
            {
              "key": "RELATED PERSON RELATIONSHIPS AND TRANSACTIONS...",
              "value": ""
            },
            {
              "key": "Introduction ... Description of Related Party Transactions",
              "value": ""
            },
            {
              "key": "Policies and Procedures for Related Party Transactions ...",
              "value": ""
            },
            {
              "key": "SHAREHOLDER PROPOSALS FOR 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS",
              "value": ""
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 11,
          "title": "Executive Compensation Best Practices and 2022 Actions",
          "data": [
            {
              "key": "Overview",
              "value": "Our compensation practices include many best practices that support our executive compensation objectives and benefit our shareholders."
            },
            {
              "key": "What We Do",
              "value": "Emphasize pay for performance; structure executive compensation so that a significant portion of pay is at risk and paid in equity; maintain competitive pay packages."
            },
            {
              "key": "What We Don't Do",
              "value": "No guaranteed salary increases or bonuses; no repricing of stock options unless approved by shareholders; no hedging or pledging of DiaMedica securities; no perquisites."
            },
            {
              "key": "Compensation Elements",
              "value": "Consists of base salary, short-term incentive, long-term incentive, and other compensation."
            },
            {
              "key": "2022 Executive Compensation Actions",
              "value": "CEO received a 5% base salary increase, CFO received a 14% increase, and the newly hired CMO did not receive a base salary increase. CEO's short-term incentive target is 50% of base salary, while CFO's and CMO's targets are 40%. Stock options vest with 25% on the one-year anniversary and the remaining 75% over 36 months. No changes were made to other compensation components."
            },
            {
              "key": "Table Summary",
              "value": "Table details: Base Salary adjustments for CEO, CFO, and CMO; Short-Term and Long-Term incentive percentages and vesting schedules; and no changes to other compensation components."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 17,
          "title": "Householding of Meeting Materials",
          "data": [
            {
              "key": "Householding Explanation",
              "value": "Some banks, brokers and other nominee record holders may be participating in the practice of 'householding' proxy statements, annual reports and the Notice of Internet Availability of Proxy Materials. This means that only one copy of these documents may be sent to a household even if multiple shareholders reside there, unless contrary instructions have been received."
            },
            {
              "key": "Separate Copy Request",
              "value": "Shareholders can request a separate copy by contacting the Corporate Secretary at DiaMedica Therapeutics Inc., 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305, telephone: (763) 496-5454."
            },
            {
              "key": "Proxy Solicitation Costs",
              "value": "The cost of soliciting proxies, including preparation, assembly, electronic availability and mailing of proxies and solicitation materials, will be borne by DiaMedica. Directors, officers and regular employees may solicit proxies without any additional compensation beyond their regular pay; brokerage firms and others may be reimbursed for forwarding solicitation materials."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 23,
          "title": "VOTING PROPOSAL TWO—APPOINTMENT OF BAKER TILLY US, LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM AND AUTHORIZATION TO FIX REMUNERATION",
          "data": [
            {
              "key": "Appointment Details",
              "value": "The Audit Committee appoints Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. Baker Tilly US, LLP was first appointed on April 27, 2018."
            },
            {
              "key": "Evaluation Criteria",
              "value": "The Audit Committee evaluated the firm's qualifications, performance, independence, quality and efficiency of services, technical expertise, and industry knowledge before re-engagement."
            },
            {
              "key": "Authorization to Fix Remuneration",
              "value": "The proposal also authorizes the Board of Directors to fix the remuneration for Baker Tilly US, LLP."
            },
            {
              "key": "Fees Table Summary",
              "value": "For fiscal 2022 and 2021, aggregate fees have been billed as follows: Audit Fees increased from $119,112 in 2021 to $130,134 in 2022, Audit-Related Fees decreased from $7,000 to $6,253, and Total Fees increased from $126,112 to $136,387. Tax Fees and All Other Fees were $0 in both years."
            },
            {
              "key": "Service Scope",
              "value": "The fees cover the audit of the annual consolidated financial statements, review of quarterly condensed consolidated financial statements, and other statutory and regulatory services. Additional fees relate to filing consents for registration statements on Forms S-8 and S-3."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 24,
          "title": "Audit Committee Pre-Approval Policies and Procedures & Board Recommendation",
          "data": [
            {
              "key": "service_provider",
              "value": "Baker Tilly US, LLP"
            },
            {
              "key": "client",
              "value": "DiaMedica"
            },
            {
              "key": "pre_approval",
              "value": "All audit and permitted non-audit services (other than de minimis non-audit services) were pre-approved by the Audit Committee."
            },
            {
              "key": "delegated_authority_limit",
              "value": "Up to $25,000 delegated to the Audit Committee Chair"
            },
            {
              "key": "board_recommendation",
              "value": "Unanimous recommendation for the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, and authorization for the Board to fix the firm's remuneration."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 34,
          "title": "Beneficial Ownership of Common Shares by Directors and Executives",
          "data": [
            {
              "key": "Row 1 - Title of Class",
              "value": "Common Shares"
            },
            {
              "key": "Row 1 - Name of Beneficial Owner",
              "value": "Michael Giuffre, M.D."
            },
            {
              "key": "Row 1 - Amount and Nature of Beneficial Ownership",
              "value": "393,216"
            },
            {
              "key": "Row 1 - Percent of Class",
              "value": "1.5%"
            },
            {
              "key": "Row 2 - Title of Class",
              "value": "Common Shares"
            },
            {
              "key": "Row 2 - Name of Beneficial Owner",
              "value": "Tanya Lewis"
            },
            {
              "key": "Row 2 - Amount and Nature of Beneficial Ownership",
              "value": "—"
            },
            {
              "key": "Row 2 - Percent of Class",
              "value": "*"
            },
            {
              "key": "Row 3 - Title of Class",
              "value": "Common Shares"
            },
            {
              "key": "Row 3 - Name of Beneficial Owner",
              "value": "James Parsons"
            },
            {
              "key": "Row 3 - Amount and Nature of Beneficial Ownership",
              "value": "109,075"
            },
            {
              "key": "Row 3 - Percent of Class",
              "value": "*"
            },
            {
              "key": "Row 4 - Title of Class",
              "value": "Common Shares"
            },
            {
              "key": "Row 4 - Name of Beneficial Owner",
              "value": "Rick Pauls"
            },
            {
              "key": "Row 4 - Amount and Nature of Beneficial Ownership",
              "value": "643,700"
            },
            {
              "key": "Row 4 - Percent of Class",
              "value": "2.4%"
            },
            {
              "key": "Row 5 - Title of Class",
              "value": "Common Shares"
            },
            {
              "key": "Row 5 - Name of Beneficial Owner",
              "value": "Richard Pilnik"
            },
            {
              "key": "Row 5 - Amount and Nature of Beneficial Ownership",
              "value": "295,284"
            },
            {
              "key": "Row 5 - Percent of Class",
              "value": "1.1%"
            },
            {
              "key": "Row 6 - Title of Class",
              "value": "Common Shares"
            },
            {
              "key": "Row 6 - Name of Beneficial Owner",
              "value": "Charles Semba, M.D."
            },
            {
              "key": "Row 6 - Amount and Nature of Beneficial Ownership",
              "value": "25,164"
            },
            {
              "key": "Row 6 - Percent of Class",
              "value": "*"
            },
            {
              "key": "Row 7 - Title of Class",
              "value": "Common Shares"
            },
            {
              "key": "Row 7 - Name of Beneficial Owner",
              "value": "Kirsten Gruis, M.D."
            },
            {
              "key": "Row 7 - Amount and Nature of Beneficial Ownership",
              "value": "53,333"
            },
            {
              "key": "Row 7 - Percent of Class",
              "value": "*"
            },
            {
              "key": "Row 8 - Title of Class",
              "value": "Common Shares"
            },
            {
              "key": "Row 8 - Name of Beneficial Owner",
              "value": "Scott Kellen"
            },
            {
              "key": "Row 8 - Amount and Nature of Beneficial Ownership",
              "value": "230,623"
            },
            {
              "key": "Row 8 - Percent of Class",
              "value": ""
            },
            {
              "key": "Row 9 - Title of Class",
              "value": "Common Shares"
            },
            {
              "key": "Row 9 - Name of Beneficial Owner",
              "value": "All current directors and executive as a group (10 persons)"
            },
            {
              "key": "Row 9 - Amount and Nature of Beneficial Ownership",
              "value": "1,793,195"
            },
            {
              "key": "Row 9 - Percent of Class",
              "value": "6.5%"
            },
            {
              "key": "Table Summary",
              "value": "This table shows the beneficial ownership of common shares by various directors and executives of the company. Rick Pauls holds the largest individual stake with 643,700 shares (2.4%), followed by Michael Giuffre, M.D. with 393,216 shares (1.5%). Collectively, all current directors and executives (10 persons) own 1,793,195 shares, representing 6.5% of the total class. Several holders are marked with asterisks (*) indicating ownership of less than 1% of the class."
            },
            {
              "key": "Footnotes",
              "value": "Percent of Class(2) represents beneficial ownership of less than one percent. (1) Includes, for the persons listed below, the shares subject to options, restricted stock units and deferred stock units held by such persons that are currently exercisable or become exercisable within 60 days of March 21, 2023: 26."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 35,
          "title": "Executive Compensation – Stock Awards and Options",
          "data": [
            {
              "key": "Table Rows",
              "value": "Rows detailing stock awards for executives: James Parsons, Rick Pauls, Richard Pilnik, Charles Semba, M.D. Executive Officers, Other Executive Officers, and a group representing all current directors and executive officers (10 persons)."
            },
            {
              "key": "Shares Underlying Stock Options",
              "value": "70566 (James Parsons), 587896 (Rick Pauls, appears twice), 119953 (Richard Pilnik), 20875 (Charles Semba), 40000 (Other Executive Officers), 1174022 (All current directors and executive officers as a group)"
            },
            {
              "key": "Shares Underlying Restricted Stock Units",
              "value": "0 for most; exception: 4289 (Charles Semba) and 4289 (group total)"
            },
            {
              "key": "Shares Underlying Deferred Stock Units",
              "value": "36259 (James Parsons), 1749 (Rick Pauls, appears twice), 72241 (Richard Pilnik), 0 (Charles Semba), 0 (Other Executive Officers), 157506 (Group total)"
            },
            {
              "key": "Table Summary",
              "value": "The table shows the distribution of different types of stock compensation among directors and executive officers. It highlights that Rick Pauls holds the largest number of stock options and that restricted stock units are uncommon."
            },
            {
              "key": "Additional Context",
              "value": "Percent of class is based on 26,460,688 shares outstanding as of March 21, 2023. Also noted are details from Section 16(a) reports regarding timely filing compliance, with one noted delinquency for TomEnterprise AB."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 40,
          "title": "Compensation Committee Responsibilities",
          "data": [
            {
              "key": "Committee Role",
              "value": "Assists the Board in oversight of executive compensation and administers equity compensation plans."
            },
            {
              "key": "Key Responsibilities",
              "value": "Determine all compensation for the CEO and other executive officers; administer equity-based compensation plans; review and approve compensation structure and succession planning; recommend non-employee director compensation."
            },
            {
              "key": "Committee Composition",
              "value": "Dr. Giuffre (Chair), Ms. Lewis, Mr. Parsons, and Dr. Semba."
            },
            {
              "key": "Independence Status",
              "value": "All members are independent directors per Nasdaq Listing Rules, Rule 16b-3 of the Exchange Act, and SEC regulations."
            },
            {
              "key": "Delegated Authority",
              "value": "Delegated authority to the CEO and CFO under the Amended and Restated 2019 Omnibus Incentive Plan to approve initial stock option grants."
            },
            {
              "key": "External Consultant",
              "value": "Engaged Radford/Aon plc (Aon) to assist in developing a comprehensive compensation strategy based on benchmark company data."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 41,
          "title": "Executive and Director Compensation Analysis",
          "data": [
            {
              "key": "Executive Compensation Consultant",
              "value": "Aon (retained in April 2021)"
            },
            {
              "key": "Non-Employee Director Compensation Consultant",
              "value": "Alpine Rewards, LLC (retained in February 2023)"
            },
            {
              "key": "Executive Compensation Determination",
              "value": "Decisions based on benchmarking data, pre-established performance objectives, overall performance of DiaMedica and individual officers; final decisions made solely by the Compensation Committee without executive presence."
            },
            {
              "key": "Director Compensation Process",
              "value": "Recommendations consider benchmark director fees, expected meeting attendance, individual responsibilities; final decision reviewed and approved by the full Board of Directors."
            },
            {
              "key": "Corporate Governance Responsibilities",
              "value": "The Nominating and Corporate Governance Committee assists in director nominations, governance guidelines, succession planning and board evaluations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 46,
          "title": "Director Compensation Overview",
          "data": [
            {
              "key": "Non-Employee Directors",
              "value": "Currently: Michael Giuffre, M.D., Tanya Lewis, James Parsons, Richard Pilnik, and Charles Semba, M.D. In 2022, Amy L. Burroughs was included and Tanya Lewis was not."
            },
            {
              "key": "Compensation Structure",
              "value": "Combination of cash retainers and long-term equity-based incentive compensation (annual stock options, restricted/deferred stock units) to attract and retain qualified board members."
            },
            {
              "key": "Cash Retainers",
              "value": "Fiscal 2022 cash retainers include: Board Member: $40,000; Chairman of the Board: $30,000; Audit Committee Chair: $15,000; Audit Committee Member: $7,500; Compensation Committee Chair: $10,000; Compensation Committee Member: $5,000; Nominating and Corporate Governance Committee Chair: $7,500; Nominating and Corporate Governance Committee Member: $3,750. (See table: 'Board and Committee Position Annual Cash Retainer Schedule')"
            },
            {
              "key": "Annual Stock Options",
              "value": "Each non-employee director is granted stock options equal to 0.05% of outstanding shares; the Chairman receives an additional 0.02%. On June 1, 2022, directors received an option to purchase 13,222 common shares at $2.45 per share, and the Chairman received an additional 5,288 shares at the same exercise price. These options vest in four nearly equal quarterly installments over one year and expire on May 31, 2032."
            },
            {
              "key": "Initial Equity Award for New Directors",
              "value": "New non-employee directors receive a stock option to purchase shares equal to 0.1% of outstanding shares in lieu of an annual equity award for their first year, vesting in 12 nearly equal quarterly installments over three years."
            },
            {
              "key": "Deferred/Restricted Stock Units",
              "value": "Directors have the option to elect Deferred Stock Units or Restricted Stock Units in lieu of up to 100% of their annual cash retainers."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 47,
          "title": "Director Compensation and DSU/RSU Awards Details",
          "data": [
            {
              "key": "Award Plan",
              "value": "DSU/RSU awards under the 2019 Plan or any other shareholder-approved plan"
            },
            {
              "key": "Calculation Formula",
              "value": "Elected portion of the annual cash retainers (for services rendered as a non-employee director, Chairman, or Board committee member) divided by the 10-trading day average closing sale price of common shares, with rounding down to the nearest whole share"
            },
            {
              "key": "Vesting Schedule",
              "value": "Awards vest in four nearly equal quarterly installments on March 31, June 30, September 30, and December 31, contingent upon continued service as a director as of the vesting date"
            },
            {
              "key": "Forfeiture Conditions",
              "value": "If a director is no longer serving before vesting, unvested shares are forfeited. Shares for the quarter during which service terminates vest ratably based on days served"
            },
            {
              "key": "Additional Compensation Adjustments",
              "value": "If a director receives an increased or additional annual cash retainer, excess amounts are paid in cash until the next election; reductions in committee memberships or Chair positions trigger forfeiture or revision of DSU/RSU awards"
            },
            {
              "key": "Director Compensation Table",
              "value": "Provides summary compensation information for non-employee directors for fiscal year ended December 31, 2022, excluding the CEO who is compensated separately"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 48,
          "title": "Executive Compensation Details and DSU Elections",
          "data": [
            {
              "key": "Amy L. Burroughs - Fees Earned or Paid in Cash",
              "value": "51250"
            },
            {
              "key": "Amy L. Burroughs - Option Awards",
              "value": "25683"
            },
            {
              "key": "Amy L. Burroughs - Stock Awards",
              "value": "3386"
            },
            {
              "key": "Amy L. Burroughs - All Other Compensation",
              "value": "0"
            },
            {
              "key": "Amy L. Burroughs - Total Compensation",
              "value": "80319"
            },
            {
              "key": "Michael Giuffre, M.D. - Fees Earned or Paid in Cash",
              "value": "53750"
            },
            {
              "key": "Michael Giuffre, M.D. - Option Awards",
              "value": "25683"
            },
            {
              "key": "Michael Giuffre, M.D. - Stock Awards",
              "value": "4551"
            },
            {
              "key": "Michael Giuffre, M.D. - All Other Compensation",
              "value": "0"
            },
            {
              "key": "Michael Giuffre, M.D. - Total Compensation",
              "value": "83984"
            },
            {
              "key": "James Parsons - Fees Earned or Paid in Cash",
              "value": "60000"
            },
            {
              "key": "James Parsons - Option Awards",
              "value": "25683"
            },
            {
              "key": "James Parsons - Stock Awards",
              "value": "5079"
            },
            {
              "key": "James Parsons - All Other Compensation",
              "value": "0"
            },
            {
              "key": "James Parsons - Total Compensation",
              "value": "90762"
            },
            {
              "key": "Richard Pilnik - Fees Earned or Paid in Cash",
              "value": "85000"
            },
            {
              "key": "Richard Pilnik - Option Awards",
              "value": "35955"
            },
            {
              "key": "Richard Pilnik - Stock Awards",
              "value": "7197"
            },
            {
              "key": "Richard Pilnik - All Other Compensation",
              "value": "0"
            },
            {
              "key": "Richard Pilnik - Total Compensation",
              "value": "128152"
            },
            {
              "key": "Charles Semba - Fees Earned or Paid in Cash",
              "value": "52500"
            },
            {
              "key": "Charles Semba - Option Awards",
              "value": "25683"
            },
            {
              "key": "Charles Semba - Stock Awards",
              "value": "0"
            },
            {
              "key": "Charles Semba - All Other Compensation",
              "value": "0"
            },
            {
              "key": "Charles Semba - Total Compensation",
              "value": "78183"
            },
            {
              "key": "Directors DSU Elections",
              "value": "Burroughs: $40,000 as 11,182 DSUs; Giuffre: $53,750 as 15,026 DSUs; Parsons: $60,000 as 16,773 DSUs; Pilnik: $85,000 as 23,762 DSUs"
            },
            {
              "key": "Additional Notes",
              "value": "Option awards are granted based on FASB ASC Topic 718. The table also includes DSU elections and summary details regarding compensation components."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 49,
          "title": "Executive Compensation Overview",
          "data": [
            {
              "key": "Section",
              "value": "EXECUTIVE COMPENSATION"
            },
            {
              "key": "Overview",
              "value": "This section addresses the compensation of our President and Chief Executive Officer and the two most highly compensated executive officers for the year ended December 31, 2022, namely Rick Pauls (President and CEO), Kirsten Gruis, M.D. (Chief Medical Officer) and Scott Kellen (Chief Financial Officer and Corporate Secretary)."
            },
            {
              "key": "Regulatory Status",
              "value": "Emerging growth company under the JOBS Act, exempt from providing a full Compensation Discussion and Analysis as required by Item 402 of SEC Regulation S-K."
            },
            {
              "key": "Compensation Philosophy",
              "value": "Targets executive pay at the 50th percentile of its peer group based on market capitalization, revenue, employee size and clinical development metrics."
            },
            {
              "key": "Market Data Usage",
              "value": "Peer group benchmarking is performed with the aid of an independent compensation consultant. The peer group, prepared in 2021, consisted of 15 companies with similar industry characteristics."
            },
            {
              "key": "Peer Group Table",
              "value": "A table listing 12 pharmaceutical and therapeutics companies arranged in a 4x3 grid. Companies include: AVEO Pharmaceuticals, Catalyst Biosciences, Galectin Therapeutics, GlycoMimetics, Heat Biologics, Idera Pharmaceuticals, Lipocine, OncoSec Medical, Soleno Therapeutics, TRACON Pharmaceuticals, Tyme Technologies, and Zynerba Pharmaceuticals."
            },
            {
              "key": "Use of Consultants",
              "value": "The Compensation Committee retains outside experts such as Aon (retained in April 2021) to assist with executive pay benchmarking and evaluation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 50,
          "title": "Executive Compensation Program Elements and 2022 Changes",
          "data": [
            {
              "key": "Overview",
              "value": "The document discusses the company's executive compensation program for 2022, including compensation analyses and services provided by Aon for the Compensation Committee."
            },
            {
              "key": "Base Salary Component",
              "value": "A table describes the Base Salary (Fixed, Cash) element, its key characteristics (fixed amount paid periodically, reviewed annually), and 2022 changes including a 5% increase for the CEO and a 14% increase for the CFO."
            },
            {
              "key": "Additional Compensation Components",
              "value": "Another table details components such as Long-Term Incentives (variable, equity-based awards with a vesting schedule of 25% at one-year, then 36 equal monthly installments) and Retirement Benefits (defined contribution plan with discretionary Company match)."
            },
            {
              "key": "Other Details",
              "value": "Additional notes mention that the CMO, hired in 2022, did not receive a base salary, and that further details on employment agreements and post-termination severance/change in control arrangements are provided on subsequent pages."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 51,
          "title": "Executive Compensation Details: Pay Mix and Base Salary",
          "data": [
            {
              "key": "Compensation Program Overview",
              "value": "The program is designed to motivate management to achieve corporate objectives and increase shareholder value through incentive plans. It emphasizes variable, at-risk pay elements that reward higher performance and reduce incentive payouts when performance falls below targeted levels."
            },
            {
              "key": "2022 CEO and NEOs Pay Mix Comparison",
              "value": "A chart breakdown shows for the CEO: Base Salary 49%, Annual Short Term Incentive 19%, Long Term Incentive 32%, and Performance Based Compensation 51%. For Other NEOs: Base Salary 49%, Annual Short Term Incentive 17%, Long Term Incentive 34%, and Performance Based Compensation 51%. The chart is represented using pie charts with performance-based compensation highlighted."
            },
            {
              "key": "Base Salary Philosophy",
              "value": "Base salary is provided as a fixed cash component that is not subject to performance risk, ensuring steady income. It plays a crucial role in retaining executives by offering financial stability irrespective of market fluctuations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 52,
          "title": "Executive Compensation Details for Fiscal 2022 vs Fiscal 2021",
          "data": [
            {
              "key": "Base Salary Comparison",
              "value": "Rick Pauls: $529,000 in 2022 (5% increase from $504,185 in 2021); Kirsten Gruis, M.D.: $380,000 in 2022 (new hire, no 2021 data); Scott Kellen: $340,000 in 2022 (14% increase from $297,567 in 2021)."
            },
            {
              "key": "STI Percentage of Base Salary",
              "value": "Rick Pauls: 50%; Kirsten Gruis, M.D.: 40%; Scott Kellen: 40%."
            },
            {
              "key": "STI Payout Details",
              "value": "Rick Pauls: Target bonus $264,500, Actual payout $198,342; Kirsten Gruis, M.D.: Target bonus $152,000, Actual payout $137,085; Scott Kellen: Target bonus $136,000, Actual payout $101,983."
            },
            {
              "key": "Additional Compensation Context",
              "value": "In April 2022, the Compensation Committee approved base salary increases (approximately 5% for the CEO and 14% for the CFO) to align salaries with peer group targets and cost of living adjustments. The STI program ties bonus payouts to the achievement of corporate and individual performance goals, including responses to an FDA-imposed clinical hold on the ReMEDy2 trial."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 53,
          "title": "Executive Compensation – Stock Option Grants",
          "data": [
            {
              "key": "Compensation Objective",
              "value": "Align the interests of executives with those of shareholders through stock option grants."
            },
            {
              "key": "Incentive Mechanism",
              "value": "Stock options with vesting provisions that incentivize long-term company performance and retention of executives."
            },
            {
              "key": "Plan Reference",
              "value": "DiaMedica Therapeutics Inc. 2021 Employment Inducement Incentive Plan (for Dr. Kirsten Gruis)"
            },
            {
              "key": "Table Title",
              "value": "Stock Option Grants to Executives"
            },
            {
              "key": "Table Summary",
              "value": "This table shows stock option grants to three company executives. Dr. Kirsten Gruis received the highest value grant of $487,789 for 160,000 shares at an exercise price of $3.88 in January 2022. Rick Pauls received 177,000 shares valued at $343,819 and Scott Kellen received 60,000 shares valued at $116,549, both granted in June 2022 at an exercise price of $2.45."
            },
            {
              "key": "Rick Pauls oe",
              "value": "Grant Date: 06/01/22; Grant Date Fair Value: 343819; Number of Shares: 177000; Exercise Price: 2.45"
            },
            {
              "key": "Kirsten Gruis, M.D.",
              "value": "Grant Date: 01/03/22; Grant Date Fair Value: 487789; Number of Shares: 160000; Exercise Price: 3.88"
            },
            {
              "key": "Scott Kellen",
              "value": "Grant Date: 06/01/22; Grant Date Fair Value: 116549; Number of Shares: 60000; Exercise Price: 2.45"
            },
            {
              "key": "Additional Details",
              "value": "The grant arrangement emphasizes vesting schedules: 25% vests at the one-year anniversary of the grant date and the remaining 75% vests in nearly equal monthly installments over the following 36 months."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 54,
          "title": "Severance and Change in Control Arrangements for Executives",
          "data": [
            {
              "key": "Severance Benefits - Termination Without Cause",
              "value": "Under the employment agreements, if an executive is terminated without 'cause', they are entitled to salary continuation (12 months for Mr. Pauls and 9 months for other executives), COBRA premium reimbursement, a pro rata portion of the annual bonus for the year of termination, and immediate acceleration of equity awards, subject to executing a separation agreement and release of claims."
            },
            {
              "key": "Definition of 'Cause'",
              "value": "Defined to include gross negligence, willful failure to perform duties, fraud, theft, embezzlement, financial dishonesty, other misconduct, conviction or plea for felony or crimes involving dishonesty, uncured material breach of obligations, or termination in connection with a liquidation, dissolution, or winding down of DiaMedica."
            },
            {
              "key": "Change in Control Arrangements",
              "value": "Designed to mitigate disruption from corporate transactions. Under the 2019 Plan and employment agreements, changes in control may trigger accelerated vesting of outstanding awards, substitution of shares, and, if termination occurs without cause or for good reason within 12 months after a change in control, extended salary continuation (18 months for Mr. Pauls and 12 months for other executives), COBRA reimbursement, pro rata bonus, and equity awards acceleration."
            },
            {
              "key": "Review Process",
              "value": "The Compensation Committee reviews these severance and change in control arrangements periodically to ensure they remain fair and appropriate."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 55,
          "title": "Change in Control & Indemnification in Executive Compensation",
          "data": [
            {
              "key": "Good Reason Definition",
              "value": "Defined in employment agreements as the executive’s resignation within 30 days following the expiration of any cure period after events such as a material reduction in duties, authority, reporting level, or base compensation, or a relocation of the executive’s service location by more than 50 miles without written consent."
            },
            {
              "key": "Change in Control Definition",
              "value": "Occurs if any individual, entity, or group acquires 50% or more of the company’s common shares or voting power, if there is a reorganization, merger or consolidation where pre-existing owners lose majority control, or if there is a sale/disposition of all or substantially all of the company’s assets."
            },
            {
              "key": "Program Rationale",
              "value": "These change in control benefits are an important part of the executive compensation program as they mitigate risk for executives in a smaller company context and are designed to attract and retain qualified executives."
            },
            {
              "key": "Indemnification Agreements",
              "value": "The company has entered into indemnification agreements with all executive officers, covering expenses and liabilities incurred in legal proceedings, subject to conditions including the executive acting in good faith and in the best interests of the company."
            },
            {
              "key": "Review Process",
              "value": "The Compensation Committee periodically reviews the change in control arrangements to ensure they remain necessary, appropriate, fair, and reasonable."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 56,
          "title": "Executive Compensation Overview",
          "data": [
            {
              "key": "Summary",
              "value": "The document provides summary information regarding all compensation awarded, earned, or paid to the named executive officers during the 2022 and 2021 fiscal years. It includes details on base salary, option awards, non-equity incentive plan compensation, and other compensation components. No discretionary bonuses were paid."
            },
            {
              "key": "Key Executives",
              "value": "Rick Pauls, President and CEO; Kirsten Gruis, M.D., Chief Medical Officer; Scott Kellen, Chief Financial Officer."
            },
            {
              "key": "Compensation Highlights",
              "value": "Rick Pauls earned total compensations of $1,080,607 in 2022 and $1,136,169 in 2021. Kirsten Gruis received $1,004,691 in 2022, and Scott Kellen earned $563,574 in 2022 and $546,720 in 2021. Base salary, option awards, and non-equity incentive plan compensations are the major components, with uniform 'All Other Compensation' of approximately $15,650 for each executive."
            },
            {
              "key": "Equity Awards Valuation",
              "value": "Stock options are valued at grant-date fair values determined using the Black-Scholes model in accordance with ASC Topic 718. Two grants in 2022 were valued at $1.94 per share, while a July 2021 grant was valued at $3.05 per share."
            },
            {
              "key": "Employee Benefits",
              "value": "Each executive received a 401(k) match of $12,200 and a Health Savings Account contribution of $3,450, totaling $15,650 in All Other Compensation."
            },
            {
              "key": "Additional Note",
              "value": "Ms. Kirsten Gruis was appointed as an executive officer on January 3, 2022, and did not serve as an executive in the 2021 fiscal year."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 57,
          "title": "Outstanding Equity Awards at Fiscal Year-End",
          "data": [
            {
              "key": "Table Title",
              "value": "Stock Options and Equity Holdings Summary"
            },
            {
              "key": "Description",
              "value": "Table presents outstanding equity awards for named executive officers as of December 31, 2022. It details exercisable stock options, unexercisable options, and unvested shares along with their corresponding values and expiration dates."
            },
            {
              "key": "Rick Pauls",
              "value": "Exercisable Options: 6 entries - 10,000 options (CAD$ 21.40, exp 06/25/2023), 67,500 (CAD$ 3.00, exp 12/01/2025), 42,500 (CAD$ 5.20, exp 11/28/2026), 42,500 (CAD$ 6.40, exp 06/19/2027), 33,500 (CAD$ 11.20, exp 04/17/2028), 264,000 (US$ 4.60, exp 06/23/2029); Unvested Shares: 1,749 (US$ 2,760)"
            },
            {
              "key": "Kirsten Gruis, M.D.",
              "value": "Exercisable Options: 2 entries - 46,667 (US$ 4.64, exp 05/31/2030) and 54,688 (US$ 5.00, exp 07/27/2031); Unexercisable Options: 2 entries - 9,333 (US$ 4.64, exp 05/31/2030) and 120,312 (US$ 5.00, exp 07/27/2031)"
            },
            {
              "key": "Scott Kellen",
              "value": "Exercisable Options: 3 entries - 160,000 (US$ 2.45, exp 01/02/2032), 50,250 (CAD$ 11.20, exp 04/17/2028), and 99,750 (US$ 4.60, exp 06/23/2029); No unexercisable options reported"
            },
            {
              "key": "General Summary",
              "value": "The exercise prices range from US$2.45 to CAD$21.40 with expirations from 2023 to 2032. One executive also recorded a figure for unvested shares, and further details regarding DSU awards and valuation methodologies are provided in the notes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 58,
          "title": "Employee Benefit and Stock Plans Amended and Restated 2019 Omnibus Incentive Plan",
          "data": [
            {
              "key": "Plan Name",
              "value": "2019 Omnibus Incentive Plan"
            },
            {
              "key": "Company",
              "value": "The DiaMedica Therapeutics Inc."
            },
            {
              "key": "Board Adoption Date",
              "value": "March 14, 2019"
            },
            {
              "key": "Shareholder Approval Date",
              "value": "May 22, 2019"
            },
            {
              "key": "Amendment",
              "value": "Amended in 2022 to increase the number of shares available"
            },
            {
              "key": "Common Shares Authorized",
              "value": "4,000,000"
            },
            {
              "key": "Maximum Incentive Stock Options",
              "value": "2,000,000"
            },
            {
              "key": "Non-Employee Director Award Limit",
              "value": "$400,000 (increased to $600,000 for Chairman/lead independent director or during initial service year)"
            },
            {
              "key": "Eligible Participants",
              "value": "Employees, non-employee directors, and consultants"
            },
            {
              "key": "Award Types",
              "value": "Non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards, and other stock-based awards"
            },
            {
              "key": "Transferability",
              "value": "Awards are generally non-transferable except as provided under the plan or by law"
            },
            {
              "key": "Termination Rules",
              "value": "Specifies defaults for termination events including cause, death, disability, and retirement with associated vesting and forfeiture conditions"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 59,
          "title": "Stock Award Termination and Adjustment Provisions under 2019 Plan",
          "data": [
            {
              "key": "Award Vesting and Termination",
              "value": "If a participant's employment or service is terminated for reasons other than cause, death, disability, or retirement, stock options and stock appreciation rights remain exercisable for three months, while outstanding restricted stock and unvested awards are forfeited. For performance-based awards, vesting may be prorated based on the portion of the performance period completed."
            },
            {
              "key": "Adjustment Provisions",
              "value": "In events such as reorganization, merger, stock splits, rights offerings, and other corporate changes, the Board of Directors will adjust or substitute securities to prevent dilution or enlargement of award rights. Adjustments may include changes to the number, kind, and exercise price of securities subject to outstanding awards."
            },
            {
              "key": "Plan Term and Amendments",
              "value": "The 2019 Plan terminates at midnight on May 21, 2029. No awards are granted after termination, though outstanding awards remain subject to existing terms. The Board of Directors retains the authority to amend or terminate the plan, with any adverse amendments requiring written consent from the affected award holders."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 60,
          "title": "Employment Inducement Plan",
          "data": [
            {
              "key": "Plan Name",
              "value": "Employment Inducement Plan"
            },
            {
              "key": "Adoption Date",
              "value": "December 3, 2021"
            },
            {
              "key": "Purpose",
              "value": "Facilitate the granting of equity awards as inducement for new employees"
            },
            {
              "key": "Approval Method",
              "value": "Adopted by the Board without shareholder approval pursuant to Nasdaq Listing Rule 5635(c)(4)"
            },
            {
              "key": "Shares Reserved",
              "value": "1,000,000 common shares"
            },
            {
              "key": "Eligible Recipients",
              "value": "New employees meeting the Nasdaq Listing Rule standards (5635(c)(4) or 5635(c)(3))"
            },
            {
              "key": "Administered By",
              "value": "Compensation Committee"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 60,
          "title": "Prior Stock Option Plan",
          "data": [
            {
              "key": "Plan Name",
              "value": "DiaMedica Therapeutics Inc. Amended and Restated Stock Option Plan"
            },
            {
              "key": "Board Adoption Date",
              "value": "September 30, 2018"
            },
            {
              "key": "Shareholder Approval Date",
              "value": "November 6, 2018"
            },
            {
              "key": "Plan Termination",
              "value": "Terminated for future grants upon shareholder approval of the 2019 Plan"
            },
            {
              "key": "Outstanding Options",
              "value": "Remain exercisable under applicable terms and conditions"
            },
            {
              "key": "Termination Provisions",
              "value": "Options may cease exercisability upon termination, subject to Board discretion"
            },
            {
              "key": "Corporate Actions",
              "value": "Equitable adjustments for any change in outstanding common shares due to corporate reorganizations"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 60,
          "title": "Prior Deferred Share Unit Plan",
          "data": [
            {
              "key": "Plan Name",
              "value": "Deferred Share Unit Plan"
            },
            {
              "key": "Board Adoption Date",
              "value": "August 25, 2011"
            },
            {
              "key": "Shareholder Approval Date",
              "value": "September 22, 2011"
            },
            {
              "key": "Plan Termination",
              "value": "Terminated for future grants upon shareholder approval of the 2019 Plan"
            },
            {
              "key": "Award Settlement",
              "value": "DSU awards settle and underlying shares become issuable only after termination of employment or service"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 62,
          "title": "RELATED PERSON RELATIONSHIPS AND TRANSACTIONS",
          "data": [
            {
              "key": "Description",
              "value": "Disclosure of related party transactions including consulting services provided by Trident Rx Consulting Services LLC, a company owned by Sydney Gilman, Ph.D. (former VP of Regulatory Affairs)."
            },
            {
              "key": "Transaction Details",
              "value": "In 2021, $149,000 was paid for regulatory consulting services, where fees were based solely on hourly rates with no markup to Dr. Gilman."
            },
            {
              "key": "Indemnification Agreements",
              "value": "The document also outlines indemnification agreements for directors and executive officers covering expenses and liabilities."
            },
            {
              "key": "Review Process",
              "value": "The Audit Committee reviewed and approved the transactions under written policies, ensuring no conflicts with related party members."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 75,
          "title": "Form 10-K Table of Contents",
          "data": [
            {
              "key": "Company",
              "value": "DIAMEDICA THERAPEUTICS INC."
            },
            {
              "key": "Report Type",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Fiscal Year Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "Sections Included",
              "value": "INDUSTRY and Market Data; PART I - Business, Risk Factors, Unresolved Staff Comments, Properties, Legal Proceedings, Mine Safety Disclosures, Market for Registrant's Common Equity, etc.; PART II - Directors, Executive Officers and Corporate Governance, Executive Compensation; Security Ownership; Related Transactions; and finally, PART IV - Exhibits and Financial Statement Schedules, Form 10-K Summary"
            },
            {
              "key": "Summary",
              "value": "This page presents the Table of Contents for the Form 10-K filing, outlining the major sections of the annual report. Notably, it includes an item on Executive Compensation under the corporate governance section."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 83,
          "title": "DM199 Clinical Trial Results Summary",
          "data": [
            {
              "key": "Treatment Target Population",
              "value": "Represents the participants most closely aligned with the target treatment population for DM199 in the ReMEDy2 trial."
            },
            {
              "key": "Phase 2 REDUX trial Summary",
              "value": "Interim data from our Phase 2 REDUX trial of DM199 in CKD was presented."
            },
            {
              "key": "Hypertensive African American Cohort Outcomes",
              "value": "Demonstrated an over 50% mean reduction in albuminuria and significant reductions in blood pressure after treatment."
            },
            {
              "key": "IgA Nephropathy Cohort Outcomes",
              "value": "Showed an average of over 30% decrease in albuminuria and early signals of potential disease modification."
            },
            {
              "key": "Adverse Events Summary",
              "value": "Primary adverse events included headache, erythema, dizziness, and local site reactions."
            },
            {
              "key": "Market Analysis of KLK1",
              "value": "Approximately 20 companies are marketing KLK1 in Asia for various diseases."
            },
            {
              "key": "Correlation Between KLK1 Levels and Stroke Recurrence",
              "value": "Lower KLK1 levels are predictors of stroke recurrence."
            },
            {
              "key": "Cumulative Event-Free Survival Data",
              "value": "Data presented in a survival curve format over a period of 60 months."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 135,
          "title": "Disclosure Exemptions and Reduced Executive Compensation Requirements",
          "data": [
            {
              "key": "Exemptions",
              "value": "Not required to comply with auditor attestation requirements under Section 404 of Sarbanes-Oxley, mandatory audit firm rotation, or provide additional audit report disclosures."
            },
            {
              "key": "Executive Compensation Disclosure",
              "value": "Reduced disclosure obligations regarding executive compensation and exemptions from holding non-binding advisory votes on executive compensation and golden parachute payments."
            },
            {
              "key": "Company Status",
              "value": "Emerging growth company and smaller reporting company, subject to scaled disclosure requirements."
            },
            {
              "key": "Market Impact Risk",
              "value": "Potential for less active trading and increased share price volatility due to reduced disclosures."
            },
            {
              "key": "Jurisdictional Considerations",
              "value": "Governed by British Columbia corporate laws (BCBCA) with differences compared to U.S. regulations, affecting shareholder rights and corporate transactions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 162,
          "title": "Share-based Compensation Details",
          "data": [
            {
              "key": "Common share fair value",
              "value": "$1.47 — $3.88"
            },
            {
              "key": "Risk-free interest rate",
              "value": "1.4-3.6%"
            },
            {
              "key": "Expected dividend yield",
              "value": "0%"
            },
            {
              "key": "Expected option life (in years)",
              "value": "5.0—5.6"
            },
            {
              "key": "Expected stock price volatility",
              "value": "102.1 — 104.0%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 162,
          "title": "Results of Operations Comparison",
          "data": [
            {
              "key": "Research and development expense",
              "value": "2022: 7,339; 2021: 8,765"
            },
            {
              "key": "General and administrative expense",
              "value": "2022: 6,162; 2021: 4,881"
            },
            {
              "key": "Other income, net",
              "value": "2022: -353; 2021: -82"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 185,
          "title": "2021 Employment Inducement Incentive Plan and Share-Based Compensation Expenses",
          "data": [
            {
              "key": "Plan Name",
              "value": "2021 Employment Inducement Incentive Plan"
            },
            {
              "key": "Adoption Date",
              "value": "December 3, 2021"
            },
            {
              "key": "Plan Purpose",
              "value": "Facilitate the granting of equity awards as an inducement to new employees"
            },
            {
              "key": "Governance",
              "value": "Adopted by the Board and administered by the Compensation Committee without shareholder approval pursuant to Nasdaq Listing Rule 5635(c)(4)"
            },
            {
              "key": "Share Reserve",
              "value": "1,000,000 common shares reserved for issuance under the Plan"
            },
            {
              "key": "Plan Term",
              "value": "10 years"
            },
            {
              "key": "Outstanding Options under Inducement Plan (as of December 31, 2022)",
              "value": "465,000 common shares"
            },
            {
              "key": "Prior Stock Option Plan Outstanding Options (as of December 31, 2022)",
              "value": "462,910 common shares"
            },
            {
              "key": "Prior Deferred Stock Unit Plan Outstanding DSUs (as of December 31, 2022)",
              "value": "17,333 common shares reserved for DSU settlement"
            },
            {
              "key": "Share-Based Compensation Expense - Research and Development",
              "value": "460 (prior period) and 463 (current period) in thousands"
            },
            {
              "key": "Share-Based Compensation Expense - General and Administrative",
              "value": "1042 (prior period) and 1095 (current period) in thousands"
            },
            {
              "key": "Total Share-Based Compensation Expense",
              "value": "1502 (prior period) and 1558 (current period) in thousands"
            },
            {
              "key": "Valuation Model",
              "value": "Black-Scholes option valuation model"
            },
            {
              "key": "Expense Recognition Note",
              "value": "Actual expense recognized over the vesting period will only be for those shares that actually vest"
            },
            {
              "key": "Table Title",
              "value": "Share-Based Compensation Expenses"
            },
            {
              "key": "Table Summary",
              "value": "The table shows compensation expenses across different functions with slight increases noted in general and administrative expenses and total expenses."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 186,
          "title": "Stock Options Activity and Compensation Summary",
          "data": [
            {
              "key": "Underlying Options",
              "value": "Increased from 1,389,564 on December 31, 2020 to 2,782,248 on December 31, 2022."
            },
            {
              "key": "Weighted Average Exercise Price",
              "value": "Decreased from $5.24 to $4.12 over the period."
            },
            {
              "key": "Stock Options Grants",
              "value": "Significant grants: 638,008 options in 2020 and 1,014,398 options in 2021."
            },
            {
              "key": "Aggregate Intrinsic Value",
              "value": "Dropped from $7,109 to $17."
            },
            {
              "key": "Unvested Shares and Fair Value",
              "value": "Unvested shares increased from 611,724 (December 31, 2021) to 1,241,137 (December 31, 2022) with weighted fair value per share declining from $3.21 to $2.31."
            },
            {
              "key": "Outstanding Options Details",
              "value": "Total of 2,782,248 outstanding shares, with 1,541,111 exercisable; largest tranche within the $4.00-$4.99 exercise price range."
            },
            {
              "key": "Grant Date Fair Value and Compensation Expense",
              "value": "Cumulative grant date fair value of vested options was $1.0M in 2022 and $1.3M in 2021; options exercised generated $0 in 2022 versus $244,000 in 2021; $2.4M unrecognized compensation expense for unvested options is to be expensed over a weighted-average period of 2.7 years."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 187,
          "title": "Executive Compensation Disclosure: Stock Options & Equity Awards",
          "data": [
            {
              "key": "Aggregate Intrinsic Value - 2022",
              "value": "$0"
            },
            {
              "key": "Aggregate Intrinsic Value - 2021",
              "value": "$132,000"
            },
            {
              "key": "Common Share Fair Value (2022)",
              "value": "$1.47 — $3.88"
            },
            {
              "key": "Common Share Fair Value (2021)",
              "value": "$3.64 — $10.04"
            },
            {
              "key": "Risk-free Interest Rate (2022)",
              "value": "1.4—3.6%"
            },
            {
              "key": "Risk-free Interest Rate (2021)",
              "value": "0.5 — 1.3%"
            },
            {
              "key": "Expected Dividend Yield",
              "value": "0% (both periods)"
            },
            {
              "key": "Expected Option Life (2022)",
              "value": "5.0-5.6 years"
            },
            {
              "key": "Expected Option Life (2021)",
              "value": "5.0-5.5 years"
            },
            {
              "key": "Expected Stock Price Volatility (2022)",
              "value": "102.1 — 104.0%"
            },
            {
              "key": "Expected Stock Price Volatility (2021)",
              "value": "94.7 — 106.1%"
            },
            {
              "key": "Vested Deferred Stock Units (DSUs)",
              "value": "134,000 units as of December 31, 2022; 68,000 units as of December 31, 2021"
            },
            {
              "key": "RSUs Outstanding",
              "value": "None"
            },
            {
              "key": "Common Shares Issued upon DSU Settlement (2021)",
              "value": "3,850 shares issued to a former non-employee director"
            },
            {
              "key": "401(k) Plan Contribution Expense (2022)",
              "value": "$112,000"
            },
            {
              "key": "401(k) Plan Contribution Expense (2021)",
              "value": "$87,000"
            },
            {
              "key": "Related Party Transaction - Consulting Charges (2021)",
              "value": "$149,000 invoiced for consulting services provided by a firm owned by a former VP of Regulatory Affairs"
            },
            {
              "key": "Description",
              "value": "Details include stock option intrinsic values, Black-Scholes valuation assumptions, non-employee director equity-based compensation (DSUs/RSUs), and employee benefit (401(k)) plan contributions."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 192,
          "title": "Directors, Executive Officers, Corporate Governance and Executive Compensation",
          "data": [
            {
              "key": "Corporate Governance",
              "value": "The document incorporates information regarding the election of directors, details on directors and executive officers, and corporate governance practices by reference to the definitive proxy statement filed with the SEC. It includes information on the 'Voting Proposal One – Election of Directors' and other related sections."
            },
            {
              "key": "Code of Ethics",
              "value": "A code of business conduct and ethics applicable to directors, officers, and employees has been adopted. Changes or waivers are disclosed on the company website (www.diamedica.com) or via Form 8-K."
            },
            {
              "key": "Nomination Procedures",
              "value": "No material changes were made to the procedures by which shareholders may recommend nominees to the Board of Directors during the fourth quarter of fiscal 2022."
            },
            {
              "key": "Audit Committee Matters",
              "value": "Information regarding the Audit Committee is incorporated by reference from the definitive proxy statement."
            },
            {
              "key": "Executive Compensation",
              "value": "Item 11 details executive and director compensation, with information incorporated by reference from the definitive proxy statement to be filed with the SEC."
            },
            {
              "key": "Stock Ownership",
              "value": "Details on security ownership of significant beneficial owners and management are incorporated by reference from the definitive proxy statement."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 193,
          "title": "Equity Compensation Plan Information",
          "data": [
            {
              "key": "Plan Category (Approved)",
              "value": "Equity compensation plans approved by security holders"
            },
            {
              "key": "Number of Securities (Approved)",
              "value": "2,451,650"
            },
            {
              "key": "Weighted-Average (Approved)",
              "value": "$4.94"
            },
            {
              "key": "Number of Securities Remaining Available (Approved)",
              "value": "2,005,260"
            },
            {
              "key": "Plan Category (Not Approved)",
              "value": "Equity compensation plans not approved by security holders"
            },
            {
              "key": "Number of Securities (Not Approved)",
              "value": "465,000"
            },
            {
              "key": "Weighted-Average (Not Approved)",
              "value": "$2.81"
            },
            {
              "key": "Number of Securities Remaining Available (Not Approved)",
              "value": "535,000"
            },
            {
              "key": "Plan Category (Total)",
              "value": "Total"
            },
            {
              "key": "Total Number of Securities",
              "value": "2,916,650"
            },
            {
              "key": "Total Weighted-Average",
              "value": "$4.12"
            },
            {
              "key": "Total Number of Securities Remaining Available",
              "value": "2,540,260"
            },
            {
              "key": "Additional Disclosure",
              "value": "Remaining Available for ______________________ (1) Amount includes 1,854,338 common shares issuable upon the exercise of stock options and 117,069 common shares issuable upon the settlement of DSU awards under the 2019 Plan, 462,910 common shares issuable under the Prior Plan and 17,333 common shares issuable under the DSU Plan. (2) Not included in the weighted-average exercise price calculation are 117,069 deferred stock unit awards under the 2019 Plan and 17,333 deferred stock unit awards under the DSU Plan. (3) On December 3, 2021, the Board adopted the Inducement Plan to facilitate the granting of equity awards as an inducement to new employees. Under the Inducement Plan, 1,000,000 common shares were reserved for issuance, and as of December 31, 2022, 465,000 option awards had been granted."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 194,
          "title": "Equity Compensation and Proxy Statement References",
          "data": [
            {
              "key": "shares_remaining_2019_plan",
              "value": "2,005,260"
            },
            {
              "key": "shares_remaining_2021_plan",
              "value": "535,000"
            },
            {
              "key": "related_section_item_13",
              "value": "Certain Relationships and Related Transactions, and Director Independence - incorporated by reference from the definitive proxy statement"
            },
            {
              "key": "related_section_item_14",
              "value": "Principal Accountant Fees and Services; Voting Proposal Two – Appointment of Baker Tilly US, LLP as our Independent Registered Public Accounting Firm and Authorization to Fix Remuneration - incorporated by reference from the definitive proxy statement"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 196,
          "title": "Exhibit Filings and Incentive Plans from DiaMedica Therapeutics Inc.",
          "data": [
            {
              "key": "Item No. 4.4",
              "value": "Warrant dated October 1, 2019 issued by DiaMedica Therapeutics Inc. to Craig- Hallum Capital Group LLC; Incorporated by reference to Exhibit 4.8 to DiaMedica's Annual Report on Form 10-K for the year ended December 31, 2019 (File No. 001-36291)"
            },
            {
              "key": "Item No. 4.5",
              "value": "Warrant dated September 11, 2020 issued by DiaMedica Therapeutics Inc. to Craig- Hallum Capital Group LLC; Incorporated by reference to Exhibit 4.1 to DiaMedica's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 (File No. 001-36291)"
            },
            {
              "key": "Item No. 4.6",
              "value": "Registration Rights Agreement dated as of September 28, 2021 among DiaMedica Therapeutics Inc. and the Purchasers Party Thereto; Incorporated by reference to Exhibit 4.5 to DiaMedica's Registration Statement on Form S-3 as filed with the Securities and Exchange Commission on October 5, 2021 (File No. 333-260066)"
            },
            {
              "key": "Item No. 10.1#",
              "value": "DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan; Incorporated by reference to Exhibit 10.1 to DiaMedica's Current Report on Form 8-K as filed with the Securities and Exchange Commission on May 19, 2022 (File No. 001-36291)"
            },
            {
              "key": "Item No. 10.2#",
              "value": "Form of Option Award Agreement under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan; Incorporated by reference to Exhibit 10.2 to DiaMedica's Annual Report on Form 10-K for the year ended December 31, 2021 (File No. 001-36291)"
            },
            {
              "key": "Item No. 10.3#",
              "value": "Form of Restricted Stock Unit Award Agreement under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan; Incorporated by reference to Exhibit 10.3 to DiaMedica's Current Report on Form 8-K as filed with the Securities and Exchange Commission on June 21, 2019 (File No. 001-36291)"
            },
            {
              "key": "Item No. 10.4#",
              "value": "Form of Deferred Stock Unit Award Agreement under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan; Incorporated by reference to Exhibit 10.1 to DiaMedica's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020 (File No. 001-36291)"
            },
            {
              "key": "Item No. 10.5#",
              "value": "DiaMedica Therapeutics Inc. 2021 Employment Inducement Incentive Plan; Incorporated by reference to Exhibit 10.5 to DiaMedica's Annual Report on Form 10-K for the year ended December 31, 2021 (File No. 001-36291)"
            },
            {
              "key": "Item No. 10.6#",
              "value": "Form of Inducement Option Award Agreement under the DiaMedica Therapeutics Inc. 2021 Employment Incentive Plan; Incorporated by reference to Exhibit 10.6 to DiaMedica's Annual Report on Form 10-K for the year ended December 31, 2021 (File No. 001-36291)"
            },
            {
              "key": "Plan Registration",
              "value": "Amended and Restated Plan as of November 6, DiaMedica’s Registration Statement on Form 2018 S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313) 120"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 197,
          "title": "Exhibit Index from DiaMedica Therapeutics SEC Filing",
          "data": [
            {
              "key": "Overview",
              "value": "The table is an exhibit index from a regulatory filing for DiaMedica Therapeutics Inc. It lists various corporate documents such as stock option agreements, a deferred share unit plan, a short-term incentive plan, employment agreements, a separation agreement, and a consulting services agreement."
            },
            {
              "key": "Key Documents",
              "value": "Includes Option Agreements under the DiaMedica Stock Option Plan, Employment Agreements for executives (Rick Pauls, Scott Kellen, Kirsten Gruis), a Separation Agreement with Harry Alcorn, Jr. Pharm.D., a Deferred Share Unit Plan, and related filing methods referencing exhibits in the SEC filings."
            },
            {
              "key": "SEC Filing References",
              "value": "Documents are incorporated by reference to DiaMedica's Registration Statement on Form S-1, Current Report on Form 8-K, and Annual Report on Form 10-K, as filed with the Securities and Exchange Commission."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 199,
          "title": "Document Filing Index and Management Contract Disclosure",
          "data": [
            {
              "key": "Item 32.2",
              "value": "Certification of Chief Financial Officer Pursuant to Rule 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Act of 2002 – Furnished herewith"
            },
            {
              "key": "Item 101",
              "value": "Filing of DiaMedica Therapeutics Inc.'s Annual Report on Form 10-K for the year ended December 31, 2022, presented in Inline XBRL including Consolidated Balance Sheets, Consolidated Statements of Operations, Consolidated Statements of Comprehensive Income (Loss), Consolidated Statements of Equity, Consolidated Statements of Cash Flows, and Notes to Consolidated Financial Statements – Filed herewith"
            },
            {
              "key": "Item 104",
              "value": "Cover Page Interactive Data File embedded within the Inline XBRL document"
            },
            {
              "key": "Management Contract Disclosure",
              "value": "Indicates a management contract or compensatory plan or arrangement. Portions of this exhibit have been redacted and are subject to an order granting confidential treatment under Rule 406 of the United States Securities Act of 1933 (File No. 333-228313, CF #36833); redacted material filed separately with the SEC."
            },
            {
              "key": "Item 16",
              "value": "Form 10-K Summary – None. 123"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": true,
      "elements": [
        {
          "type": "rnd_investment",
          "page": 81,
          "title": "Phase 2 REDUX Trial Update for DM199 in CKD",
          "data": [
            {
              "key": "Drug Candidate",
              "value": "DM199 (synthetic KLK1)"
            },
            {
              "key": "Clinical Trial Phase",
              "value": "Phase 2 REDUX trial"
            },
            {
              "key": "Indications",
              "value": "Chronic Kidney Disease (CKD) and IgA Nephropathy (IgAN)"
            },
            {
              "key": "Biomarker Results",
              "value": "APRIL decreased by 35%, IgA1 decreased by 22%, albuminuria reduced over 30% in IgAN cohort and over 50% in African American cohort"
            },
            {
              "key": "Regulatory Pathway",
              "value": "Fast Track product status with opportunities for pre-IND, end-of-phase meetings and potential rolling review"
            },
            {
              "key": "Mechanism of Action",
              "value": "Restores KLK1 levels to activate the kallikrein-kinin system (KKS) for vasodilation, anti-inflammatory effects, and tissue protection"
            },
            {
              "key": "Next Steps",
              "value": "Evaluating complete data set from the REDUX trial to determine future direction for the CKD program"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 82,
          "title": "Clinical Development and Trial Results Summary for DM199 (KLK1)",
          "data": [
            {
              "key": "Therapeutic Agent",
              "value": "DM199 (KLK1)"
            },
            {
              "key": "Mechanism of Action",
              "value": "Improves blood flow and reduces inflammation in damaged end-organs (brain, kidneys) by supporting structural integrity and normal functioning. Diagram illustrates the DM199 → Kininogen → Lys-Bradykinin → Nitric oxide/Prostaglandins pathway."
            },
            {
              "key": "Comparative Analysis",
              "value": "DM199 is structurally and functionally equivalent to KLK1 derived from human urine with similar enzymatic and pharmacokinetic profiles as porcine-derived KLK1."
            },
            {
              "key": "Clinical Trial Phase",
              "value": "Phase 2 ReMEDy1 trial"
            },
            {
              "key": "Key Clinical Outcomes",
              "value": "Active treatment group had 0% recurrent ischemic stroke vs. 13% placebo (p=0.012), with subgroup analysis showing a 22% absolute improvement in excellent outcomes (NIHSS 0-1) and reduced mortality (from 24% to 12%)."
            },
            {
              "key": "Therapeutic Indications",
              "value": "Acute Ischemic Stroke (AIS) and Chronic Kidney Disease (CKD)"
            },
            {
              "key": "Geographic Scope of Trials",
              "value": "United States, Europe, Australia"
            },
            {
              "key": "Future Outlook",
              "value": "DM199 may provide new treatment options with significant benefits and potentially fewer side effects compared to marketed KLK1 forms in Asia."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 84,
          "title": "Analysis of KLK1 Levels in Chronic Kidney Disease & DM199 Clinical Strategy",
          "data": [
            {
              "key": "Clinical Observation",
              "value": "Studies indicate that urinary KLK1 levels are significantly decreased in patients with chronic kidney disease, with a more pronounced decrease in severe cases requiring dialysis."
            },
            {
              "key": "Chart Data",
              "value": "Bar chart titled 'KLK1 Levels in Kidney Disease': Normal - 78 ng/μg, Mild - 17 ng/μg, Severe - 2 ng/μg; inverse relationship noted."
            },
            {
              "key": "References",
              "value": "Multiple studies cited from journals such as Clinical Nephrology, Immunopharmacology, Nephrology, Kidney International, J. Clin. Invest, Japanese J. Nephrology, Nephron, Lancet, and Gun. Nephrology (years ranging from 1972 to 2008)."
            },
            {
              "key": "Clinical Development Strategy",
              "value": "The company’s strategy focuses on executing the ReMEDy2 Phase 2/3 trial of DM199 in Acute Ischemic Stroke (AIS) and finalizing next steps for the CKD program. Emphasis is also on manufacturing process development for DM199 and seeking strategic partnerships for future clinical development and commercialization."
            },
            {
              "key": "Mission Statement",
              "value": "Improve the lives of people suffering from serious diseases through innovative clinical trials and therapeutic development."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 85,
          "title": "Unmet Medical Need in AIS and Next Generation Stroke Therapy Development",
          "data": [
            {
              "key": "ischemic_core_zone",
              "value": "Region with nearly complete loss of blood flow (below 10%-25%), leading to rapid energy depletion and neuronal apoptosis"
            },
            {
              "key": "ischemic_penumbra",
              "value": "Surrounding rim of tissue with mild to moderate ischemia that remains viable for several hours via collateral blood flow"
            },
            {
              "key": "mechanism_of_damage",
              "value": "Loss of glucose and oxygen, depletion of energy stores, loss of ion gradients triggering neuronal cell death; edema and intracranial pressure contribute further ischemia"
            },
            {
              "key": "stroke_statistics",
              "value": "Approximately 1.7 million people in the US, Europe, and Japan and 15 million worldwide suffer a stroke annually, with 5 million deaths and 5 million permanent disabilities"
            },
            {
              "key": "current_treatments",
              "value": "tPA (approved within 3 hours, typically administered up to 4.5 hours) and mechanical thrombectomy, which are applicable to only about 20% of ischemic stroke patients"
            },
            {
              "key": "therapy_candidate",
              "value": "KLK1 therapy (DM199) proposed with a treatment window of up to 24 hours, potentially addressing a significant unmet medical need in AIS patients"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 88,
          "title": "Retrospective Study Outcomes & CKD Background",
          "data": [
            {
              "key": "Study Cohort",
              "value": "300 consecutive AIS patients from a retrospective study published in Brain and Behavior (March 2018)"
            },
            {
              "key": "Stroke Outcome",
              "value": "Patients treated with human urinary KLK1 experienced a 6.5% absolute reduction (p=0.009) in recurrent strokes (39% relative) within one year"
            },
            {
              "key": "CKD Pathophysiology",
              "value": "CKD is characterized by a progressive decline in kidney function measured by eGFR and albuminuria; increased blood glucose leads to glomerular fibrosis, elevated blood pressure, reactive oxygen species and inflammation"
            },
            {
              "key": "Unmet Medical Need",
              "value": "CKD affects a large population (37 million Americans) with major economic burden; 1 in 3 Americans are at risk, and many eventually progress to end-stage renal disease requiring dialysis or transplant"
            },
            {
              "key": "Potential Therapeutic Candidate",
              "value": "DM199, leveraging KLK1 protein, is proposed as a novel approach for the treatment of CKD"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 96,
          "title": "CKD Clinical Trial Results for DM199",
          "data": [
            {
              "key": "Drug",
              "value": "DM199"
            },
            {
              "key": "Trial Name",
              "value": "REDUX"
            },
            {
              "key": "Study Populations",
              "value": "Cohort 1: Non-diabetic, hypertensive African Americans with Stage II/III CKD; Cohort 2: Participants with IgA Nephropathy; Cohort 3: Participants with Type 2 diabetes mellitus with CKD, hypertension and albuminuria"
            },
            {
              "key": "Treatment Regimen",
              "value": "Subcutaneous injection twice weekly for 95 days with two dose levels of DM199 evaluated in each cohort"
            },
            {
              "key": "Primary Endpoints",
              "value": "Safety, tolerability, blood pressure, albuminuria (UACR), and kidney function (eGFR change)"
            },
            {
              "key": "Interim Results",
              "value": "June 2021 and November 2021 interim announcements showed clinically meaningful improvements in kidney function in Cohorts 1 and 2, significant blood pressure reduction in hypertensive participants, and stability in eGFR"
            },
            {
              "key": "Enrollment",
              "value": "84 subjects total (24 African Americans in Cohort 1, 25 with IgAN in Cohort 2, and 35 with Type 2 diabetes in Cohort 3)"
            },
            {
              "key": "Phase 1b Trial",
              "value": "Completed in July 2019 for DM199 in moderate or severe CKD caused by diabetes; evaluated PK at three dose levels (3, 5, 8 µg/kg) and confirmed good tolerability"
            },
            {
              "key": "Safety Profile",
              "value": "DM199 was generally safe and well tolerated with mainly mild to moderate adverse events, the most common being local injection site irritation"
            },
            {
              "key": "Next Steps",
              "value": "Ongoing evaluation of the complete data set from the REDUX trial and planning further steps for the CKD program"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 100,
          "title": "Clinical Study Phases and FDA Approval Process",
          "data": [
            {
              "key": "Phase 1",
              "value": "Tests on volunteers at various doses to determine safe dosage range; decision to proceed to Phase 2."
            },
            {
              "key": "Phase 2",
              "value": "Controlled studies in patients with the disease; assessment of short-term safety, side effects, and general effectiveness; includes placebo or active comparator."
            },
            {
              "key": "Phase 3",
              "value": "Expanded trials with a larger patient population (often thousands); typically double-blinded and placebo-controlled to further assess safety and effectiveness."
            },
            {
              "key": "Phase 4",
              "value": "Post-approval studies to compare the drug with others and further monitor safety in broader patient groups."
            },
            {
              "key": "FDA Review",
              "value": "Submission of a New Drug Application (NDA) with comprehensive clinical and nonclinical data; includes advisory panel meeting for expert feedback."
            },
            {
              "key": "Marketing",
              "value": "Approved drug becomes available to physicians and patients; further research for additional uses may trigger new approval processes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 104,
          "title": "Intellectual Property and Patent Protection Strategy for DM199",
          "data": [
            {
              "key": "Protection Strategy",
              "value": "File patent applications to protect product candidates, manufacturing methods, administration and usage methods."
            },
            {
              "key": "Prior Art Searches",
              "value": "Conducted on patent and scientific databases to evaluate novelty, inventiveness and freedom-to-operate."
            },
            {
              "key": "Confidentiality Measures",
              "value": "Employees, consultants and collaborators execute confidentiality agreements to safeguard information and inventions."
            },
            {
              "key": "Patent Portfolio Overview",
              "value": "DM199 portfolio includes three granted U.S. patents, a granted European patent, a granted Canadian patent, and pending applications in Australia, Canada, China, Europe, India, Japan, Korea, Hong Kong and the United States."
            },
            {
              "key": "Patent Claims and Expirations",
              "value": "Issued patents cover compositions of matter and methods for treating diseases; expirations predicted in 2033 for certain claims and 2038 for others covering dose levels and regimens."
            },
            {
              "key": "Manufacturing and Licensing",
              "value": "Manufacturing is contracted with Catalent; related gene expression technology is licensed along with associated milestone and royalty arrangements."
            },
            {
              "key": "Competitive Protection",
              "value": "Reliance on proprietary technology, trade secrets, and specialized manufacturing knowledge to prevent reverse engineering and protect against competitors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 105,
          "title": "Patent Portfolio Analysis for Tissue Kallikrein 1 Technology",
          "data": [
            {
              "key": "Patent/Application Number",
              "value": "Issued patents"
            },
            {
              "key": "Title",
              "value": ""
            },
            {
              "key": "Geography",
              "value": ""
            },
            {
              "key": "Expiratio",
              "value": ""
            },
            {
              "key": "Patent/Application Number",
              "value": "US 9,364,521"
            },
            {
              "key": "Title",
              "value": "Human Tissue Kallikrein 1 Glycosylation Isoforms"
            },
            {
              "key": "Geography",
              "value": "US"
            },
            {
              "key": "Expiratio",
              "value": "2033"
            },
            {
              "key": "Patent/Application Number",
              "value": "US 9,839,678"
            },
            {
              "key": "Title",
              "value": "Human Tissue Kallikrein 1 Glycosylation Isoforms"
            },
            {
              "key": "Geography",
              "value": "US"
            },
            {
              "key": "Expiratio",
              "value": "2033"
            },
            {
              "key": "Patent/Application Number",
              "value": "CA 2880085"
            },
            {
              "key": "Title",
              "value": "Human Tissue Kallikrein 1 Glycosylation Isoforms"
            },
            {
              "key": "Geography",
              "value": "CA"
            },
            {
              "key": "Expiratio",
              "value": "2033"
            },
            {
              "key": "Patent/Application Number",
              "value": "EP 2 854 841"
            },
            {
              "key": "Title",
              "value": "Human Tissue Kallikrein 1 Glycosylation Isoforms"
            },
            {
              "key": "Geography",
              "value": "Europe"
            },
            {
              "key": "Expiratio",
              "value": "2033"
            },
            {
              "key": "Patent/Application Number",
              "value": "US 9,616,015"
            },
            {
              "key": "Title",
              "value": "Formulations for Human Tissue Kallikrein-1 for Parenteral Delivery and Related Methods"
            },
            {
              "key": "Geography",
              "value": "US"
            },
            {
              "key": "Expiratio",
              "value": "2033"
            },
            {
              "key": "Patent/Application Number",
              "value": "Pending applications"
            },
            {
              "key": "Title",
              "value": ""
            },
            {
              "key": "Geography",
              "value": ""
            },
            {
              "key": "Expiratio",
              "value": ""
            },
            {
              "key": "Patent/Application Number",
              "value": "AU 2018230478"
            },
            {
              "key": "Title",
              "value": "Dosage Forms of Tissue Kallikrein 1"
            },
            {
              "key": "Geography",
              "value": "Australia"
            },
            {
              "key": "Expiratio",
              "value": "2038"
            },
            {
              "key": "Patent/Application Number",
              "value": "CA 3054962"
            },
            {
              "key": "Title",
              "value": "Dosage Forms of Tissue Kallikrein 1"
            },
            {
              "key": "Geography",
              "value": "Canada"
            },
            {
              "key": "Expiratio",
              "value": "2038"
            },
            {
              "key": "Patent/Application Number",
              "value": "CN 201880016380.4"
            },
            {
              "key": "Title",
              "value": "Dosage Forms of Tissue Kallikrein 1"
            },
            {
              "key": "Geography",
              "value": "China"
            },
            {
              "key": "Expiratio",
              "value": "2038"
            },
            {
              "key": "Patent/Application Number",
              "value": "EP 18763243.5"
            },
            {
              "key": "Title",
              "value": "Dosage Forms of Tissue Kallikrein 1"
            },
            {
              "key": "Geography",
              "value": "Europe"
            },
            {
              "key": "Expiratio",
              "value": "2038"
            },
            {
              "key": "Patent/Application Number",
              "value": "IN 201917037712"
            },
            {
              "key": "Title",
              "value": "Dosage Forms of Tissue Kallikrein 1"
            },
            {
              "key": "Geography",
              "value": "India"
            },
            {
              "key": "Expiratio",
              "value": "2038"
            },
            {
              "key": "Patent/Application Number",
              "value": "JP 2019-548655"
            },
            {
              "key": "Title",
              "value": "Dosage Forms of Tissue Kallikrein 1"
            },
            {
              "key": "Geography",
              "value": "Japan"
            },
            {
              "key": "Expiratio",
              "value": "2038"
            },
            {
              "key": "Patent/Application Number",
              "value": "KR 10-2019-7026369"
            },
            {
              "key": "Title",
              "value": "Dosage Forms of Tissue Kallikrein 1"
            },
            {
              "key": "Geography",
              "value": "Korea"
            },
            {
              "key": "Expiratio",
              "value": "2038"
            },
            {
              "key": "Patent/Application Number",
              "value": "HK 62020009783.5"
            },
            {
              "key": "Title",
              "value": "Dosage Forms of Tissue Kallikrein 1"
            },
            {
              "key": "Geography",
              "value": "Hong Kong"
            },
            {
              "key": "Expiratio",
              "value": "2038"
            },
            {
              "key": "Patent/Application Number",
              "value": "US 16/492,059"
            },
            {
              "key": "Title",
              "value": "Dosage Forms of Tissue Kallikrein 1"
            },
            {
              "key": "Geography",
              "value": "US"
            },
            {
              "key": "Expiratio",
              "value": "2038"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 160,
          "title": "Research and Development Expenses",
          "data": [
            {
              "key": "R&D Expenses 2022",
              "value": "$7.8 million"
            },
            {
              "key": "R&D Expenses 2021",
              "value": "$8.8 million"
            },
            {
              "key": "G&A Expenses 2022",
              "value": "$6.2 million"
            },
            {
              "key": "G&A Expenses 2021",
              "value": "$4.9 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 163,
          "title": "Research and Development Expenses and Liquidity/Capital Resources Analysis",
          "data": [
            {
              "key": "R&D expenses 2022",
              "value": "$7.8 million"
            },
            {
              "key": "R&D expenses 2021",
              "value": "$8.8 million"
            },
            {
              "key": "Cost drivers",
              "value": "Reduced costs for REDUX Phase 2 CKD trial wrap-up and decreased non-clinical testing costs for Phase 2/3 ReMEDy2 trial preparation"
            },
            {
              "key": "Offset factors",
              "value": "Increased personnel costs for expanding R&D operations and increased manufacturing process development activities"
            },
            {
              "key": "Near-term expense outlook",
              "value": "Quarterly expenses expected to remain consistent until FDA lifts clinical hold on the IND for ReMEDy2 trial"
            },
            {
              "key": "G&A expenses 2022",
              "value": "$6.2 million"
            },
            {
              "key": "G&A expenses 2021",
              "value": "$4.9 million"
            },
            {
              "key": "G&A cost drivers",
              "value": "Increased directors’ and officers’ liability insurance, personnel and professional services costs, and legal fees for lawsuit against PRA; partially offset by reduced non-cash, share-based compensation"
            },
            {
              "key": "Other income 2022",
              "value": "$0.4 million"
            },
            {
              "key": "Other income 2021",
              "value": "$0.1 million"
            },
            {
              "key": "Other income driver",
              "value": "Increase in interest income due to higher interest rates in 2022"
            },
            {
              "key": "Table Title",
              "value": "Liquidity Capital"
            },
            {
              "key": "Cash, cash equivalents and marketable securities 2022",
              "value": "33502"
            },
            {
              "key": "Cash, cash equivalents and marketable securities 2021",
              "value": "45112"
            },
            {
              "key": "Total assets 2022",
              "value": "34395"
            },
            {
              "key": "Total assets 2021",
              "value": "45551"
            },
            {
              "key": "Total current liabilities 2022",
              "value": "2168"
            },
            {
              "key": "Total current liabilities 2021",
              "value": "1524"
            },
            {
              "key": "Total shareholders' equity 2022",
              "value": "31827"
            },
            {
              "key": "Total shareholders' equity 2021",
              "value": "44024"
            },
            {
              "key": "Working capital 2022",
              "value": "31667"
            },
            {
              "key": "Working capital 2021",
              "value": "43915"
            },
            {
              "key": "Liquidity summary",
              "value": "Significant decreases observed in cash, assets, shareholders' equity, and working capital, with an increase in current liabilities, indicating an overall reduction in financial position from 2021 to 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "rnd_investment",
          "page": 177,
          "title": "Operating Lease, R&D, Patent Costs and Share-Based Compensation Disclosure",
          "data": [
            {
              "key": "Operating Lease Disclosure",
              "value": "ROU asset and operating lease obligation are recognized based on the present value of lease payments over the lease term. The lease does not provide an implicit rate; incremental borrowing rate is estimated based on quoted rates for the lowest investment-grade debt and rates implicit in recent financing leases. Lease expense is recognized on a straight-line basis over the lease term, and lease modifications are evaluated separately if they grant additional rights of use."
            },
            {
              "key": "Research and Development Costs",
              "value": "Includes expenses incurred in human clinical trials, work performed by third-party service providers for clinical studies, sponsored non‐clinical research, development of manufacturing processes for the DM199 compound, and related personnel costs. Costs are expensed when incurred."
            },
            {
              "key": "Patent Costs",
              "value": "Costs for applying, prosecuting and maintaining patents are expensed as incurred. Reported amounts are $146,000 for 2022 and $96,000 for 2021, primarily consisting of legal expenses and filing/maintenance fees."
            },
            {
              "key": "Share-Based Compensation",
              "value": "Cost of employee and non-employee services received in exchange for equity awards is measured at grant date fair value and recognized ratably over the vesting period using a straight-line method. Forfeitures are recorded in the period they occur."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "rnd_investment",
          "page": 182,
          "title": "Operating Lease Maturities and R&D Commitments",
          "data": [
            {
              "key": "Operating Lease Table",
              "value": "Maturities of our operating lease obligation as of December 31, 2022 (in thousands): Year codes 024 to 028 with lease payments totaling 564, interest portion of -105, and a present value of lease obligation of 459. Notable lower payment in year code 028."
            },
            {
              "key": "Former Office Lease",
              "value": "Leased office space under a non-cancelable operating lease terminated on August 31, 2022; the right‐of‐use asset was fully amortized as of that date."
            },
            {
              "key": "Commitments and Contingencies – Clinical Trials and Product Development",
              "value": "Disclosure of future payment obligations related to clinical studies, manufacturing process development and related services (e.g., payments to contract research organizations, central laboratories, clinical study sites, etc.). Outstanding commitments are estimated at approximately $4.0 million over the next 12 months and ~$3.0 million for the following 12 months, excluding commitments contingent upon the resumption of the ReMEDy2 AIS trial."
            },
            {
              "key": "Clinical Trial Details",
              "value": "Description of the ReMEDy2 trial (a randomized, double-blind, placebo-controlled Phase 2/3 adaptive trial intended to enroll ~350 participants) and mention of the completed enrollment for the REDUX trial in patients with Stage II or III CKD."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 79,
          "title": "Business Overview and Clinical Trial Details",
          "data": [
            {
              "key": "Company Name",
              "value": "DiaMedica"
            },
            {
              "key": "Lead Candidate",
              "value": "DM199"
            },
            {
              "key": "Indication",
              "value": "Acute Ischemic Stroke (AIS), Chronic Kidney Disease (CKD)"
            },
            {
              "key": "Trial Name",
              "value": "ReMEDy2"
            },
            {
              "key": "Trial Phase",
              "value": "Phase 2/3"
            },
            {
              "key": "Trial Enrollment Status",
              "value": "Clinical hold placed by FDA"
            },
            {
              "key": "Primary Endpoint 1",
              "value": "Physical recovery from stroke (modified Rankin Scale at day 90)"
            },
            {
              "key": "Primary Endpoint 2",
              "value": "Rate of ischemic stroke recurrence through day 90"
            },
            {
              "key": "Participant Enrollment",
              "value": "Approximately 350 participants at up to 75 sites in the United States"
            },
            {
              "key": "Start of Trial",
              "value": "Initiated first site in September 2021"
            },
            {
              "key": "First Patient Enrolled",
              "value": "November 2021"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 86,
          "title": "Acute Ischemic Stroke Treatment Options & DM199 Launch",
          "data": [
            {
              "key": "Chart Title",
              "value": "Treatment Window Post Stroke is Critical"
            },
            {
              "key": "Treatment Options",
              "value": "tPA (Activase): 3-4.5 hours; Mechanical Thrombectomy (MT): 6+ hours; DM199: up to 24 hours"
            },
            {
              "key": "Timeline",
              "value": "From ONSET to 24 HOURS with intervals at 6, 12, 18, and 24 hours"
            },
            {
              "key": "Additional Info",
              "value": "Patient Coverage ~20%; MT note: extension limited to specific patients; DM199 note: most patients should reach hospital by 24 hours"
            },
            {
              "key": "CDC Stroke Statistics",
              "value": "Approximately 800,000 strokes per year in the US (600,000 first events, 200,000 recurrent), stroke every 40 seconds, death every 3.5 minutes, fifth leading cause of death, and $53 billion in stroke-related costs (2017-2018)"
            },
            {
              "key": "DM199 Potential",
              "value": "Increases cerebral blood flow, preserves at-risk brain tissue in the ischemic penumbra, improves stroke recovery, and reduces risk of stroke recurrence"
            },
            {
              "key": "Visualization Type",
              "value": "Timeline diagram showing treatment windows for different stroke interventions"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 87,
          "title": "DM199 Acute Ischemic Stroke: Proposed Mechanism",
          "data": [
            {
              "key": "Therapeutic Application",
              "value": "DM199 is being developed as a treatment for Acute Ischemic Stroke (AIS) patients with a therapeutic window up to 24 hours after symptom onset."
            },
            {
              "key": "Publication Date",
              "value": "January 2019"
            },
            {
              "key": "Publication Title",
              "value": "Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke"
            },
            {
              "key": "Journal",
              "value": "Therapeutic Advances in Neurological Disorders"
            },
            {
              "key": "Approved Treatments in China",
              "value": "Kailikang is approved for treatment of AIS in China."
            },
            {
              "key": "Market Approval and Company",
              "value": "Kailikang is marketed by Techpool Bio-Pharma Inc., under Shanghai Pharmaceuticals Holding Co. Ltd."
            },
            {
              "key": "Number of Patients Treated",
              "value": "Over 600,000 stroke patients were treated with Kailikang in 2021."
            },
            {
              "key": "Clinical Studies",
              "value": "More than 50 published clinical studies involving over 4,000 stroke patients demonstrated beneficial effects."
            },
            {
              "key": "Treatment Window",
              "value": "Initial treatment window is up to 48 hours after stroke symptom onset."
            },
            {
              "key": "Trial Results",
              "value": "A trial of 446 participants showed significant improvement in stroke scores with Kailikang."
            },
            {
              "key": "Meta-Analysis Conclusion",
              "value": "Human urinary KLK1 improves neurological deficits and long-term outcomes for AIS patients."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 89,
          "title": "DM199 – Our Novel Solution for the Treatment of CKD, Including Hypertensive Nephrosclerosis",
          "data": [
            {
              "key": "Product Name",
              "value": "DM199"
            },
            {
              "key": "Target Condition",
              "value": "Chronic Kidney Disease (CKD), including Hypertensive Nephrosclerosis"
            },
            {
              "key": "Mechanism of Action",
              "value": "Replenishes KLK1 levels to restore kidney function by promoting nitric oxide, prostaglandin production, and regulating the epithelial sodium channel (ENaC) to induce natriuresis and potentially lower blood pressure."
            },
            {
              "key": "Scientific Rationale",
              "value": "Observational studies indicate that reduced urinary KLK1 correlates with CKD severity. DM199 aims to directly replenish KLK1, thereby maintaining or restoring normal kidney function, a process that may avoid side effects seen with ACE inhibitors."
            },
            {
              "key": "Comparative Advantage",
              "value": "Unlike ACE inhibitors that can cause side effects such as persistent cough, angioedema, and hyperkalemia due to unregulated bradykinin levels, DM199 may offer a more targeted approach by only releasing BK as needed."
            },
            {
              "key": "Image Description",
              "value": "An anatomical diagram of a nephron, illustrating key components (afferent arteriole, efferent arteriole, renal tubule, peritubular capillaries) and functions such as glomerular blood flow regulation, ENaC regulation, and improvement of glomerular function."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 92,
          "title": "Clinical Pipeline and Treatment Strategies for CKD and IgAN",
          "data": [
            {
              "key": "Endothelin A receptor antagonists",
              "value": "Chinook Therapeutics, Inc."
            },
            {
              "key": "Cyclin nucleotide phosphodiesterase inhibitor",
              "value": "Pfizer Inc."
            },
            {
              "key": "Aldosterone synthase inhibitors",
              "value": "Cincor Pharma/AstraZeneca, Mineralys Therapeutics"
            },
            {
              "key": "Aldosterone receptor antagonists",
              "value": "Mitsubishi Tanabe Pharma Corporation"
            },
            {
              "key": "Nitric oxide enzyme inhibitor",
              "value": "GenKyoTex SA"
            },
            {
              "key": "Current CKD Treatment Strategies",
              "value": "Strict control of high blood pressure and high blood sugar; use of ACEi (e.g., Captopril®) and ARBs"
            },
            {
              "key": "ACEi Treatment Side Effects",
              "value": "Hyperkalemia, angioedema, persistent cough, abnormal heart rhythms, sudden death"
            },
            {
              "key": "SGLT-2 Inhibitors",
              "value": "INVOKANA® (canagliflozin) approved to reduce risk of ESRD, kidney function worsening, cardiovascular death, and hospitalization for heart failure; potential side effects include amputations, dehydration, diabetic ketoacidosis, and genital mycotic infections"
            },
            {
              "key": "Approved IgAN Treatment",
              "value": "TARPEYO™ (budesonide) granted accelerated FDA approval on December 15, 2021 for reduction of albuminuria in adult primary IgAN patients"
            },
            {
              "key": "IgAN Treatments in Development",
              "value": "Includes dual acting ARB and endothelin receptor antagonists (Travere Therapeutics, Inc.), MASP-2 antibody inhibitor (Omeros Corporation), complement factor B inhibitor (Novartis AG), Nrf2 activator/NFkB inhibitor (Reata Pharmaceuticals, Inc.), and APRIL inhibitor (Vera Therapeutic and Chinook Therapeutics)"
            },
            {
              "key": "DM199 Treatment",
              "value": "Aims to replenish KLK1 to restore kidney function; Phase 2/3 ReMEDy2 trial initiated with first site in September 2021 and first participant enrolled on November 16"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 115,
          "title": "Product Development for DM199 and DM300",
          "data": [
            {
              "key": "Cures Act",
              "value": "Modernizes regulation of drugs and stimulates innovation."
            },
            {
              "key": "FDA Guidance",
              "value": "Issues final guidance on antibacterial drugs for serious bacterial diseases."
            },
            {
              "key": "DM199 Status",
              "value": "Clinical stage of development with significant resources expended."
            },
            {
              "key": "Investment Requirement",
              "value": "Requires significant additional clinical testing and investment prior to marketing approval."
            },
            {
              "key": "Regulatory Approval Risks",
              "value": "Dependence on FDA approvals and success in clinical trials."
            },
            {
              "key": "Market Viability Timeline",
              "value": "Not expected to be viable for at least 3-4 years."
            },
            {
              "key": "Adverse Events",
              "value": "Noted hypotension events in clinical trials."
            },
            {
              "key": "DM300 Product Candidate",
              "value": "New product candidate in early preclinical stage for treating inflammatory diseases."
            },
            {
              "key": "Commercial Success Factors",
              "value": "Dependent on safety, efficacy, regulatory approvals, and market strategy."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 157,
          "title": "Management’s Discussion and Analysis & Clinical Development Pipeline",
          "data": [
            {
              "key": "Company",
              "value": "DiaMedica Therapeutics Inc. and its subsidiaries"
            },
            {
              "key": "Reporting Period",
              "value": "Years ended December 31, 2022 and 2021"
            },
            {
              "key": "Business Overview",
              "value": "Clinical stage biopharmaceutical company committed to improving lives with novel recombinant protein therapeutics"
            },
            {
              "key": "Focus Areas",
              "value": "Acute Ischemic Stroke (AIS) and Chronic Kidney Disease (CKD)"
            },
            {
              "key": "Lead Candidate",
              "value": "DM199 – recombinant human tissue kallikrein-1, being evaluated in clinical trials"
            },
            {
              "key": "Additional Candidate",
              "value": "DM300 – potential treatment for severe inflammatory diseases in the preclinical stage"
            },
            {
              "key": "Clinical Development Pipeline",
              "value": "Programs include: 'Acute Ischemic Stroke (AIS): DM199 IV/SC, ReMEDy2 Pivotal Phase 2/3 (Trial initiated and Fast track designation in September 2021)', 'Hypertensive Nephrosclerosis: DM199 SC, REDUX Phase 2 (Interim update Nov 2021, Study complete, Evaluating next steps)', 'IgA Nephropathy: DM199 SC, REDUX Phase 2 (Interim update Nov 2021, Study complete, Evaluating next steps)', 'Severe Inflammatory Diseases: DM300, Preclinical (Ongoing development)'"
            },
            {
              "key": "Risk Disclosures",
              "value": "Contains forward-looking statements subject to risks and uncertainties as detailed in the 'Cautionary Note Regarding Forward-Looking Statements'"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 204,
          "title": "DiaMedica Therapeutics Inc. Contact and Product Information",
          "data": [
            {
              "key": "Company",
              "value": "DiaMedica Therapeutics Inc."
            },
            {
              "key": "Address",
              "value": "301 Carlson Parkway, Ste 210 Minneapolis, MN 55305"
            },
            {
              "key": "Phone",
              "value": "+1.763.496.5454"
            },
            {
              "key": "Website",
              "value": "www.diamedica.com"
            },
            {
              "key": "Email",
              "value": "bd@diamedica.com"
            },
            {
              "key": "Image Data",
              "value": "BR25253X-0422-COMBO"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 181,
          "title": "Property, Equipment and Leasing Disclosures",
          "data": [
            {
              "key": "Vendor Funds Advance Terms",
              "value": "Periodic, interest-free advances to vendors supporting clinical trials; funds held for varying periods and recovered via invoice reductions, application on final invoices, or refunds upon service completion."
            },
            {
              "key": "Property and Equipment - Furniture and Equipment",
              "value": "Current period: $124K; Previous period: $70K"
            },
            {
              "key": "Property and Equipment - Computer Equipment",
              "value": "Current period: $76K; Previous period: $66K"
            },
            {
              "key": "Property and Equipment - Leasehold Improvements",
              "value": "Current period: $16K; Previous period: $1K"
            },
            {
              "key": "Property and Equipment - Gross Subtotal",
              "value": "Current period: $216K; Previous period: $137K"
            },
            {
              "key": "Property and Equipment - Less Accumulated Depreciation",
              "value": "Current period: -$80K; Previous period: -$67K"
            },
            {
              "key": "Property and Equipment - Net",
              "value": "Current period: $136K; Previous period: $70K"
            },
            {
              "key": "Depreciation Expense",
              "value": "$25K for year ended December 31, 2022; $24K for year ended December 31, 2021"
            },
            {
              "key": "Disposed Equipment",
              "value": "$12K in 2022; $17K in 2021"
            },
            {
              "key": "Accrued Liabilities - Total",
              "value": "Current period: $1,365K; Previous period: $966K"
            },
            {
              "key": "Operating Lease - New Office Lease",
              "value": "Lease agreement for approximately 6,000 sq ft office space in Minneapolis; Commenced September 1, 2022 with a 65-month term expiring January 31, 2028; includes five months of full rent abatement incentive (subject to repayment if default occurs before the 48th month); recognized right-of-use asset and corresponding liability of $446K; operating lease costs were $78K (2022) and $65K (2021); variable lease costs were $25K (2022) and $56K (2021)"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 39,
          "title": "Audit Committee Report",
          "data": [
            {
              "key": "Audit Committee Qualification",
              "value": "Determined that Mr. Parsons qualifies as an “audit committee financial expert” under SEC rules and meets Nasdaq Listing Rules criteria for financial sophistication."
            },
            {
              "key": "Audit Committee Role",
              "value": "Oversees DiaMedica’s accounting and financial reporting processes as well as the audit of its annual consolidated financial statements."
            },
            {
              "key": "Financial Statements Period",
              "value": "Year ended December 31, 2022"
            },
            {
              "key": "Audit Firm",
              "value": "Baker Tilly US, LLP"
            },
            {
              "key": "Audit Opinion",
              "value": "Unqualified opinion issued by Baker Tilly US, LLP"
            },
            {
              "key": "Report Date",
              "value": "March 9, 2023"
            },
            {
              "key": "SEC Filing",
              "value": "Recommended inclusion in DiaMedica’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 65,
          "title": "COPIES OF FISCAL 2022 ANNUAL REPORT AND ADDITIONAL INFORMATION",
          "data": [
            {
              "key": "Document Type",
              "value": "Annual Report on Form 10-K (without exhibits)"
            },
            {
              "key": "Fiscal Year Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "Content Highlights",
              "value": "Includes consolidated annual financial statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations"
            },
            {
              "key": "Access Information",
              "value": "Electronically available on www.diamedica.com, via SEC EDGAR (www.sec.gov) and SEDAR (www.sedar.com)"
            },
            {
              "key": "Exhibit Request",
              "value": "Exhibits available on SEC EDGAR; paper copies available upon written request with payment of expenses sent to DiaMedica Therapeutics Inc., 301 Carlson Parkway, Suite 210, Minneapolis, MN 55305"
            },
            {
              "key": "Proxy Voting Information",
              "value": "Shareholders are encouraged to vote their shares using internet, telephone, or paper proxy card"
            },
            {
              "key": "Signature",
              "value": "Richard Pilnik, Chairman of the Board, dated April 4, 2023, Minneapolis, Minnesota"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 72,
          "title": "This page intentionally left blank",
          "data": [],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 74,
          "title": "Страница намеренно оставлена пустой",
          "data": [
            {
              "key": "message",
              "value": "На данной странице отсутствует содержимое для анализа."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 161,
          "title": "Critical Accounting Policies, Estimates, and Research & Development Costs",
          "data": [
            {
              "key": "Insurance",
              "value": "Includes insurance expenses such as directors and officers liability coverage"
            },
            {
              "key": "Rent and Utilities",
              "value": "Expenses related to rent and utilities"
            },
            {
              "key": "Travel Expenses",
              "value": "Costs incurred for travel"
            },
            {
              "key": "Patent Costs",
              "value": "Costs associated with patents"
            },
            {
              "key": "Professional Fees",
              "value": "Fees for auditing, tax, legal services and other professional services"
            },
            {
              "key": "Milestone Payments",
              "value": "Payments under the technology license agreement with Catalent"
            },
            {
              "key": "Other Income, Net",
              "value": "Primarily interest income offset by foreign currency exchange losses"
            },
            {
              "key": "Critical Accounting Policies and Estimates",
              "value": "Discussion on management’s estimates for assets, liabilities, revenues, expenses and related disclosures in accordance with U.S. GAAP"
            },
            {
              "key": "Research and Development Costs",
              "value": "Includes costs for human clinical trials, fees to external service providers (e.g., CROs), contractual clinical development obligations, fees for contract manufacturing, laboratory testing, consulting resources, personnel costs, and expense recognition policy for clinical trials"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 167,
          "title": "Report of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Type",
              "value": "Independent auditor's report"
            },
            {
              "key": "Firm ID",
              "value": "PCAOB Firm ID 23"
            },
            {
              "key": "Contents",
              "value": "Consolidated Balance Sheets as of December 31, 2022 and 2021, Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2022 and 2021, Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021, Notes to Consolidated Financial Statements"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 168,
          "title": "REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM",
          "data": [
            {
              "key": "Company",
              "value": "DiaMedica Therapeutics Inc. and Subsidiaries"
            },
            {
              "key": "Financial Statements Date",
              "value": "December 31, 2022 and 2021"
            },
            {
              "key": "Audit Opinion",
              "value": "The consolidated financial statements present fairly, in all material respects, the financial position of the Company"
            },
            {
              "key": "Basis for Opinion",
              "value": "Audited in accordance with PCAOB standards; procedures included risk assessment, testing of evidence, and evaluation of accounting principles and significant estimates"
            },
            {
              "key": "Audit Firm",
              "value": "Baker Tilly US, LLP"
            },
            {
              "key": "Audit Opinion Date",
              "value": "March 28, 2023"
            },
            {
              "key": "Location",
              "value": "Minneapolis, MN"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 170,
          "title": "Operating Expenses and Income Statement",
          "data": [
            {
              "key": "Operating expenses: Research and development",
              "value": "2022: 7,839, 2021: 8,765"
            },
            {
              "key": "Operating expenses: General and administrative",
              "value": "2022: 6,162, 2021: 4,881"
            },
            {
              "key": "Operating expenses: Total operating expenses",
              "value": "2022: 14,001, 2021: 13,646"
            },
            {
              "key": "Operating expenses: Operating loss",
              "value": "2022: (14,001), 2021: (13,646)"
            },
            {
              "key": "Operating expenses: Other income, net",
              "value": "2022: 353, 2021: 82"
            },
            {
              "key": "Operating expenses: Loss before income tax",
              "value": "2022: (13,648), 2021: (13,564)"
            },
            {
              "key": "Operating expenses: Income tax expense",
              "value": "2022: (28), 2021: (28)"
            },
            {
              "key": "Operating expenses: Net loss",
              "value": "2022: (13,676), 2021: (13,592)"
            },
            {
              "key": "Operating expenses: Basic and diluted net loss per share",
              "value": "2022: (0.52), 2021: (0.65)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 172,
          "title": "Cash Flow Statement",
          "data": [
            {
              "key": "Summary",
              "value": "This is a cash flow statement comparing fiscal years 2022 and 2021. The company reported net losses in both years (-13,676 in 2022 and -13,592 in 2021). Despite similar operating losses, cash management improved in 2022, with net cash used in operating activities decreasing from -12,252 to -11,511. The company saw a significant reduction in marketable securities purchases (from -69,813 to -45,684) and ended both years with similar cash positions (approximately 4,707 at beginning and 4,728 at end in 2022). Notable is the absence of significant financing activities in 2022 compared to 2021, which provided 30,087."
            },
            {
              "key": "Net loss",
              "value": "2022: -13676; 2021: -13592"
            },
            {
              "key": "Share-based compensation",
              "value": "2022: 1502; 2021: 1558"
            },
            {
              "key": "Amortization of premium (discount) on marketable securities",
              "value": "2022: -11; 2021: 161"
            },
            {
              "key": "Non-cash lease expense",
              "value": "2022: 64; 2021: 58"
            },
            {
              "key": "Depreciation",
              "value": "2022: 25; 2021: 24"
            },
            {
              "key": "Amounts receivable",
              "value": "2022: 48; 2021: 210"
            },
            {
              "key": "Prepaid expenses and other assets",
              "value": "2022: -54; 2021: -123"
            },
            {
              "key": "Accounts payable",
              "value": "2022: 225; 2021: -590"
            },
            {
              "key": "Accrued liabilities",
              "value": "2022: 366; 2021: 42"
            },
            {
              "key": "Net cash used in operating activities",
              "value": "2022: -11511; 2021: -12252"
            },
            {
              "key": "Purchase of marketable securities",
              "value": "2022: -45684; 2021: -69813"
            },
            {
              "key": "Maturities of marketable securities",
              "value": "2022: 57303; 2021: 49296"
            },
            {
              "key": "Purchase of property and equipment",
              "value": "2022: -81; 2021: -22"
            },
            {
              "key": "Net cash provided by (used in) financing activities",
              "value": "2022: -6; 2021: 30087"
            },
            {
              "key": "Net increase (decrease) in cash and cash equivalents",
              "value": "2022: 21; 2021: -2702"
            },
            {
              "key": "Cash and cash equivalents at beginning of period",
              "value": "2022: 4707; 2021: 7409"
            },
            {
              "key": "Cash and cash equivalents at end of period",
              "value": "2022: 4728; 2021: 4707"
            },
            {
              "key": "Cash paid for income taxes",
              "value": "$27; See accompanying notes to consolidated financial statements; Additional figures: 96, 28"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 174,
          "title": "Financial Performance and Funding Requirements",
          "data": [
            {
              "key": "Net Loss (2022)",
              "value": "$13.7 million"
            },
            {
              "key": "Operating Cash Flow (2022)",
              "value": "Negative $11.5 million"
            },
            {
              "key": "Cumulative Loss since Inception",
              "value": "$96.2 million"
            },
            {
              "key": "Cash, Cash Equivalents and Marketable Securities (Dec 31, 2022)",
              "value": "$33.5 million"
            },
            {
              "key": "Working Capital (Dec 31, 2022)",
              "value": "$31.7 million"
            },
            {
              "key": "Shareholders’ Equity (Dec 31, 2022)",
              "value": "$31.8 million"
            },
            {
              "key": "Capital Funding Outlook",
              "value": "Substantial additional capital will be necessary to further R&D, complete clinical studies, secure regulatory approvals, and support ongoing operations"
            },
            {
              "key": "Financing Source",
              "value": "Historically, net proceeds from the issuance of equity securities"
            },
            {
              "key": "Risks Highlighted",
              "value": "Potential delays due to clinical hold, uncertain market conditions, and challenges in resolving operational issues"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 175,
          "title": "Accounting Policies and Financial Instruments",
          "data": [
            {
              "key": "functional_currency_change",
              "value": "A change in the functional currency occurs only when there is a material change in the underlying transactions, events and conditions. Such a change can result in material differences in the amounts recorded for foreign exchange gains and losses in the consolidated statements."
            },
            {
              "key": "currency_used",
              "value": "All amounts in the accompanying consolidated financial statements are in U.S. dollars unless otherwise indicated."
            },
            {
              "key": "use_of_estimates",
              "value": "The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts, with actual results potentially differing from those estimates."
            },
            {
              "key": "cash_and_cash_equivalents",
              "value": "Includes all bank deposits, money market funds, and other investments with an original maturity of three months or less, carried at amounts close to fair value due to short maturities."
            },
            {
              "key": "marketable_securities",
              "value": "Typically consist of U.S. government obligations, bank certificates of deposit, and investment grade corporate obligations classified as available-for-sale, with fair value adjustments recognized in shareholders’ equity."
            },
            {
              "key": "fair_value_measurements",
              "value": "Fair value is defined as the exit price in an orderly transaction and is measured using a hierarchy of observable inputs, ensuring that the most market-based inputs are utilized."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 176,
          "title": "Financial Instruments and Long-lived Assets Valuation",
          "data": [
            {
              "key": "financial_instruments_valuation_assumptions",
              "value": "The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement."
            },
            {
              "key": "valuation_hierarchy_levels",
              "value": "1. Level 1 Inputs — quoted prices in active markets for identical assets and liabilities; 2. Level 2 Inputs — observable inputs other than quoted prices in active markets for identical assets and liabilities; 3. Level 3 Inputs — unobservable inputs."
            },
            {
              "key": "fair_value_equity_liabilities",
              "value": "The carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments."
            },
            {
              "key": "credit_risk_exposure",
              "value": "Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities."
            },
            {
              "key": "long_lived_assets_depreciation",
              "value": "Property and equipment are stated at purchased cost less accumulated depreciation, computed using straight-line method over their estimated useful lives of three to ten years for office equipment and four years for computer equipment."
            },
            {
              "key": "impairment_evaluation",
              "value": "Long-lived assets are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable."
            },
            {
              "key": "leases_classification",
              "value": "Leases related to corporate offices are classified as operating leases."
            },
            {
              "key": "operating_lease_accounting",
              "value": "Our operating lease ROU asset represents our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 178,
          "title": "Financial Performance Metrics",
          "data": [
            {
              "key": "Option Award Valuation Model",
              "value": "Black-Scholes"
            },
            {
              "key": "Dividend Yield Assumption",
              "value": "0 (no expected dividends)"
            },
            {
              "key": "Net loss 2022",
              "value": "-13676"
            },
            {
              "key": "Net loss 2021",
              "value": "-13592"
            },
            {
              "key": "Weighted average shares outstanding—basic and diluted 2022",
              "value": "26443067"
            },
            {
              "key": "Weighted average shares outstanding—basic and diluted 2021",
              "value": "20773399"
            },
            {
              "key": "Basic and diluted net loss per share 2022",
              "value": "-0.52"
            },
            {
              "key": "Basic and diluted net loss per share 2021",
              "value": "-0.65"
            },
            {
              "key": "Summary",
              "value": "The table presents key financial metrics where similar net losses were recorded in 2021 and 2022, but with a reduction in loss per share due to an increase in weighted average shares outstanding."
            },
            {
              "key": "Deferred Tax Policy",
              "value": "Deferred tax assets and liabilities are measured under the asset and liability method using enacted rates, with full valuation allowances provided as of December 31, 2022 and 2021."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 179,
          "title": "Employee and non-employee stock options & Diluted EPS Disclosure",
          "data": [
            {
              "key": "Diluted EPS Disclosure",
              "value": "The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive"
            },
            {
              "key": "Employee and non-employee stock options (2022)",
              "value": "2,782,248"
            },
            {
              "key": "Employee and non-employee stock options (2021)",
              "value": "1,896,600"
            },
            {
              "key": "Common shares issuable under common share purchase warrants (2022)",
              "value": "265,000"
            },
            {
              "key": "Common shares issuable under common share purchase warrants (2021)",
              "value": "265,000"
            },
            {
              "key": "Common shares issuable upon settlement of deferred stock units (2022)",
              "value": "134,402"
            },
            {
              "key": "Common shares issuable upon settlement of deferred stock units (2021)",
              "value": "67,659"
            },
            {
              "key": "Total potential common shares (2022)",
              "value": "3,181,650"
            },
            {
              "key": "Total potential common shares (2021)",
              "value": "2,229,259"
            },
            {
              "key": "Table Summary",
              "value": "Employee and non-employee stock options increased significantly from 1,896,600 in 2021 to 2,782,248 in 2022; common share purchase warrants remained constant at 265,000 shares; deferred stock units increased from 67,659 to 134,402; overall potential share issuance rose by approximately 43%."
            },
            {
              "key": "Recent Accounting Pronouncements - Not Yet Adopted",
              "value": "ASU No. 2016-13 requires measurement of expected credit losses for financial assets held at amortized cost; effective for smaller reporting companies for fiscal years beginning after December 15, 2022, with early adoption permitted from periods after December 15, 2018. Planned early adoption on January 1, 2023 with no expected impact on consolidated financial statements."
            },
            {
              "key": "Recent Accounting Pronouncements - Adopted",
              "value": "ASU No. 2021-04 provides guidance on modifications or exchanges of freestanding equity-classified written call options; effective for smaller reporting companies for fiscal years beginning after December 15, 2021, with early adoption permitted. Adopted on January 1, 2022 with no material impact on consolidated financial statements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 180,
          "title": "Marketable Securities Fair Value Classification (Table 1)",
          "data": [
            {
              "key": "Categories",
              "value": "Commercial paper and corporate bonds: Fair Value = 14,209; Level 2 = 14,209. Government securities: Fair Value = 14,565; Level 2 = 14,565. Total marketable securities: Fair Value = 28,774; Level 2 = 28,774 (all values in thousands)."
            },
            {
              "key": "Summary",
              "value": "This table presents a breakdown of marketable securities by type and their fair value classification levels. All securities are classified as Level 2 instruments, with no Level 1 or Level 3 holdings."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 180,
          "title": "Marketable Securities Fair Value Classification (Table 2)",
          "data": [
            {
              "key": "Categories",
              "value": "Commercial paper and corporate bonds: Fair Value = 29,421; Level 2 = 29,421. Government securities: Fair Value = 10,984; Level 2 = 10,984. Total marketable securities: Fair Value = 40,405; Level 2 = 40,405."
            },
            {
              "key": "Summary",
              "value": "This table presents a breakdown of marketable securities by type and their fair value classification levels. As in Table 1, all securities are reported as Level 2 instruments with no Level 1 or Level 3 values provided."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 180,
          "title": "Amounts Receivable Breakdown",
          "data": [
            {
              "key": "Accrued interest receivable on marketable securities",
              "value": "Current period = 80; Previous period = 130 (in thousands)"
            },
            {
              "key": "Other",
              "value": "Current period = 2; Previous period = 0 (in thousands)"
            },
            {
              "key": "Total amounts receivable",
              "value": "Current period = 82; Previous period = 130 (in thousands)"
            },
            {
              "key": "Summary",
              "value": "The table presents a breakdown of amounts receivable, primarily from accrued interest on marketable securities, showing a decrease in the total from the previous period."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 180,
          "title": "Prepaid Expenses and Other Assets",
          "data": [
            {
              "key": "Prepaid expenses",
              "value": "Current value = 209; Previous value = 84 (in thousands)"
            },
            {
              "key": "Advances to vendors",
              "value": "Current value = 42; Previous value = 113 (in thousands)"
            },
            {
              "key": "Total prepaid expenses and other assets",
              "value": "Current value = 251; Previous value = 197 (in thousands)"
            },
            {
              "key": "Additional note",
              "value": "Separate disclosure: 'Prepaid expenses Advances to vendors 104' observed, potentially indicating an aggregated or reconciled figure."
            },
            {
              "key": "Summary",
              "value": "This table shows a significant increase in prepaid expenses and a decrease in advances to vendors, resulting in a net increase of $54 thousand in total prepaid expenses and other assets."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 180,
          "title": "Investment Policy and Fair Value Notes",
          "data": [
            {
              "key": "Accrued interest receivable on available-for-sale securities",
              "value": "2022 = $80,000; 2021 = $130,000 (included in amounts receivable)"
            },
            {
              "key": "Transfers between Fair Value Levels",
              "value": "No transfers of assets between Level 1 and Level 2 during the year ended December 31, 2022."
            },
            {
              "key": "Investment Policy",
              "value": "Purchases of marketable securities are limited to investment grade governmental and corporate obligations with a primary objective of principal preservation. Maturities of individual securities are less than one year, and the amortized cost approximates fair value as of December 31, 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 180,
          "title": "Note on Measurement Basis",
          "data": [
            {
              "key": "Measurement Basis",
              "value": "All fair value measurements are performed on a recurring basis using the relevant levels of the fair value hierarchy. The securities reported are primarily classified at Level 2."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 180,
          "title": "Amounts Receivable - Periodic Comparison (Additional Detail)",
          "data": [
            {
              "key": "Accrued interest receivable change",
              "value": "Declined from $130,000 in 2021 to $80,000 in 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 180,
          "title": "Prepaid Expenses and Other Assets - Periodic Comparison (Additional Detail)",
          "data": [
            {
              "key": "Net Change",
              "value": "Increase of $54,000 from 2021 to 2022."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 188,
          "title": "Income Taxes - Deferred Tax Assets (Liabilities)",
          "data": [
            {
              "key": "Non-capital losses carried forward 2022",
              "value": "21000"
            },
            {
              "key": "Non-capital losses carried forward 2021",
              "value": "17596"
            },
            {
              "key": "Research and development expenditures 2022",
              "value": "817"
            },
            {
              "key": "Research and development expenditures 2021",
              "value": "817"
            },
            {
              "key": "Share issue costs 2022",
              "value": "338"
            },
            {
              "key": "Share issue costs 2021",
              "value": "608"
            },
            {
              "key": "Patents and other 2022",
              "value": "320"
            },
            {
              "key": "Patents and other 2021",
              "value": "309"
            },
            {
              "key": "Accruals 2022",
              "value": "213"
            },
            {
              "key": "Accruals 2021",
              "value": "76"
            },
            {
              "key": "Share-based compensation 2022",
              "value": "166"
            },
            {
              "key": "Share-based compensation 2021",
              "value": "0"
            },
            {
              "key": "Property and equipment 2022",
              "value": "-117"
            },
            {
              "key": "Property and equipment 2021",
              "value": "-13"
            },
            {
              "key": "Total deferred tax asset, net 2022",
              "value": "22737"
            },
            {
              "key": "Total deferred tax asset, net 2021",
              "value": "19393"
            },
            {
              "key": "Valuation allowance 2022",
              "value": "-22737"
            },
            {
              "key": "Valuation allowance 2021",
              "value": "-19393"
            },
            {
              "key": "Net deferred tax asset 2022",
              "value": "0"
            },
            {
              "key": "Net deferred tax asset 2021",
              "value": "0"
            },
            {
              "key": "Summary",
              "value": "The table shows that the total deferred tax asset increased from 19393 in 2021 to 22737 in 2022 primarily due to higher non-capital losses carried forward. However, a full valuation allowance was established, leading to a net deferred tax asset of zero in both years. Notable changes include the introduction of share-based compensation in 2022 and an increased liability in property and equipment."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 188,
          "title": "Income Taxes - Tax Reconciliation Statement",
          "data": [
            {
              "key": "Statutory income tax rate 2022",
              "value": "27.0%"
            },
            {
              "key": "Income tax recovery based on statutory rate 2022",
              "value": "-3685"
            },
            {
              "key": "Statutory income tax rate 2021",
              "value": "27.0%"
            },
            {
              "key": "Income tax recovery based on statutory rate 2021",
              "value": "-3656"
            },
            {
              "key": "Share-based compensation 2022",
              "value": "340"
            },
            {
              "key": "Share-based compensation 2021",
              "value": "421"
            },
            {
              "key": "Prior-year true-ups 2022",
              "value": "-33"
            },
            {
              "key": "Prior-year true-ups 2021",
              "value": "134"
            },
            {
              "key": "Share issuance costs 2022",
              "value": "0"
            },
            {
              "key": "Share issuance costs 2021",
              "value": "-41"
            },
            {
              "key": "Other 2022",
              "value": "62"
            },
            {
              "key": "Other 2021",
              "value": "44"
            },
            {
              "key": "Change in valuation allowance 2022",
              "value": "3344"
            },
            {
              "key": "Change in valuation allowance 2021",
              "value": "3126"
            },
            {
              "key": "Income tax expense 2022",
              "value": "28"
            },
            {
              "key": "Income tax expense 2021",
              "value": "28"
            },
            {
              "key": "Summary",
              "value": "Despite various adjustments, including changes in share-based compensation and valuation allowance, the statutory rate remained constant at 27.0% for both years, and the final income tax expense stayed stable at 28."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 189,
          "title": "Tax Loss Carry Forwards and Credits",
          "data": [
            {
              "key": "Non-capital income tax losses, net",
              "value": "74,479 (Expiration: Beginning 2026)"
            },
            {
              "key": "Research and development expense carry forwards",
              "value": "3,027 (Expiration: Indefinitely)"
            },
            {
              "key": "Tax credits",
              "value": "474 (Expiration: Beginning 2024)"
            },
            {
              "key": "Summary",
              "value": "The table presents tax-related carry forwards and credits with their respective amounts (in thousands) and expiration periods. The largest item is non-capital income tax losses at $74,479,000, expiring from 2026. R&D expense carry forwards of $3,027,000 have no expiration, while tax credits of $474,000 will begin expiring in 2024."
            },
            {
              "key": "Jurisdictions",
              "value": "Canada, United States, Australia"
            },
            {
              "key": "Additional Note",
              "value": "Tax returns for DiaMedica Therapeutics Inc., DiaMedica USA, Inc., and DiaMedica Therapeutics Australia Pty Ltd. are subject to examinations by respective tax authorities."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 195,
          "title": "PART IV Item 15. Exhibits and Financial Statement Schedules",
          "data": [
            {
              "key": "Summary",
              "value": "Our consolidated financial statements are included by reference in 'Part II, Item 8. Financial Statements and Supplementary Data'. All financial statement schedules are omitted as inapplicable for a smaller reporting company. The exhibits list includes items related to management contracts or compensatory plans, with copies available upon written request."
            },
            {
              "key": "Exhibit 3.1",
              "value": "Notice of Articles of DiaMedica Therapeutics Inc. dated May 31, 2019. Reference: Incorporated by reference to Exhibit 3.1 to DiaMedica's Current Report on Form 8-K as filed with the SEC on June 4, 2019 (File No. 001-36291)."
            },
            {
              "key": "Exhibit 3.2",
              "value": "Articles of DiaMedica Therapeutics Inc. dated May 31, 2019. Reference: Incorporated by reference to Exhibit 3.2 to DiaMedica's Current Report on Form 8-K as filed with the SEC on June 4, 2019 (File No. 001-36291)."
            },
            {
              "key": "Exhibit 4.1",
              "value": "Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. Reference: Incorporated by reference to Exhibit 4.1 to DiaMedica's Annual Report on Form 10-K for the year ended December 31, 2020 (File No. 001-36291)."
            },
            {
              "key": "Exhibit 4.2",
              "value": "Specimen Certificate representing Voting Common Shares of DiaMedica Therapeutics Inc. Reference: Incorporated by reference to Exhibit 4.2 to DiaMedica's Current Report on Form 8-K as filed with the SEC on June 4, 2019 (File No. 001-36291)."
            },
            {
              "key": "Exhibit 4.3",
              "value": "Warrant dated December 11, 2018 issued by DiaMedica Therapeutics Inc. to Craig-Hallum Capital Group LLC. Reference: Incorporated by reference to Exhibit 10.1 to DiaMedica's Current Report on Form 8-K as filed with the SEC on December 11, 2018 (File No. 001-36291)."
            },
            {
              "key": "Contact",
              "value": "Mr. Scott Kellen, Chief Financial Officer and Corporate Secretary, DiaMedica Therapeutics Inc., 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305. Attn: Shareholder Information."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 201,
          "title": "[page intentionally left blank]",
          "data": [],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 202,
          "title": "Страница намеренно оставлена пустой",
          "data": [
            {
              "key": "message",
              "value": "Данная страница не содержит информации для анализа"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": true,
      "elements": [
        {
          "type": "dividend_policy",
          "page": 146,
          "title": "Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities",
          "data": [
            {
              "key": "Common Shares Listing",
              "value": "Listed on The Nasdaq Capital Market under the trading symbol “DMAC”."
            },
            {
              "key": "Number of Record Holders",
              "value": "As of March 21, 2023, there were 33 holders of record of the company’s common shares (excluding nominee or “street name” accounts)."
            },
            {
              "key": "Dividend Policy",
              "value": "The company has never declared or paid cash dividends on its common shares and currently has no plans to do so. Future earnings are expected to be retained for operations and expansion. Any future cash dividend, if declared, will be at the discretion of the Board of Directors based on various factors."
            },
            {
              "key": "Purchases of Equity Securities",
              "value": "The company did not purchase any common shares or other equity securities during the fourth quarter ended December 31, 2022."
            },
            {
              "key": "Recent Sales of Unregistered Equity Securities",
              "value": "No unregistered equity securities were sold during the fourth quarter ended December 31, 2022."
            },
            {
              "key": "Exchange Controls",
              "value": "There are no Canadian governmental restrictions affecting the export or import of capital, aside from Canadian withholding tax."
            },
            {
              "key": "Canadian Federal Income Tax Considerations",
              "value": "A summary as of March 15, 2023, outlines the principal federal income tax considerations under the Income Tax Act (Canada) applicable to non-resident holders of the company’s common shares."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "dividend_policy",
          "page": 147,
          "title": "Tax Treatment of Dividends and Disposition of Common Shares",
          "data": [
            {
              "key": "Specified Shareholder Definition",
              "value": "A ‘specified shareholder’ includes a person (or group of persons not dealing at arm’s length) who owns or has the right to acquire or control 25% or more of the common shares, determined on a votes or fair market value basis."
            },
            {
              "key": "Capital Property of Common Shares",
              "value": "Common shares are generally considered capital property provided the Holder does not hold them in the course of carrying on a business and they were not acquired in transactions considered to be an adventure or concern in the nature of trade."
            },
            {
              "key": "Dividend Withholding Tax",
              "value": "Dividends paid or credited to a Holder are subject to Canadian withholding tax at a rate of 25%, which may be reduced under applicable tax treaties (e.g., under the US Tax Convention the rate may be reduced to 15% or 5% for qualifying entities)."
            },
            {
              "key": "Tax Act and Policy Basis",
              "value": "This summary is based on the provisions of the Tax Act (including regulations) in force as of March 1, 2023, taking into account current CRA administrative policies and public Tax Proposals."
            },
            {
              "key": "Advisory Note",
              "value": "Holders are advised to consult their own tax advisors regarding the specific tax consequences applicable to their circumstances."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "dividend_policy",
          "page": 149,
          "title": "U.S. Federal Income Tax Considerations for Common Shares Distributions",
          "data": [
            {
              "key": "Tax Law Scope",
              "value": "Under U.S. federal income tax law; applies to various entities including financial institutions, insurance companies, broker-dealers, traders, tax-exempt entities, retirement plans, regulated investment companies, REITs, certain former U.S. citizens/residents, and others."
            },
            {
              "key": "U.S. Holder Definition",
              "value": "A beneficial owner of common shares qualifying as a U.S. Holder if an individual (citizen/resident), a U.S.-organized corporation, an estate subject to U.S. federal income tax, or a trust with U.S. court supervision or electing domestic trust status."
            },
            {
              "key": "Distribution Tax Treatment",
              "value": "A distribution is generally included as dividend income up to the U.S. Holder’s pro rata share of current/accumulated earnings and profits; any excess is treated as a tax-free return of capital reducing the tax basis, with amounts beyond basis taxed as capital gain."
            },
            {
              "key": "Additional Considerations",
              "value": "No assurance is provided regarding earnings and profits determinations, and state, local, or non-U.S. tax considerations are not addressed. Entities are advised to consult their own tax advisors."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "dividend_policy",
          "page": 150,
          "title": "Tax Treatment and Calculation of Dividends on Common Shares",
          "data": [
            {
              "key": "Exchange Rate Calculation",
              "value": "The USD value of distributions made in CAD is determined by the exchange rate on the receipt (or deemed receipt) date."
            },
            {
              "key": "Currency Conversion Treatment",
              "value": "If Canadian dollars are converted to USD on the receipt date, no currency gain or loss is recognized."
            },
            {
              "key": "Cost Basis for Non-Converted CAD",
              "value": "A US Holder's basis in CAD not converted on the receipt date equals the USD value on that date."
            },
            {
              "key": "Subsequent Conversion or Disposition",
              "value": "Any gain or loss on later conversion or disposition of CAD is treated as ordinary income or loss from US sources."
            },
            {
              "key": "Dividend Income Characterization",
              "value": "Dividends are generally treated as income from sources outside the US and as passive category income; qualified dividend income treatment may apply if certain conditions are met."
            },
            {
              "key": "PFIC Consideration",
              "value": "If classified as a PFIC, the reduced capital gains tax rate for qualified dividends does not apply."
            },
            {
              "key": "Foreign Tax Credit",
              "value": "U.S. Holders may claim a tax credit or deduction for Canadian withholding tax, subject to complex limitations and ownership conditions."
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_share_buyback_plans": {
      "value": false,
      "elements": []
    },
    "has_capital_structure_changes": {
      "value": true,
      "elements": [
        {
          "type": "capital_structure",
          "page": 33,
          "title": "Stock Ownership Disclosure",
          "data": [
            {
              "key": "Disclosure Description",
              "value": "Security Ownership of Significant Beneficial Owners. Entities that own more than 5% of common shares are disclosed."
            },
            {
              "key": "Summary",
              "value": "The table shows the three largest beneficial owners of Common Shares: TomEqt Private AB (10.8%), Trill AB (9.6%), and Richard Jacinto II (9.5%). Together they control approximately 29.9% of the total 26,460,688 shares outstanding as of March 21, 2023."
            },
            {
              "key": "Row 1",
              "value": "Title of Class: Common Shares; Beneficial Owner: TomEqt Private AB c/o KinKon AB, Biblioteksgatan 25, 11435 Stockholm, Sweden; Amount: 2,855,847 shares; Percent: 10.8%"
            },
            {
              "key": "Row 2",
              "value": "Title of Class: Common Shares; Beneficial Owner: Trill AB, Sveavagen 17, 18th Floor, SE-111 57 Stockholm, Sweden; Amount: 2,551,020 shares; Percent: 9.6%"
            },
            {
              "key": "Row 3",
              "value": "Title of Class: Common Shares; Beneficial Owner: Richard Jacinto II, 394 Saddle Back Trail, Franklin Lakes, NJ 07417; Amount: 2,500,000 shares; Percent: 9.5%"
            },
            {
              "key": "Additional Notes",
              "value": "Percentages are based on 26,460,688 shares outstanding as of March 21, 2023. Footnotes detail record holder information and joint filings disclaimed group membership."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 151,
          "title": "Sale, Exchange or Other Disposition of Common Shares and PFIC Considerations",
          "data": [
            {
              "key": "Transaction Type",
              "value": "Sale, exchange or other disposition of common shares"
            },
            {
              "key": "Tax Implications",
              "value": "U.S. Holder generally recognizes capital gain or loss, where gain equals cash plus fair market value of any property received minus adjusted tax basis; losses are determined conversely"
            },
            {
              "key": "Holding Period",
              "value": "More than one year holding results in long-term capital gain or loss"
            },
            {
              "key": "PFIC Status Determination",
              "value": "Based on tests for passive income and assets: PFIC for taxable years ended December 31, 2016 and December 31, 2022; not PFIC for taxable years ended December 31, 2017 through 2021"
            },
            {
              "key": "Working Capital Rule",
              "value": "Cash held in a non-interest bearing account for current operating needs (up to 90 days of operating expenses) is not treated as a passive asset"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 169,
          "title": "Assets, Liabilities and Equity Statement",
          "data": [
            {
              "key": "Company",
              "value": "DiaMedica Therapeutics Inc."
            },
            {
              "key": "Statement Period",
              "value": "December 31, 2021 and December 31, 2022"
            },
            {
              "key": "Key Observations",
              "value": "Total assets decreased (e.g., current assets from $45,551 to $34,395), shareholders' equity declined from $44,024 to $31,827, and there is a significant accumulated deficit. Marketable securities represent the largest component of current assets, while liabilities remain relatively low."
            },
            {
              "key": "Balance Sheet Categories",
              "value": "Current assets, Non-current assets, Current liabilities, and Shareholders' equity"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_structure",
          "page": 171,
          "title": "Shareholders' Equity Statement",
          "data": [
            {
              "key": "Period",
              "value": "December 31, 2020; December 31, 2021; December 31, 2022"
            },
            {
              "key": "Common Shares",
              "value": "18,746,157 (2020), 26,443,067 (2021 and 2022)"
            },
            {
              "key": "Paid-in Capital",
              "value": "94,925 (2020), 126,576 (2021), 128,078 (2022)"
            },
            {
              "key": "Accumulated Other Comprehensive Loss",
              "value": "(2) (2020), (51) (2021), (74) (2022)"
            },
            {
              "key": "Accumulated Deficit",
              "value": "(68,909) (2020), (82,501) (2021), (96,177) (2022)"
            },
            {
              "key": "Shareholders' Equity",
              "value": "26,014 (2020), 44,024 (2021), 31,827 (2022)"
            },
            {
              "key": "Summary",
              "value": "Table presents the evolution of DiaMedica Therapeutics Inc.'s shareholders' equity from 2020 to 2022, highlighting an increase in common shares, growth in paid-in capital, consistent net losses (approximately $13.592M in 2021 and $13.676M in 2022), and an overall increase in total shareholders' equity primarily driven by new share issuances and minor unrealized losses on marketable securities."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 183,
          "title": "Shareholders’ Equity, Licensing Agreement, and Indemnification",
          "data": [
            {
              "key": "Clinical Cohorts",
              "value": "Cohort 2: Participants with IgA Nephropathy; Cohort 3: Participants with Type 2 Diabetes Mellitus with CKD, hypertension, and albuminuria"
            },
            {
              "key": "Enrollment Closure",
              "value": "Closed at the end of 2021"
            },
            {
              "key": "Final Data Analysis Expected",
              "value": "Mid-2023"
            },
            {
              "key": "Technology License Agreement",
              "value": "Entered into a license agreement with Catalent Pharma Solutions, LLC for gene expression technology and manufacture of DM199. Under the agreement, milestone payment obligations (one remaining as of December 31, 2022) are due upon first regulatory approval of DM199 for commercial sale and royalty payments (<1% on net sales) will apply indefinitely. The company may cancel the license with 90 days’ notice, while Catalent can only terminate if milestone/royalty payments are not met."
            },
            {
              "key": "Indemnification Policy",
              "value": "The Company indemnifies and advances expenses to its directors and officers, secures insurance for potential liabilities, and as of December 31, 2022, no pending litigation exists. Indemnification under US Securities Act provisions may be unenforceable."
            },
            {
              "key": "Authorized Share Capital",
              "value": "Unlimited number of common voting shares with no stated par value. Common shareholders are entitled to dividends if declared and one vote per share."
            },
            {
              "key": "Equity Issuance in 2022",
              "value": "No common shares or other equity securities were issued except for stock options and deferred stock units."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "capital_structure",
          "page": 184,
          "title": "Equity Issuance and Share-Based Compensation Details",
          "data": [
            {
              "key": "Private Placement Date",
              "value": "September 26, 2021"
            },
            {
              "key": "Common Shares Issued in Private Placement",
              "value": "7,653,060"
            },
            {
              "key": "Price per Share",
              "value": "$3.92"
            },
            {
              "key": "Gross Proceeds",
              "value": "$30.0 million"
            },
            {
              "key": "Net Proceeds",
              "value": "$29.8 million"
            },
            {
              "key": "Registration Rights Terms",
              "value": "Resale registration statement must remain effective until shares are no longer considered Registrable Securities. Failure to maintain may result in liquidated damages up to 10% of invested capital."
            },
            {
              "key": "Options Exercise",
              "value": "40,000 common shares issued upon exercise for gross proceeds of $244,000"
            },
            {
              "key": "Deferred Stock Units Settlement",
              "value": "3,850 common shares issued"
            },
            {
              "key": "Share-Based Compensation Reserved Shares Breakdown",
              "value": "Employee and non-employee stock options: 2,782,248; Deferred stock units: 134,402; Common shares under purchase warrants: 265,000; Shares available under 2019 Omnibus Incentive Plan: 2,005,260; Shares available under 2021 Employment Inducement Incentive Plan: 535,000; Total: 5,721,910"
            },
            {
              "key": "2019 Omnibus Incentive Plan Details",
              "value": "Adopted March 10, 2022 and approved by shareholders on May 18, 2022. Under the plan, options have maximum terms of ten years (employees/directors) and five years (non-employees)."
            },
            {
              "key": "Outstanding Options under 2019 Plan",
              "value": "1,845,338 common shares"
            },
            {
              "key": "DSU Reserved Shares under 2019 Plan",
              "value": "117,069 common shares"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 61,
          "title": "Ограничения на операции с ценными бумагами DiaMedica",
          "data": [
            {
              "key": "Short Sales",
              "value": "Запрещены, так как указывают на ожидание снижения стоимости и отсутствие доверия к компании"
            },
            {
              "key": "Publicly Traded Options",
              "value": "Запрещены, так как создают видимость спекуляций на краткосрочное движение акций и возможность торговли на основе инсайдерской информации"
            },
            {
              "key": "Hedging Transactions",
              "value": "Запрещены, поскольку позволяют зафиксировать стоимость доли и изменяют соотношение рисков и стимулов руководства по сравнению с акционерами"
            },
            {
              "key": "Margin Purchases and Pledging Securities",
              "value": "Запрещены, включая покупку акций с заемными средствами и использование акций в качестве залога для получения кредитов"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 77,
          "title": "CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS",
          "data": [
            {
              "key": "Disclosure",
              "value": "Statements in this annual report that are not historical facts are forward-looking statements subject to risks and uncertainties."
            },
            {
              "key": "Product Candidate",
              "value": "DM199 for the treatment of Acute Ischemic Stroke (AIS) and Chronic Kidney Disease (CKD)."
            },
            {
              "key": "Regulatory Risk",
              "value": "Clinical hold by the FDA on the IND for the ReMEDy2 trial, including risks related to hypotension events and potential delays in FDA approval."
            },
            {
              "key": "Trial and Operational Risks",
              "value": "Uncertainties regarding the success, cost, timing, and adaptive design of the ReMEDy2 clinical trial, including impacts from COVID-19 on site activations, enrollment, staffing, and logistics."
            },
            {
              "key": "Market and Commercialization Risks",
              "value": "Risks concerning market acceptance, reimbursement, and the ability to generate revenue through partnerships for the DM199 product candidate."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 78,
          "title": "Forward-Looking Statements and Risk Factors",
          "data": [
            {
              "key": "regulatory_requirements",
              "value": "Expectations regarding federal, state and foreign regulatory requirements and developments, including potential FDA regulation of DM199 for AIS and CKD."
            },
            {
              "key": "financial_estimates",
              "value": "Projections on expenses, future revenue, capital requirements, and the duration of current cash resources as well as potential need for additional financing."
            },
            {
              "key": "intellectual_property",
              "value": "Expectations regarding the ability to obtain and maintain intellectual property protection for the DM199 product candidate."
            },
            {
              "key": "competition_and_exclusivity",
              "value": "Expectations regarding competitive landscape and ability to obtain data exclusivity for DM199."
            },
            {
              "key": "funding_for_operations",
              "value": "Expectations about obtaining funding necessary for operations, including financing for clinical trials and regulatory approvals."
            },
            {
              "key": "risk_disclosures",
              "value": "Forward-looking statements are subject to risks, uncertainties, and assumptions as described under 'Risk Factors', noting that actual results may differ materially."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 91,
          "title": "Competitive Risks in Therapeutic Development",
          "data": [
            {
              "key": "MarketOpportunityRisk",
              "value": "Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize treatments that are viewed as safer, more effective, or less expensive."
            },
            {
              "key": "AIS_TherapeuticChallenge",
              "value": "In Acute Ischemic Stroke (AIS), current treatment (tPA) has a 4.5-hour window. There is significant competition from companies developing alternative approaches, including extended treatment options and mechanical thrombectomy."
            },
            {
              "key": "CKD_TreatmentCompetition",
              "value": "In Chronic Kidney Disease (CKD), despite only two approved treatments in the US, several products are in clinical development targeting various mechanisms, increasing competitive pressure."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 94,
          "title": "Clinical Hold, FDA Feedback and Enrollment Risks",
          "data": [
            {
              "key": "Clinical Hold Status",
              "value": "Uncertainty regarding the FDA lifting the clinical hold; potential for additional FDA requests and delays."
            },
            {
              "key": "Phase 1C Study",
              "value": "Initiated as an open label, single ascending dose (SAD) study in Australia with DM199 administered with PVC IV bags; up to 15 healthy adult participants; preliminary data expected in May 2023."
            },
            {
              "key": "FDA Interaction",
              "value": "Data submission from part 2 of in-use testing anticipated in April 2023; conclusions sent to FDA for feedback and confirmation on addressing clinical hold issues."
            },
            {
              "key": "Enrollment Challenges",
              "value": "Enrollment in the ReMEDy2 trial is on hold pending FDA data review; prior slower than expected site activations and enrollment due to reduced research activities, staffing shortages, and logistical concerns."
            },
            {
              "key": "Fast Track Designation",
              "value": "DM199 granted Fast Track designation in September 2021 for the treatment of AIS, allowing for frequent FDA interactions and potential rolling review."
            },
            {
              "key": "ReMEDy1 Trial Summary",
              "value": "Phase 2 ReMEDy1 trial for AIS included 92 participants, assessing safety, tolerability, and biomarkers, with treatment initiated in February 2018 and enrollment completed in October 2019."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 98,
          "title": "Overview of DM199 Manufacturing, Formulation, and Regulatory Advantages",
          "data": [
            {
              "key": "Pharmacokinetic Profile",
              "value": "DM199 demonstrates a longer acting profile when administered subcutaneously compared to intravenous options."
            },
            {
              "key": "Manufacturing Risks with Traditional Sources",
              "value": "KLK1 derived from human urine or pig pancreas poses risks of impurities, endotoxins, and chemical byproducts due to variability in isolation and purification."
            },
            {
              "key": "Recombinant Manufacturing Advantages",
              "value": "The novel recombinant process offers consistent formulation free of impurities and endotoxins, with significant cost and scalability benefits."
            },
            {
              "key": "Regulatory Considerations",
              "value": "Recombinant manufacturing provides a regulatory advantage, ensuring compliance with safety standards in regions such as the United States, Europe, and Canada, and may qualify for extended data exclusivity."
            },
            {
              "key": "Strategic Alternatives",
              "value": "The company is exploring strategic alternatives including licensing and collaborations to advance clinical development."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 102,
          "title": "Pharmaceutical Coverage, Pricing and Reimbursement Risks and R&D Disclosures",
          "data": [
            {
              "key": "Coverage and Reimbursement Uncertainty",
              "value": "Sales of approved products depend on the availability of coverage and adequate reimbursement from third-party payers, which is subject to regulatory pricing controls and cost-effectiveness evaluations in key markets such as the United States and the European Union."
            },
            {
              "key": "Pricing Pressure",
              "value": "Government entities and managed care providers are increasingly attempting to regulate prices, leading to downward pricing pressures and potential delays in market acceptance for new and innovative therapeutics."
            },
            {
              "key": "Approval Process Risk",
              "value": "Obtaining inclusion in drug formularies is a time-consuming, costly process requiring separate scientific and economic validation for each third-party payer, with no assurance of success."
            },
            {
              "key": "Impact on Financial Performance",
              "value": "Inadequate coverage and reimbursement may negatively affect product sales, overall profitability, operating results, and the return on investment in research and development."
            },
            {
              "key": "Research and Development Investment",
              "value": "The company has focused substantial efforts on R&D, particularly for its lead product candidate DM199 (targeting AIS and CKD), and expects ongoing increases in R&D expenses."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 109,
          "title": "Risk Factors Summary",
          "data": [
            {
              "key": "Material factors",
              "value": "Factors that could materially adversely affect our business, operating results or financial condition."
            },
            {
              "key": "ReMEDy2 Trial Risk",
              "value": "FDA placed a clinical hold on the IND for our Phase 2/3 ReMEDy2 trial, which may adversely affect business."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Delays in clinical trial site activations and patient enrollments due to COVID-19 may adversely affect results."
            },
            {
              "key": "Funding Requirement",
              "value": "Need additional funding for clinical development activities due to no anticipated revenue for 3-4 years."
            },
            {
              "key": "Regulatory Approval Risk",
              "value": "Regulatory approval process is costly and uncertain, may prevent commercialization of DM199."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 110,
          "title": "Risks Related to Our Reliance on Third Parties",
          "data": [
            {
              "key": "Risk Description",
              "value": "We rely and will continue to rely on third parties to support the planning, execution and/or monitoring of our preclinical and clinical trials, and their failure to perform as required could cause delays in completing our product development and substantial harm to our business."
            },
            {
              "key": "Third Parties Risks",
              "value": "We rely on contract manufacturers over whom we have limited control."
            },
            {
              "key": "Future Collaborations",
              "value": "Future development collaborations are expected to be important to us."
            },
            {
              "key": "Intellectual Property Risks",
              "value": "We could lose important intellectual property rights that we currently license from a third party if we fail to comply with our obligations under the license agreements."
            },
            {
              "key": "Protection of Technology",
              "value": "We may be unable to adequately protect our technology and enforce our intellectual property rights."
            },
            {
              "key": "Need for Additional Licenses",
              "value": "We or a future partner may require additional third-party licenses, and such licenses might not be available on commercially acceptable terms."
            },
            {
              "key": "Changes in Patent Law",
              "value": "Changes in patent law and its interpretation could diminish the value of our patents."
            },
            {
              "key": "Litigation Costs",
              "value": "Intellectual property litigation may be expensive, time consuming and may cause delays in development."
            },
            {
              "key": "Human Capital Risks",
              "value": "We rely heavily on the capabilities and experience of our key executives, clinical personnel and advisors, and loss of any may affect our ability to develop DM199."
            },
            {
              "key": "Growth Management",
              "value": "We will likely need to expand operations and may experience difficulties in managing our growth."
            },
            {
              "key": "Commercialization Risks",
              "value": "Successful commercialization of DM199 will depend on achieving market acceptance, which may not occur."
            },
            {
              "key": "Competition Risks",
              "value": "We or any future partner will likely face competition from other biotechnology and pharmaceutical companies with greater resources."
            },
            {
              "key": "Share Price Volatility",
              "value": "Our common share price has been volatile and may continue to be."
            },
            {
              "key": "Dilution of Shares",
              "value": "We may issue additional common shares resulting in share ownership dilution."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 112,
          "title": "Risk Factors Related to Clinical Trial Delays and Product Development Costs",
          "data": [
            {
              "key": "clinical_trial_delays",
              "value": "Significant clinical trial delays could impair the ability to successfully commercialize DM199 and may harm financial condition."
            },
            {
              "key": "impact_of_COVID-19",
              "value": "COVID-19 resulted in delays in clinical trial site activations and patient enrollments affecting the ReMEDy2 trial."
            },
            {
              "key": "regulatory_approvals",
              "value": "Delays could extend the time for obtaining regulatory approval of DM199."
            },
            {
              "key": "financial_implications",
              "value": "Delays or increased product development costs would likely have a material adverse effect on business, financial condition, and prospects."
            },
            {
              "key": "potential_reasons_for_delay",
              "value": "Concerns over prior adverse events, participant enrollment issues, regulatory inspections potentially causing suspension."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 117,
          "title": "Discussion on Development Costs and Financing Risks",
          "data": [
            {
              "key": "development_costs",
              "value": "Costs include clinical trials for DM199 and potential future product candidates, identification and expansion of development programs, regulatory approval expenses, manufacturing process development, public reporting costs, IP filing and defense, and general administrative support."
            },
            {
              "key": "financing_strategy",
              "value": "Historically financed operations through public/private equity sales, warrants, stock options, interest income, government grants and tax incentives. Future financing might involve equity and debt financings or strategic collaborations."
            },
            {
              "key": "financing_risk",
              "value": "There is a risk of requiring additional funds earlier than expected with no assurance of obtaining them; raising additional capital might lead to share dilution, unfavorable debt terms, or loss of valuable rights through collaborations."
            },
            {
              "key": "conditional_factors",
              "value": "Factors influencing financing include clinical trial outcomes, ability to lift clinical holds, adverse events, market conditions, economic and geopolitical events (e.g., war between Russia and Ukraine), and the status of strategic alliances."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 118,
          "title": "Financial and Regulatory Risks Associated with Product Development",
          "data": [
            {
              "key": "Financial Loss Projection",
              "value": "Expected to continue incurring substantial losses for at least three or four years."
            },
            {
              "key": "Accumulated Deficit",
              "value": "As of December 31, 2022, accumulated deficit of $96.2 million."
            },
            {
              "key": "Net Loss 2022",
              "value": "Net loss of $13.7 million for the year ended December 31, 2022."
            },
            {
              "key": "Net Loss 2021",
              "value": "Net loss of $13.6 million for the year ended December 31, 2021."
            },
            {
              "key": "Regulatory Challenges",
              "value": "Regulatory approval process is expensive, time-consuming and uncertain."
            },
            {
              "key": "Lack of Profitable Products",
              "value": "No products approved by regulatory authorities and no revenue generated from product sales."
            },
            {
              "key": "Future Profitability Uncertainty",
              "value": "Unable to predict future losses or when profitability will be achieved."
            },
            {
              "key": "R&D Financial Burden",
              "value": "Significant ongoing R&D and administrative expenses expected."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 120,
          "title": "Regulatory and IND Compliance Risks",
          "data": [
            {
              "key": "Non-compliance Penalties",
              "value": "Failure to comply with regulatory requirements regarding ongoing safety monitoring, pharmacovigilance, and data protection may lead to significant financial penalties and sanctions."
            },
            {
              "key": "IND Approval Challenges",
              "value": "Issues such as failure to obtain FDA acceptance of INDs, clinical holds on trials, and subsequent delays in commencing further clinical trials could materially affect development timelines."
            },
            {
              "key": "Fast Track Designation Uncertainty",
              "value": "Although DM199 received Fast Track designation, this may not result in faster development, review or approval, and the designation itself can be rescinded by the FDA."
            },
            {
              "key": "Legislative and Regulatory Changes",
              "value": "Current and future changes in healthcare system legislation and data privacy regulations may impede timely marketing approval and commercialization, affecting revenue and increasing capital expenditure."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 121,
          "title": "Risk Factors: Impact of Healthcare Reform and Third Party Dependence",
          "data": [
            {
              "key": "Marketing Approval Risk",
              "value": "Post-approval regulatory restrictions may affect the profitability and commercial success of DM199 or future product candidates."
            },
            {
              "key": "Healthcare Reform Impact",
              "value": "Legislation such as the Affordable Care Act, Inflation Reduction Act, and other proposed measures are expected to change health care financing and drug pricing mechanisms."
            },
            {
              "key": "Legislative and Regulatory Environment",
              "value": "Pending laws and executive actions, including the Prescription Drug Pricing Reduction Act and Elijah E. Cummings Lower Drug Costs Now Act, could lead to lower reimbursement rates and increase compliance costs."
            },
            {
              "key": "Third Party Dependence",
              "value": "Reliance on third parties for preclinical and clinical trial activities poses risks of delays and quality issues impacting product development."
            },
            {
              "key": "Overall Risk Implication",
              "value": "The combined effect of cost containment measures, changes in coverage and reimbursement, and operational dependencies may hinder revenue generation and the ability to commercialize products."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 122,
          "title": "Risk Factors in Clinical Trials and Manufacturing",
          "data": [
            {
              "key": "Third Party Performance",
              "value": "Delays, cancellations, or ineffective clinical testing if third parties do not meet expectations or regulatory requirements."
            },
            {
              "key": "Litigation History",
              "value": "Past litigation initiated against Pharmaceutical Research Associates Group B.V. due to issues in a clinical study; PRA was acquired by ICON plc in July 2021."
            },
            {
              "key": "Reliance on Contract Manufacturers",
              "value": "Dependence on CMOs with limited control, posing risks related to quality, cost, delivery, and adherence to cGMP regulations."
            },
            {
              "key": "Manufacturing and Supply Chain Challenges",
              "value": "Potential issues include scale-up difficulties, supply chain disruptions, raw material availability, capacity limitations, and other force majeure events."
            },
            {
              "key": "Regulatory Compliance Risks",
              "value": "Non-compliance by CMOs with cGMP regulations may force repeat trials and delay regulatory approval and commercialization."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 123,
          "title": "Manufacturing and Collaboration Risks",
          "data": [
            {
              "key": "Manufacturing Dependency",
              "value": "The company is unable to secure alternative third-party manufacturing sources on commercially reasonable terms or in a timely manner, potentially delaying the development of DM199 or other future product candidates. This dependence on current CMOs may adversely affect its development timeline and competitiveness."
            },
            {
              "key": "Collaboration Risks",
              "value": "The text highlights significant risks in forming or maintaining future development collaborations with pharmaceutical and biotechnology companies. Failure to secure suitable collaborations or partners may lead to delays, reduced scope of development activities, and adverse effects on commercialization and revenues."
            },
            {
              "key": "Impact on Business",
              "value": "Delays in product development and commercialization due to manufacturing and partnership challenges could materially and adversely affect the company's revenue from product sales and overall business performance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 124,
          "title": "Risks Related to Collaborations, Intellectual Property, and Product Development",
          "data": [
            {
              "key": "collaboration_termination",
              "value": "Collaborations may be terminated by the partner for convenience, potentially requiring the company to raise additional capital and adversely affecting its ability to attract new collaborators."
            },
            {
              "key": "litigation_risk",
              "value": "Collaborators may infringe on third-party intellectual property rights, exposing the company to litigation and potential liability."
            },
            {
              "key": "product_development",
              "value": "If collaborations do not lead to the successful development of DM199 or other product candidates, development could be delayed and additional resources may be needed."
            },
            {
              "key": "intellectual_property_license",
              "value": "Failure to comply with licensing obligations or disruptions in business relationships with licensors could result in loss of important intellectual property rights and necessitate seeking additional licenses."
            },
            {
              "key": "physician_relationships",
              "value": "Inability to maintain contractual relationships with physicians may negatively impact clinical trial design, interpretation, regulatory approvals, and commercialization efforts."
            },
            {
              "key": "regulatory_disclosure",
              "value": "US federal, state, and international laws requiring disclosure of payments to healthcare providers could deter potential relationships, impacting collaborations and the company’s overall perception."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 125,
          "title": "Intellectual Property and Licensing Risk Factors",
          "data": [
            {
              "key": "description",
              "value": "The text discusses various risks related to intellectual property including sublicensing of patents, diligence obligations under licensing agreements, disputes over contract interpretation, and the potential material adverse effects on business operations due to inadequate protection or enforcement of proprietary rights. It also covers concerns about the enforceability of contracts, the uncertainty of pending patent applications, reliance on trade secrets, and risks arising from third party contractor agreements."
            },
            {
              "key": "potential_effect",
              "value": "Material adverse effect on business, financial condition, results of operations, and prospects."
            },
            {
              "key": "focus_areas",
              "value": "Intellectual property licensing, patent protection, contractual disputes, enforcement of patents, and technology commercialization."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 126,
          "title": "Patent and Intellectual Property Risk Factors",
          "data": [
            {
              "key": "Competitive Advantage of Patents",
              "value": "Uncertainty whether issued or to-be-issued patents will provide a competitive advantage or be subject to challenges."
            },
            {
              "key": "Third-Party Interference",
              "value": "Risk that patents held by others may interfere with marketing our products or lead to design-arounds."
            },
            {
              "key": "Licensing Arrangements",
              "value": "Concerns over inability to secure licensing on commercially reasonable terms for third-party patents relevant to our products."
            },
            {
              "key": "Legal and Regulatory Risks",
              "value": "Potential for substantial legal costs from defending or initiating patent infringement suits and uncertainty in patent litigation outcomes."
            },
            {
              "key": "Intellectual Property Ownership",
              "value": "Uncertainty about being the original inventor and obtaining all necessary rights from creators, along with risks regarding trade secret protection."
            },
            {
              "key": "Impact on Business Operations",
              "value": "Inability to obtain essential licenses could delay or prevent development, manufacture, and commercialization, adversely affecting financial condition and prospects."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 127,
          "title": "Risks Related to Changes in Patent Law and Interpretation",
          "data": [
            {
              "key": "Summary",
              "value": "Changes in patent law and its interpretation may diminish the value of our patents, affecting our ability to protect key product candidates like DM199. The document outlines the inherent uncertainties and increased costs in obtaining and enforcing patents due to evolving legal interpretations, the transition to a 'first inventor to file' system under the America Invents Act, and the potential for third parties to challenge patent claims using lower evidentiary standards in USPTO proceedings. These factors could have a material adverse effect on our business and operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 128,
          "title": "Intellectual Property Litigation Risk Factors",
          "data": [
            {
              "key": "Litigation Type",
              "value": "Intellectual property litigation involving patent infringement, validity, and enforceability challenges"
            },
            {
              "key": "Risks Identified",
              "value": "High litigation costs, delays in product development, diversion of managerial attention, potential monetary liability including treble damages and attorney fees"
            },
            {
              "key": "Potential Consequences",
              "value": "Need to defend against third-party claims, risk of adverse outcomes in litigation or administrative proceedings, potential requirement to obtain licenses on unfavorable terms, and risk of confidential information disclosure"
            },
            {
              "key": "Business Impact",
              "value": "Could hinder clinical trials, research programs, licensing efforts, and development partnerships, possibly affecting market share and share price"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 129,
          "title": "Trade Secrets and Intellectual Property Risk Factors",
          "data": [
            {
              "key": "Reliance on Third Parties",
              "value": "The document highlights that reliance on third parties for developing and manufacturing the DM199 product candidate may require sharing trade secrets, increasing the risk of competitor discovery."
            },
            {
              "key": "Confidentiality Measures",
              "value": "It describes the use of confidentiality agreements, material transfer agreements, collaborative research agreements, and employment or consulting contracts to protect proprietary technology."
            },
            {
              "key": "Patent Limitations",
              "value": "The text notes that patent protection may be limited by the patent's lifespan and could expire before or shortly after a product candidate is commercialized, exposing the company to competition."
            },
            {
              "key": "Litigation and Misappropriation Risk",
              "value": "There is an emphasis on the risk of litigation arising from potential misappropriation or wrongful disclosure of trade secrets by employees, consultants, or independent contractors, which could have a material adverse effect on the business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 130,
          "title": "Patent Compliance and Enforcement Risks",
          "data": [
            {
              "key": "Compliance Requirements",
              "value": "Obtaining and maintaining patent protection depends on strict adherence to procedural, documentary, fee payment, and other requirements imposed by governmental patent agencies."
            },
            {
              "key": "Fee Obligations",
              "value": "Periodic maintenance, renewal, annuity, and other governmental fees must be paid in multiple stages over the patent lifetime, with involvement from external legal counsel and specialized firms."
            },
            {
              "key": "Risk of Non-Compliance",
              "value": "Inadvertent lapses or non-compliance can lead to the abandonment or lapse of patents or applications, resulting in partial or complete loss of rights."
            },
            {
              "key": "Competitive Impact",
              "value": "Loss of patent protection could allow competitors to enter the market and exploit the technology, undermining the company’s competitive position."
            },
            {
              "key": "Enforcement Challenges",
              "value": "Enforcing patent rights globally can be expensive and less effective in certain foreign jurisdictions, where legal protections may be limited."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 131,
          "title": "Risks Related to Human Capital Management",
          "data": [
            {
              "key": "Reliance on Key Personnel",
              "value": "The company depends heavily on the capabilities and experience of key executives, clinical personnel, and advisors, and the loss of any could affect product development."
            },
            {
              "key": "Hiring and Retention Challenges",
              "value": "There is significant competition for highly skilled scientific, managerial, clinical, and regulatory staff, making it challenging to attract and retain personnel as the company grows."
            },
            {
              "key": "Operational Expansion Risks",
              "value": "As the company advances its DM199 product candidate and future products, it will need to increase headcount in various functions, and its current management and operational systems may not be adequate to support this growth."
            },
            {
              "key": "Recent Key Hires",
              "value": "New appointments such as Chief Medical Officer, Chief Commercial Officer, and Senior Vice President of Clinical Development Operations in 2022 indicate efforts to strengthen the team."
            },
            {
              "key": "Dependency on External Collaborators",
              "value": "The company relies on agreements with clinical collaborators, advisors, and academic partners, whose external commitments may limit their availability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 132,
          "title": "Risks Related to the Future Commercialization of DM199 or Any Future Product Candidate",
          "data": [
            {
              "key": "Market Acceptance",
              "value": "The successful commercialization of DM199 or any future product candidate depends on achieving sufficient market acceptance among physicians, patients, healthcare payers, and governments. Without it, significant revenue generation is unlikely."
            },
            {
              "key": "Regulatory Approval and Labeling",
              "value": "Even if regulatory approval is obtained, the product might not secure market acceptance due to limitations or warnings in its approved labeling, adverse side effects, or insufficient clinical efficacy and safety."
            },
            {
              "key": "Coverage and Reimbursement",
              "value": "The availability of adequate coverage and reimbursement from governmental and private insurers is critical. Lack of sufficient reimbursement could severely diminish the product’s revenue potential."
            },
            {
              "key": "Healthcare Reform Impact",
              "value": "Changes in healthcare policies and spending controls could limit the product’s pricing, affect reimbursement rates, and ultimately reduce the volumes sold, impacting overall commercialization."
            },
            {
              "key": "International Commercialization",
              "value": "Outside the United States, successful commercialization will largely depend on securing government coverage, which may delay market entry."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 133,
          "title": "Risk Factors in Pricing, Competition, and Regulatory Exclusivity for DM199",
          "data": [
            {
              "key": "Product Candidate",
              "value": "DM199"
            },
            {
              "key": "Pricing Risks",
              "value": "Governments in international markets control prescription pharmaceutical prices through reference pricing, price cuts, rebates, revenue-related taxes, and profit control, leading to expected declines as product life or volumes increase."
            },
            {
              "key": "Competitive Risks",
              "value": "Intense technological competition from larger biotechnology and pharmaceutical companies with greater financial and R&D resources; risk that competitors may develop superior or faster-to-market products."
            },
            {
              "key": "Regulatory & Exclusivity Risks",
              "value": "DM199 may qualify for 12 years of data exclusivity under the BPCIA, but risks remain if the FDA accelerates approval for competing products or if Congress amends/repeals the BPCIA, shortening the exclusivity period."
            },
            {
              "key": "Market Dynamics",
              "value": "Regulatory factors and evolving market conditions may lead to biosimilar substitution and diminished competitiveness of the product candidate."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 134,
          "title": "Risks Related to Our Common Shares",
          "data": [
            {
              "key": "Share Price Volatility",
              "value": "Our common share price has been volatile and may continue to be volatile."
            },
            {
              "key": "Trading Market",
              "value": "Our common shares trade on The Nasdaq Capital Market under the symbol “DMAC.”"
            },
            {
              "key": "2022 Trading Range",
              "value": "The sale price ranged from $1.12 to $3.94 per share."
            },
            {
              "key": "Trading Volume",
              "value": "Daily trading volume ranged from 4,200 shares to 3.5 million shares."
            },
            {
              "key": "Market Influences",
              "value": "Factors include economic changes, industry decline in biotech since February 2021, clinical results, and operational changes such as the current clinical hold on the IND for the ReMEDy2 trial."
            },
            {
              "key": "Dilution Risk",
              "value": "Potential dilution from additional equity issuance, warrants, options, and deferred stock units may occur, adversely affecting share price and the ability to raise capital."
            },
            {
              "key": "Emerging Growth Company Status",
              "value": "The company is an “emerging growth company” and a “smaller reporting company” under reduced disclosure requirements."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 136,
          "title": "PFIC Status and Related Tax Risks",
          "data": [
            {
              "key": "Share Structure Voting Requirements",
              "value": "Under the DGCL, amending a corporation's certificate of incorporation generally requires a majority vote by shareholders, and sometimes a separate class vote to alter the authorized share structure."
            },
            {
              "key": "PFIC Status Determination",
              "value": "The document details tests for PFIC status based on passive income percentages and asset valuation. It states that the company was considered a PFIC for the taxable year ended December 31, 2016 and December 31, 2022, but not for the years 2017 through 2021, with future status remaining uncertain."
            },
            {
              "key": "Working Capital Exception",
              "value": "A new rule exempts cash held in non-interest bearing accounts up to an amount covering 90 days of operating expenses from being treated as a passive asset."
            },
            {
              "key": "PFIC Consequences",
              "value": "If classified as a PFIC, non-corporate U.S. shareholders may be required to file IRS Form 8621 annually and treat gains from share dispositions or excess distributions as ordinary income rather than capital gains, unless a QEF or mark-to-market election is made."
            },
            {
              "key": "Market and Tax Risk",
              "value": "Material differences in share classes may lead to lower attractiveness among investors, potentially resulting in a less active trading market, higher share price volatility, and adverse tax consequences for U.S. shareholders."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 137,
          "title": "Tax Elections and PFIC Tax Implications",
          "data": [
            {
              "key": "Common Shares Taxation",
              "value": "Обыкновенные акции и суммы, распределённые по предыдущим годам, подлежат налогообложению по наиболее высокой налоговой ставке, действующей в соответствующий год, с начислением процентной ставки на отложенный налог."
            },
            {
              "key": "PFIC Rules Application",
              "value": "При определённых условиях, таких как передача акций по залогу, дарению или в случае корпоративных распределений, возможно получение прироста капитала в рамках применения правил PFIC."
            },
            {
              "key": "QEF Election",
              "value": "Выбор QEF позволяет избежать неблагоприятных налоговых последствий, но требует текущей отчётности о доле обычного дохода и капиталовыгод при выполнении требований U.S. Treasury."
            },
            {
              "key": "Mark-to-Market Election",
              "value": "Этот выбор требует ежегодного включения в налогооблагаемый доход увеличения рыночной стоимости акций, а также допускает вычет уменьшения их стоимости, при этом потери признаются только в пределах накопленной прибыли."
            },
            {
              "key": "Tax Election Risks",
              "value": "Оба метода выбора (QEF и mark-to-market) сопряжены с экономическими рисками, такими как уплата налогов на нераспределённый доход ('phantom income') и потенциальными потерями из-за отсутствия распределения или выгодной продажи акций."
            },
            {
              "key": "Proposed Regulatory Changes",
              "value": "Предлагаемые нормативные изменения касаются прав партнерств и S-корпораций в отношении выборов QEF и mark-to-market, что может изменить порядок отчетности и налоговых оснований при передаче акций."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 138,
          "title": "PFIC Taxation, Elections, and Associated Legal Risks",
          "data": [
            {
              "key": "Income Tax Liability",
              "value": "The text highlights a significant income tax liability that may arise, which could be offset in future years by significant losses."
            },
            {
              "key": "Variable Tax Gain/Loss",
              "value": "A mark-to-market election may result in a highly variable tax gain or loss, leading to substantial and unpredictable changes in taxable income."
            },
            {
              "key": "Binding Elections",
              "value": "Both QEF and mark-to-market elections are binding on the U.S. shareholder for all subsequent years unless revocation is permitted by the IRS."
            },
            {
              "key": "Purging Election",
              "value": "A purging election may allow a U.S. shareholder to avoid PFIC classification for subsequent years by recognizing income based on the unrealized appreciation in common shares."
            },
            {
              "key": "PFIC Classification Risk",
              "value": "The potential classification as a PFIC may deter certain U.S. investors, adversely impacting market price and the ability to raise additional equity financing."
            },
            {
              "key": "Legal and Jurisdictional Risks",
              "value": "The document outlines challenges in obtaining and enforcing judgments against the corporation or its directors, especially given its organization as a British Columbia corporation and the cross-border legal implications."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 139,
          "title": "Risk Factors and Forward-Looking Statements",
          "data": [
            {
              "key": "Risk Disclosure",
              "value": "The document details potential risks including failure to meet publicly announced milestones, variations in the timing of clinical trials and regulatory actions, and other uncertainties that may impact the company’s business, financial condition, operating results, and share price."
            },
            {
              "key": "Forward-Looking Statements",
              "value": "It emphasizes that many statements are forward-looking, based on management's estimates, and subject to significant differences from actual outcomes due to various uncertainties such as clinical holds, regulatory developments, and operational issues."
            },
            {
              "key": "Market and Analyst Risk",
              "value": "The text discusses risks related to securities analysts’ coverage, including the potential for downgraded opinions or cessation of coverage, which might lead to declines in market price and trading volume."
            },
            {
              "key": "Litigation Risk",
              "value": "It also mentions the possibility of securities class action litigation and its associated costs, which could divert management attention and harm the business."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 140,
          "title": "Risks Associated with International Operations",
          "data": [
            {
              "key": "Overview",
              "value": "The document outlines a variety of risks associated with conducting business internationally, including regulatory differences, variations in standards of care, and the complexities of conducting clinical trials outside the United States."
            },
            {
              "key": "Key Risk Factors",
              "value": "Differing regulatory requirements, complex clinical trial designs, varied reimbursement systems, differences in drug import/export rules, reduced IP protection, trade policy changes, exposure to sanctions, economic instability, compliance issues with international laws (tax, labor, immigration), anti-corruption measures, currency fluctuations, increased infrastructure and operating costs, staffing challenges, supply chain disruptions, production shortages, shipping delays, business interruptions (natural disasters, geopolitical actions, cybersecurity breaches), and evolving international data privacy laws."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 141,
          "title": "Product Liability and Insurance Risk Disclosure",
          "data": [
            {
              "key": "Risk Description",
              "value": "We face the risk of product liability claims which could exceed our insurance coverage, deplete our cash resources and lead to clinical trial delays. The text explains that such claims may arise at any stage of product development, testing, manufacture, marketing or sale, potentially causing expensive legal defenses, delays in clinical trials, and adverse impacts on collaborations. It also discusses the challenges of obtaining adequate insurance coverage and the possible financial and operational consequences if such coverage is insufficient or becomes unavailable."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 142,
          "title": "ESG Regulatory Impact and Compliance Risks",
          "data": [
            {
              "key": "Regulatory Scrutiny",
              "value": "Increased scrutiny and evolving expectations from regulators, investors, and stakeholders regarding ESG practices."
            },
            {
              "key": "Compliance and Disclosure Costs",
              "value": "Additional costs related to assessing, quantifying, and disclosing climate-related risks and metrics, including greenhouse gas emissions."
            },
            {
              "key": "Litigation Risks",
              "value": "Potential for increased litigation risks associated with new climate disclosure rules and expanded disclosure obligations."
            },
            {
              "key": "Emerging Growth Company Status",
              "value": "Loss of emerging growth company status will subject the firm to enhanced public disclosure and compliance requirements, potentially diverting management attention."
            },
            {
              "key": "Operational Impact",
              "value": "Increased ESG-related compliance may materially affect future operational results and financial condition."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 143,
          "title": "Risk Factors from Activist Shareholders",
          "data": [
            {
              "key": "Risk Factor",
              "value": "Our business and share value could suffer due to activities by activist shareholders."
            },
            {
              "key": "Operational Impact",
              "value": "Responding to proxy contests and activist actions can be costly, time-consuming, and disruptive to operations."
            },
            {
              "key": "Market Uncertainty",
              "value": "Activist initiatives may lead to uncertainty in company direction, potential loss of opportunities, and increased volatility or stagnation in stock price."
            },
            {
              "key": "Management Distraction",
              "value": "Efforts to counteract activist shareholder moves can divert the Board of Directors and senior management from pursuing business strategies."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 152,
          "title": "PFIC Tax Consequences and Disclosure",
          "data": [
            {
              "key": "PFIC Filing Requirement",
              "value": "U.S. holders owning our common shares during any period as a PFIC must file IRS Form 8621 for each relevant tax year."
            },
            {
              "key": "Legal Counsel Opinion",
              "value": "No legal counsel opinion or IRS ruling has been obtained or is planned regarding our status as a PFIC."
            },
            {
              "key": "PFIC Status Determination",
              "value": "Our PFIC status is determined annually after the close of each taxable year, and there is uncertainty about whether we will be classified as a PFIC."
            },
            {
              "key": "Tax Consequences",
              "value": "If we are a PFIC and a U.S. Holder does not make a QEF or mark-to-market election, the excess distribution rules apply to distributions and gains, potentially leading to additional taxes and interest charges."
            },
            {
              "key": "QEF Election",
              "value": "A valid QEF election would alter the tax treatment, requiring inclusion of a pro rata share of ordinary income and net capital gains, along with adjusting the tax basis of common shares."
            },
            {
              "key": "Excess Distribution Rules",
              "value": "These rules allocate taxable amounts to each day of the holding period, tax portions at ordinary income rates, and prevent preferential tax rates on gains or dividends."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 153,
          "title": "PFIC Election Disclosure and Associated Tax Risks",
          "data": [
            {
              "key": "PFIC Election Overview",
              "value": "Describes the requirements for U.S. Holders regarding QEF and mark-to-market elections on IRS Form 8621, applicable for the first taxable year in which common shares are held."
            },
            {
              "key": "QEF Election",
              "value": "Outlines that a separate QEF election is required for subsidiaries classified as PFIC and the need to provide U.S. Holders with the necessary information to comply with QEF rules."
            },
            {
              "key": "Mark-to-Market Election",
              "value": "Explains the mechanism of the mark-to-market election as an alternative to QEF, including annual income inclusion for increases in fair market value and deductions for decreases, with tax basis adjustments."
            },
            {
              "key": "Tax Risk Disclosures",
              "value": "Highlights potential election tax risks such as the reporting of phantom income, significant annual tax liabilities from share price gains, and variability in tax outcomes."
            },
            {
              "key": "Subsidiary and Applicability Notes",
              "value": "Indicates that mark-to-market elections do not apply to subsidiaries and that the availability of the election depends on the common shares being marketable and regularly traded."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 154,
          "title": "Tax Elections and PFIC Implications",
          "data": [
            {
              "key": "Mark-to-Market vs QEF",
              "value": "The document discusses how the amount included in income under a mark-to-market election may be substantially greater than the amount included under a QEF election."
            },
            {
              "key": "Binding Elections",
              "value": "Both the QEF and mark-to-market elections are binding on the U.S. shareholder for all subsequent years that the U.S. shareholder owns the shares, unless the IRS grants permission to revoke the election."
            },
            {
              "key": "PFIC Classification and Purging Election",
              "value": "The document explains that if the company is treated as a PFIC, the U.S. Holder can make a special Purging Election to recognize gain via a “deemed sale” election, thereby resetting the holding period for the common shares."
            },
            {
              "key": "Filing Requirements",
              "value": "U.S. Holders must file IRS Form 8621 annually; failure to file may lead to penalties and an extension of the statute of limitations for tax returns."
            },
            {
              "key": "Additional Tax on Passive Income",
              "value": "Certain U.S. Holders with adjusted income above specified thresholds face a 3.8% tax on net investment income, which includes dividends, net gains, and mark-to-market inclusions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 165,
          "title": "Discussion on Funding, Capital Requirements, and Financial Risks",
          "data": [
            {
              "key": "Product Candidate",
              "value": "DM199 product candidate and potential future candidates"
            },
            {
              "key": "Commercialization Expenses",
              "value": "Expected significant expenses for sales, marketing, manufacturing, and distribution in the absence of a strategic partner"
            },
            {
              "key": "Additional Capital Requirement",
              "value": "Substantial additional capital needed to further R&D activities, clinical studies, regulatory and development efforts"
            },
            {
              "key": "Funding Assurance",
              "value": "Current cash, cash equivalents and marketable securities are expected to fund operations for at least 12 months, but future funding is uncertain"
            },
            {
              "key": "Financing History",
              "value": "Historically financed via equity securities and exercised warrants/stock options; most recent financing in September 2021 yielded approximately $30.0 million in gross proceeds"
            },
            {
              "key": "Risks Highlighted",
              "value": "Potential delays due to FDA clinical hold, market conditions, and the risk of shareholder dilution from future equity or convertible debt financings"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "risk_factor",
          "page": 190,
          "title": "Disclosure Controls, Procedures and Internal Control over Financial Reporting",
          "data": [
            {
              "key": "Changes In and Disagreements With Accountants on Accounting and Financial Disclosure",
              "value": "None"
            },
            {
              "key": "Evaluation of Disclosure Controls and Procedures",
              "value": "Management, including the CEO and CFO, evaluated the design and operation of disclosure controls and procedures and concluded they are effective as of the end of the period."
            },
            {
              "key": "Management’s Report on Internal Control over Financial Reporting",
              "value": "Management assessed internal control over financial reporting based on the 'Internal Control—Integrated Framework (2013)' and concluded it was effective as of December 31, 2022; no attestation report is included due to an exemption for emerging growth companies."
            },
            {
              "key": "Changes in Internal Control over Financial Reporting",
              "value": "There were no changes during the fourth quarter ended December 31, 2022 that materially affected or are likely to materially affect internal control over financial reporting."
            },
            {
              "key": "Other Information",
              "value": "Not applicable (Item 9B)"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 76,
          "title": "Cautionary Note Regarding Forward-Looking Statements",
          "data": [
            {
              "key": "statement_type",
              "value": "forward-looking"
            },
            {
              "key": "relevant_sections",
              "value": "Section 27A of the United States Securities Act of 1933, Section 21E of the United States Securities Exchange Act of 1934"
            },
            {
              "key": "company_reference",
              "value": "DiaMedica Therapeutics Inc. and its subsidiaries"
            },
            {
              "key": "trademarks",
              "value": "various unregistered trademarks and service marks"
            },
            {
              "key": "common_shares",
              "value": "voting common shares, no par value per share"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 93,
          "title": "Update on Phase 2/3 ReMEDy2 trial and FDA clinical hold",
          "data": [
            {
              "key": "Trial Name",
              "value": "ReMEDy2"
            },
            {
              "key": "Trial Phase",
              "value": "Phase 2/3"
            },
            {
              "key": "Purpose",
              "value": "To enroll approximately 350 participants for treatment of acute ischemic stroke (AIS) using DM199."
            },
            {
              "key": "Participants Enrolled",
              "value": "Approximately 350"
            },
            {
              "key": "Endpoints",
              "value": "Primary endpoints: physical recovery as measured by modified Rankin Scale (mRS) at day 90, and rate of ischemic stroke recurrence through day 90."
            },
            {
              "key": "Clinical Hold Announcement Date",
              "value": "July 6, 2022"
            },
            {
              "key": "Reason for Hold",
              "value": "FDA placed a clinical hold after three incidents of significant hypotension following the IV dose."
            },
            {
              "key": "Submission to FDA Date",
              "value": "September 16, 2022"
            },
            {
              "key": "FDA Response",
              "value": "Requested additional stability studies and confirmed protocol modifications."
            },
            {
              "key": "In-Use Study",
              "value": "Initiated, conducted in two parts simulating actual hospital use."
            },
            {
              "key": "Part 1 Status",
              "value": "Complete"
            },
            {
              "key": "Part 1 Findings",
              "value": "Administered IV dose was higher than planned, likely caused hypotension."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 95,
          "title": "DM199 vs. Supportive Care and/or tPA Outcomes",
          "data": [
            {
              "key": "Group",
              "value": "Placebo (n=21)"
            },
            {
              "key": "0-1",
              "value": "14%"
            },
            {
              "key": "2-8",
              "value": "57%"
            },
            {
              "key": "29",
              "value": "5%"
            },
            {
              "key": "Death",
              "value": "24%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 95,
          "title": "DM199 vs. Supportive Care and/or tPA Outcomes",
          "data": [
            {
              "key": "Group",
              "value": "DM199 (n=25)"
            },
            {
              "key": "0-1",
              "value": "36%"
            },
            {
              "key": "2-8",
              "value": "36%"
            },
            {
              "key": "29",
              "value": "16%"
            },
            {
              "key": "Death",
              "value": "12%"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 103,
          "title": "R&D Expenses and Clinical Pipeline Management",
          "data": [
            {
              "key": "Clinical Development and Regulatory Approval",
              "value": "The process of conducting the necessary development and clinical research to obtain regulatory approval is costly and time-consuming."
            },
            {
              "key": "Factors Affecting Probability of Success",
              "value": "The actual probability of success for each product candidate may be affected by various factors including safety and efficacy data, investments, competition, manufacturing capability, and commercial viability."
            },
            {
              "key": "Components of R&D Costs",
              "value": "Expenses include contract research agreements, clinical trial site agreements, laboratory and vendor expenses, employee and consultant-related expenses, and facility costs."
            },
            {
              "key": "FDA Clinical Hold",
              "value": "Provided that the FDA lifts the clinical hold on the IND for our ReMEDy2 clinical trial, it will be at least three to four years before any product candidates are ready for commercialization."
            },
            {
              "key": "Manufacturing Strategy",
              "value": "We rely on Catalent Pharma Solutions, LLC for all raw materials and active pharmaceutical ingredients for our clinical trials."
            },
            {
              "key": "Sales and Marketing Strategy",
              "value": "We have not yet defined our sales, marketing, or product distribution strategy for DM199."
            },
            {
              "key": "Intellectual Property Focus",
              "value": "We focus on patents and other means of protection to safeguard our proprietary technology."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 116,
          "title": "Risks Related to Our Financial Position and Need for Additional Capital",
          "data": [
            {
              "key": "regulatory concerns",
              "value": "our ability to demonstrate the safety and efficacy of DM199 to the satisfaction of regulatory authorities"
            },
            {
              "key": "FDA requirements",
              "value": "whether we are required to conduct additional clinical trials before or after approval"
            },
            {
              "key": "marketing approvals",
              "value": "the timely receipt of necessary marketing approvals from the FDA and foreign authorities"
            },
            {
              "key": "commercialization ability",
              "value": "the ability to successfully commercialize DM199 if approved"
            },
            {
              "key": "manufacturing capabilities",
              "value": "the ability of third-party manufacturers to produce DM199 with necessary quality"
            },
            {
              "key": "product acceptance",
              "value": "acceptance of DM199 as safe and effective by patients and healthcare providers"
            },
            {
              "key": "regulatory compliance",
              "value": "achievement and maintenance of compliance with regulatory requirements"
            },
            {
              "key": "safety profile maintenance",
              "value": "the maintenance of an acceptable safety profile of DM199"
            },
            {
              "key": "competition",
              "value": "the availability and perceived advantages of alternative treatments"
            },
            {
              "key": "administration method",
              "value": "acceptability of patient administration method for DM199"
            },
            {
              "key": "intellectual property enforcement",
              "value": "ability to successfully enforce our intellectual property rights"
            },
            {
              "key": "patent-related risks",
              "value": "potential patent interference or infringement claims"
            },
            {
              "key": "profitability warning",
              "value": "no assurance of profitability through sales or royalties"
            },
            {
              "key": "revenue expectations",
              "value": "no expected revenue from product sales for at least three to four years"
            },
            {
              "key": "funding requirements",
              "value": "expectation for substantial additional capital for clinical trials and operations"
            },
            {
              "key": "current cash resources",
              "value": "$33.5 million sufficient to fund operations for at least the next 12 months"
            },
            {
              "key": "future funding factors",
              "value": "the amount and timing of future funding requirements depends on various factors including trial progress and development efforts"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 45,
          "title": "Corporate Governance Disclosures & Code of Conduct",
          "data": [
            {
              "key": "Code of Business Conduct and Ethics",
              "value": "Adopted for all directors, officers, and employees in accordance with Section 406 of the Sarbanes-Oxley Act of 2002, SEC rules, and Nasdaq Listing Rules. Changes or waivers are disclosed on the website or via Form 8-K."
            },
            {
              "key": "Reporting & Compliance",
              "value": "Employee and director compliance is monitored via reporting channels to supervisors, CFO, or Audit Committee Chair via e-mail. Reported violations are investigated and disciplined as appropriate."
            },
            {
              "key": "Board and Committee Meetings",
              "value": "The Board of Directors met 12 times during fiscal year ended December 31, 2022. The Audit Committee met 4 times, the Compensation Committee 5 times, and the Nominating and Corporate Governance Committee 5 times. Each director attended at least 75% of total meetings."
            },
            {
              "key": "Complaint Procedures",
              "value": "The Audit Committee has procedures for receiving, retaining, and treating complaints related to accounting, internal controls, or auditing matters, allowing confidential and anonymous reporting."
            },
            {
              "key": "Shareholder Communications",
              "value": "Shareholders may contact the Board of Directors through the Corporate Secretary at the provided address, with communications promptly forwarded (excluding certain types of solicitations)."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 63,
          "title": "Related Party Transaction Policy",
          "data": [
            {
              "key": "Definition",
              "value": "A related party transaction is defined as a transaction, arrangement or relationship (or series of similar transactions) in which we (including subsidiaries and affiliates) participate and in which any related party holds a direct or indirect interest (excluding situations solely by being a director or holding less than 10% beneficial ownership)."
            },
            {
              "key": "Notification Requirement",
              "value": "Before entering into or amending a related party transaction, the involved party must notify our Chief Financial Officer with the facts and circumstances of the proposed transaction."
            },
            {
              "key": "Required Information",
              "value": "The notification must include the related party’s relationship to us and their interest in the transaction; material facts including the proposed aggregate value (or principal amount for indebtedness); the purpose and benefits of the transaction; availability of comparable products or services; and an assessment of whether the terms are comparable to those available to unrelated third parties or employees generally."
            },
            {
              "key": "Approval Threshold and Process",
              "value": "If the proposed transaction is expected to exceed $10,000 in any calendar year, it will be submitted to the Audit Committee (or its Chair) for consideration. The review assesses the purpose, benefits, impact on directors' independence, availability of comparable alternatives, and the terms of the transaction."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 68,
          "title": "Disclosure of Ownership and Interests",
          "data": [
            {
              "key": "security_derivative_instruments",
              "value": "Disclosure of derivative instruments, including rights to profit or share in profits from Company securities."
            },
            {
              "key": "contracts_and_arrangements",
              "value": "Details regarding contracts or arrangements that provide voting rights or involve economic interests in the Company."
            },
            {
              "key": "short_interest",
              "value": "Any short interests in Company securities held by the party."
            },
            {
              "key": "dividends",
              "value": "Rights to dividends on Company shares owned directly or indirectly."
            },
            {
              "key": "partnership_interest",
              "value": "Proportionate interest in the Company's shares or derivative instruments held by partnerships."
            },
            {
              "key": "performance_fees",
              "value": "Description of performance-related fees linked to the value of Company shares."
            },
            {
              "key": "pending_legal_proceedings",
              "value": "Information about pending or threatened legal proceedings involving the party."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 80,
          "title": "FDA Clinical Hold and IV Dose Revision Response for DM199",
          "data": [
            {
              "key": "Safety Issue",
              "value": "Unexpected clinically significant hypotension observed shortly after initiating IV DM199"
            },
            {
              "key": "Cause Analysis",
              "value": "Attributed to a change in IV bag materials leading to altered DM199 binding and elevated administered dose compared to ReMEDy1 trial"
            },
            {
              "key": "Regulatory Interaction",
              "value": "Response to FDA clinical hold letter; submission of in-vitro data and proposed protocol modifications"
            },
            {
              "key": "FDA Requests",
              "value": "Additional in-use stability study including testing of IV bag, tubing, and materials, with part 1 completed and part 2 anticipated"
            },
            {
              "key": "Planned Actions",
              "value": "Dose reduction for initial IV administration in ReMEDy2 trial; initiation of a Phase 1C open label, single ascending dose study"
            },
            {
              "key": "Risk/Uncertainty",
              "value": "Uncertainty remains whether FDA will fully lift clinical hold or require further studies, potentially delaying re-enrollment in ReMEDy2 trial"
            },
            {
              "key": "Additional Regulatory Milestone",
              "value": "DM199 granted Fast Track designation for AIS treatment in September 2021"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 97,
          "title": "Interim PD Results and Regulatory Hold in DM199 Clinical Trial",
          "data": [
            {
              "key": "PD Results - NO Levels",
              "value": "Average increase of 35%"
            },
            {
              "key": "PD Results - PG Levels",
              "value": "Average increase of 41%"
            },
            {
              "key": "PD Results - eGFR",
              "value": "Average increase of 4.08 mL/min/1732"
            },
            {
              "key": "PD Results - UACR",
              "value": "Average decrease of 18.7% (excluding subjects with normal baseline UACR)"
            },
            {
              "key": "Adverse Event",
              "value": "Clinically significant, transient hypotension observed in three participants during ReMEDy2 trial"
            },
            {
              "key": "Regulatory Action",
              "value": "FDA placed a clinical hold on the IND for the ReMEDy2 trial; enrollment paused"
            },
            {
              "key": "Commercial Insight",
              "value": "Discussion of DM199 (a recombinant KLK1) advantages and market opportunity in Asia compared to existing human urine and porcine-derived KLK1 products"
            },
            {
              "key": "Potential Cause",
              "value": "Switch in IV bag type led to unintended elevated dose delivery in ReMEDy2 trial compared to ReMEDy1"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 99,
          "title": "Regulatory Approval Process for Drug Products",
          "data": [
            {
              "key": "National Regulatory Agencies",
              "value": "Various statutes and regulations govern the principal development activities of drug products."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Controlled research and testing, governmental review, and approval of submissions containing preclinical and clinical data."
            },
            {
              "key": "Good Manufacturing Practices (GMP)",
              "value": "Approval of manufacturing facilities must adhere to GMP during production and storage."
            },
            {
              "key": "Consequences of Non-Compliance",
              "value": "Potential administrative or judicial sanctions including refusal to approve applications, withdrawal of approval, product recalls, and criminal investigations."
            },
            {
              "key": "FDA's Role",
              "value": "The FDA is responsible for ensuring medications are safe and effective, which involves thorough reviews and compliance with specific regulations."
            },
            {
              "key": "Drug Approval Stages",
              "value": "Stages include Preclinical Research, Clinical Research, and several phases of trials to ensure drug safety and effectiveness."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 101,
          "title": "FDA Compliance and Regulatory Challenges",
          "data": [
            {
              "key": "Consequences",
              "value": "Failure to comply with FDA requirements is likely to have negative consequences, including adverse publicity, warning or enforcement letters from the FDA or the Federal Trade Commission (FTC), mandated corrective advertising or communications with doctors, product seizures or recalls and state or federal civil or criminal prosecution."
            },
            {
              "key": "FDA Requirements",
              "value": "The FDA may require post-marketing testing, known as Phase 4 testing, risk evaluation and mitigation strategies and surveillance."
            },
            {
              "key": "12 Years Data Exclusivity",
              "value": "DM199 may qualify for 12 years of data exclusivity under the Biologics Price Competition and Innovation Act of 2009."
            },
            {
              "key": "BPCIA",
              "value": "Under the BPCIA, an application for a biosimilar product cannot be submitted to the FDA until four years after the original product is approved."
            },
            {
              "key": "European Approval Process",
              "value": "The EMA drug review and approval process is roughly parallel to that of the FDA."
            },
            {
              "key": "U.S. Healthcare Laws",
              "value": "Activities are potentially subject to regulation by various federal, state and local authorities including the Centers for Medicare and Medicaid Services."
            },
            {
              "key": "Compliance Requirements",
              "value": "Companies must comply with various healthcare laws including the federal Food, Drug & Cosmetic Act and the federal False Claims Act."
            },
            {
              "key": "Additional Proposals",
              "value": "Further proposals relating to U.S. healthcare reform could limit reimbursement of drug products."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 111,
          "title": "Risks Related to Our Jurisdiction of Organization",
          "data": [
            {
              "key": "Jurisdiction",
              "value": "British Columbia"
            },
            {
              "key": "Classification",
              "value": "Passive foreign investment company for 2022"
            },
            {
              "key": "Implication",
              "value": "Adverse U.S. federal income tax consequences for U.S. shareholders"
            },
            {
              "key": "FDA Clinical Hold",
              "value": "Clinical hold placed on Phase 2/3 ReMEDy2 trial"
            },
            {
              "key": "Reason for Clinical Hold",
              "value": "Investigating unexpected hypotension incidents after IV dose of DM199"
            },
            {
              "key": "Trial Start Date",
              "value": "First patient enrolled in November 2021"
            },
            {
              "key": "Clinical Hold Notice Date",
              "value": "July 6, 2022"
            },
            {
              "key": "FDA Response Date",
              "value": "Pending after submission of additional data on September 16, 2022."
            },
            {
              "key": "Expected Completion of In-Use Study",
              "value": "April 2023"
            },
            {
              "key": "Potential Risks",
              "value": "Delayed enrollment and additional FDA requests may prevent lifting of clinical hold."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 114,
          "title": "Clinical Trial Risks and Regulatory Challenges",
          "data": [
            {
              "key": "Clinical Trial Risks",
              "value": "Potential severe illness or death linked to DM199."
            },
            {
              "key": "Regulatory Approval Delays",
              "value": "Concerns may hinder marketing approval for DM199."
            },
            {
              "key": "FDA Oversight",
              "value": "Clinical trials oversight by FDA and other regulatory agencies."
            },
            {
              "key": "Requirements for Clinical Trials",
              "value": "Must comply with Good Clinical Practices."
            },
            {
              "key": "Trial Suspension Reasons",
              "value": "Possible deficiencies in trial design or execution."
            },
            {
              "key": "Future Regulatory Changes",
              "value": "New regulations may impact clinical trial processes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 119,
          "title": "Regulatory Compliance and Marketing Approval Challenges",
          "data": [
            {
              "key": "Main Concerns",
              "value": "Limited experience in filing and supporting applications for marketing approvals."
            },
            {
              "key": "Regulatory Authorities",
              "value": "FDA, EMA, and other authorities."
            },
            {
              "key": "Potential Outcomes",
              "value": "Marketing approval may be limited or subject to restrictions."
            },
            {
              "key": "Risks",
              "value": "Inability to obtain regulatory approval could harm business."
            },
            {
              "key": "Compliance Issues",
              "value": "Violations may lead to investigations and legal consequences."
            },
            {
              "key": "Consequences of Non-Compliance",
              "value": "Litigation, product recalls, fines, and damage to reputation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 144,
          "title": "Item 3. Legal Proceedings",
          "data": [
            {
              "key": "Clinical Research Agreement",
              "value": "Initiated in March 2013 with Pharmaceutical Research Associates Group B.V. (PRA Netherlands), later acquired by ICON plc."
            },
            {
              "key": "Study Details",
              "value": "Double-blinded, placebo-controlled, single-dose and multiple-dose study to evaluate DM199 in healthy subjects and Type 2 diabetes patients; primary endpoint met but secondary endpoints not met due to protocol deviations."
            },
            {
              "key": "Litigation Initiation",
              "value": "Complaint filed on November 14, 2017 in the United States District Court, Southern District of New York against PRA Netherlands for failure to adhere to study protocol and provide full study records."
            },
            {
              "key": "Refiled Complaint",
              "value": "On August 24, 2018, complaint refiled in the United States District Court, District of Delaware against both PRA Netherlands and PRA Health Sciences, Inc. (PRA USA)."
            },
            {
              "key": "Transfer Motion and Dismissal",
              "value": "Motion to transfer filed on February 20, 2019; transfer denied on September 21, 2020; final dismissal order issued on November 2, 2020."
            },
            {
              "key": "Dutch Court Proceedings",
              "value": "Filed claims against PRA Netherlands in a Dutch Court on November 13, 2020; initial appearances on February 24, 2021; case moved to the Netherlands Commercial Court (NCC) with prejudgment attachment granted on November 28, 2022 and formal introduction on December 28, 2022."
            },
            {
              "key": "NCC Scheduling",
              "value": "A scheduling hearing was held on January 12, 2023, with a hearing set for March 2023."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 145,
          "title": "Litigation Timeline and Ongoing Legal Proceedings",
          "data": [
            {
              "key": "records_seized",
              "value": "DiaMedica records seized on or about December 7-8, 2022"
            },
            {
              "key": "court_judgement",
              "value": "Judgement expected in April 2023 (4 weeks after the hearing date)"
            },
            {
              "key": "claim_submission_period",
              "value": "8 weeks after judgement to submit amended/additional grounds against PRA"
            },
            {
              "key": "extension_request",
              "value": "May request an extension of up to 4 weeks"
            },
            {
              "key": "PRA_defense_period",
              "value": "PRA has 8 weeks after claim submission to submit its statement of defense and counterclaims"
            },
            {
              "key": "counterclaims_response_period",
              "value": "4 weeks after PRA’s statement to submit a defense against any counterclaims"
            },
            {
              "key": "hearing_date",
              "value": "Provisional hearing date for claims and counterclaims set for September 2023"
            },
            {
              "key": "other_legal_actions",
              "value": "Subject to various ongoing or threatened legal actions including employment matters and breach of contract disputes"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 148,
          "title": "Tax Considerations on Canadian Property & U.S. Federal Income Tax",
          "data": [
            {
              "key": "Taxable Canadian Property Definition",
              "value": "Common shares constitute 'taxable Canadian property' under the Tax Act unless exempt through an applicable tax treaty or convention."
            },
            {
              "key": "Designated Stock Exchange",
              "value": "If common shares are listed on a designated stock exchange (e.g., The Nasdaq Capital Market), they generally are not considered taxable Canadian property unless additional criteria are met."
            },
            {
              "key": "Ownership Criteria for Canadian Taxation",
              "value": "Within the preceding 60 months, if a Holder or related parties own 25% or more of issued shares and over 50% of the value derives from specific Canadian assets, the shares may be considered taxable Canadian property."
            },
            {
              "key": "U.S. Federal Income Tax Considerations",
              "value": "The discussion includes U.S. tax implications for Holders (capital asset holders) based on the U.S. Internal Revenue Code, Treasury regulations, and the tax treaty between the United States and Canada."
            },
            {
              "key": "Legal and Advisory Disclaimer",
              "value": "No legal opinion or IRS ruling has been requested or obtained; U.S. Holders are advised to consult their own tax advisers as positions may vary."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 155,
          "title": "U.S. Federal Income Taxation and Reporting Requirements Disclosure",
          "data": [
            {
              "key": "US Holder Election",
              "value": "A U.S. Holder may elect for all interests in controlled foreign corporations and PFICs subject to a QEF election, with the election applying to current and future holdings."
            },
            {
              "key": "Additional Tax",
              "value": "Under this election, U.S. Holders pay an additional 3.8% tax on QEF election income inclusions and on gains after tax basis adjustments."
            },
            {
              "key": "Non-U.S. Holder Taxation",
              "value": "Non-U.S. Holders generally are not subject to U.S. federal income or withholding tax on dividends from common shares, unless the income is effectively connected with a U.S. trade or business."
            },
            {
              "key": "Tax Treaty & Permanent Establishment",
              "value": "If Non-U.S. Holders benefit from U.S. income tax treaties, taxation applies only if income is attributable to a permanent establishment in the U.S. or if specific presence conditions are met."
            },
            {
              "key": "Corporate Non-U.S. Holder",
              "value": "Corporate Non-U.S. Holders may face an additional branch profits tax at 30% (or a lower treaty-specified rate) on earnings attributable to effectively connected income."
            },
            {
              "key": "Information Reporting Requirement",
              "value": "U.S. individuals owning specified foreign financial assets must file IRS Form 8938, with penalties for non-compliance, including potential extension of the federal tax return statute of limitations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 156,
          "title": "Tax Reporting and Backup Withholding Disclosure",
          "data": [
            {
              "key": "Reporting Requirements",
              "value": "U.S. Holders must file IRS Form 926 if, immediately after acquisition, they own at least 10% of common shares or have transferred cash exceeding USD $100,000 in the preceding 12 months."
            },
            {
              "key": "Backup Withholding",
              "value": "Backup withholding may apply if the U.S. Holder fails to provide accurate taxpayer information, is notified by the IRS, or if payment falls under specified categories."
            },
            {
              "key": "Broker Conditions",
              "value": "Different rules apply depending on whether common shares are sold through a U.S. or non-U.S. office of a broker."
            },
            {
              "key": "Tax Advisor Consultation",
              "value": "U.S. Holders are urged to consult their own tax advisors regarding the tax implications of their investment."
            },
            {
              "key": "General Summary",
              "value": "The discussion provides a general summary and does not cover all relevant tax matters; each U.S. Holder should consult its tax advisor."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "regulatory_litigation",
          "page": 158,
          "title": "AIS Phase 2/3 ReMEDy2 Trial Update",
          "data": [
            {
              "key": "Trial Name",
              "value": "AIS Phase 2/3 ReMEDy2 Trial"
            },
            {
              "key": "Trial Design",
              "value": "Adaptive design, randomized, double-blind, placebo-controlled"
            },
            {
              "key": "Enrollment Details",
              "value": "Approximately 350 participants across up to 75 sites in the United States"
            },
            {
              "key": "Treatment",
              "value": "Participants receive either DM199 or placebo within 24 hours of AIS symptom onset"
            },
            {
              "key": "Exclusion Criteria",
              "value": "Patients with large vessel occlusions, imaging evidence of brain damage, or those treated with tPA/other thrombolytics are excluded"
            },
            {
              "key": "Regulatory Milestones",
              "value": "IND submitted in April 2021, accepted in May 2021; FDA granted Fast Track designation in September 2021"
            },
            {
              "key": "Clinical Hold",
              "value": "FDA placed a clinical hold on July 6, 2022 following three unexpected cases of clinically significant hypotension after initiating IV DM199"
            },
            {
              "key": "Issue Analysis",
              "value": "Hypotension linked to a change in IV bag materials which altered DM199 binding, inadvertently increasing the administered dose"
            },
            {
              "key": "Corrective Actions",
              "value": "Submission of in-vitro data and proposed protocol modifications including dose reduction to align with previous safe dosing; initiation of an in-use stability study split into parts simulating actual use and worst-case scenarios"
            },
            {
              "key": "FDA Follow-Up",
              "value": "FDA maintained the clinical hold, requested additional stability studies and communicated expectations, with subsequent protocol adjustments and study initiation at an independent laboratory"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 173,
          "title": "Risks and Uncertainties",
          "data": [
            {
              "key": "Company Name",
              "value": "DiaMedica Therapeutics Inc."
            },
            {
              "key": "Parent Companies",
              "value": "DiaMedica USA, Inc., DiaMedica Australia Pty Ltd."
            },
            {
              "key": "Primary Focus",
              "value": "acute ischemic stroke (AIS) and chronic kidney disease (CKD)"
            },
            {
              "key": "FDA Clinical Hold Date",
              "value": "July 6, 2022"
            },
            {
              "key": "DM199",
              "value": "Investigational new drug application (IND) for treatment of AIS and CKD"
            },
            {
              "key": "Reason for Hold",
              "value": "unexpected instances of clinically significant hypotension following IV dose"
            },
            {
              "key": "Current Status",
              "value": "clinical hold due to FDA's request for additional studies"
            },
            {
              "key": "In-use stability study completion date",
              "value": "Expected completion April 2023"
            },
            {
              "key": "Potential Risks of Approval Delay",
              "value": "Additional requests from FDA or requirement for more clinical testing"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 191,
          "title": "Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections",
          "data": [
            {
              "key": "Disclosure Detail",
              "value": "Not applicable"
            },
            {
              "key": "Reference",
              "value": "115"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": true,
      "elements": [
        {
          "type": "strategic_restructuring",
          "page": 15,
          "title": "Voting Proposals and Proxy Voting Instructions",
          "data": [
            {
              "key": "Voting Proposal One",
              "value": "Election of Directors; requires an affirmative majority of votes cast. Votes withheld, abstentions, and broker non-votes have no effect."
            },
            {
              "key": "Voting Proposal Two",
              "value": "Appointment of Baker Tilly US, LLP as Independent Registered Public Accounting Firm and Authorization to Fix Remuneration; considered a routine matter where broker may vote at its discretion in the absence of shareholder instruction; no broker non-votes expected."
            },
            {
              "key": "Voting Proposal Three",
              "value": "Approval of Amendment to Articles Regarding Director Nominations by Shareholders; requires at least a two-thirds majority of votes cast; votes against count against the proposal, while abstentions and broker non-votes have no effect."
            },
            {
              "key": "Voting Proposal Four",
              "value": "Approval of Amendment to Articles Regarding Board Authority to Fix Number of Directors; non-routine matter where if no instruction is provided, the broker may not vote, and such shares will be represented by proxy without counting as votes cast."
            },
            {
              "key": "Summary",
              "value": "The table outlines voting requirements and effects for corporate proposals involving director elections and amendments to corporate governance articles. Routine matters allow broker discretion, while non-routine matters require explicit shareholder instructions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 29,
          "title": "VOTING PROPOSAL FOUR—APPROVAL OF AMENDMENT TO ARTICLES REGARDING BOARD AUTHORITY TO FIX NUMBER OF DIRECTORS",
          "data": [
            {
              "key": "Background",
              "value": "Pursuant to Article 13.1 of the current Articles, the number of directors is set based on the greater of three and the most recently set figures by ordinary resolution or as provided under Article 14.4. The current system allows both shareholders and the Board of Directors to fix the number of directors."
            },
            {
              "key": "Proposed Change",
              "value": "Amend Articles 13.1 and 13.2 so that only the Board of Directors will have the authority to fix the number of directors, a change intended to align with typical corporate governance practices and reduce the likelihood of an unsolicited takeover attempt."
            },
            {
              "key": "Recommendation Date",
              "value": "March 9, 2023 (upon recommendation of the Nominating and Corporate Governance Committee)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 32,
          "title": "Timing and Effect of Proposed Articles Amendment; Board Recommendation",
          "data": [
            {
              "key": "Voting Proposal",
              "value": "Voting Proposal Four"
            },
            {
              "key": "Effect if Approved",
              "value": "Changes described will become effective immediately"
            },
            {
              "key": "Effect if Not Approved",
              "value": "No changes; Articles 13.1 and 13.2 remain effective"
            },
            {
              "key": "Conditionality",
              "value": "Approval of Voting Proposal Four is not conditioned on Voting Proposal Three and vice versa"
            },
            {
              "key": "Board Recommendation",
              "value": "The Board of Directors unanimously recommends a vote FOR approval to allow only the Board to fix the number of directors"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "strategic_restructuring",
          "page": 108,
          "title": "Corporate Information and Restructuring Disclosures",
          "data": [
            {
              "key": "Employment History",
              "value": "Clinical Project Manager for Inveresk/Chares River Clinical/Kendle (Dec 2002 - Feb 2005)"
            },
            {
              "key": "Professional Credentials",
              "value": "Ms. Daves is a certified clinical research professional; holds an MSHS in Clinical Research Administration from The George Washington University School of Medicine and Health Sciences and a BS in Zoology from North Carolina State University"
            },
            {
              "key": "Corporate Governance",
              "value": "Corporation governed under British Columbia’s Business Corporations Act (BCBCA)"
            },
            {
              "key": "Incorporation Details",
              "value": "Initially incorporated pursuant to The Corporations Act (Manitoba) by articles dated January 21, 2000"
            },
            {
              "key": "Restructuring Amendments",
              "value": "Amended on April 11, 2016 to continue from The Corporations Act (Manitoba) to the Canada Business Corporations Act (CBCA); amended on May 31, 2019 to continue existence from CBCA into British Columbia under the BCBCA"
            },
            {
              "key": "Registered Office",
              "value": "301-1665 Ellis Street, Kelowna, British Columbia, Canada V1Y 2B3"
            },
            {
              "key": "Principal Executive Office",
              "value": "DiaMedica USA Inc., 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota, USA 55305"
            },
            {
              "key": "Contact Details",
              "value": "Telephone: 763-496-5454; Website: http://www.diamedica.com"
            },
            {
              "key": "Emerging Growth Company Status",
              "value": "Currently an emerging growth company as defined in the JOBS Act; anticipated status until December 31, 2023"
            },
            {
              "key": "SEC Disclosure Information",
              "value": "Annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) available on www.sec.gov"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_supply_chain_disruptions": {
      "value": false,
      "elements": []
    },
    "has_esg_initiatives": {
      "value": true,
      "elements": [
        {
          "type": "esg_initiative",
          "page": 43,
          "title": "Board Diversity Matrix and Governance Overview",
          "data": [
            {
              "key": "Table Title",
              "value": "Board Diversity Matrix"
            },
            {
              "key": "Total Number of Directors (Female)",
              "value": "1"
            },
            {
              "key": "African American or Black",
              "value": "Not provided"
            },
            {
              "key": "Alaskan Native or Native American",
              "value": "Not provided"
            },
            {
              "key": "Asian",
              "value": "—"
            },
            {
              "key": "Native Hawaiian or Pacific Islander",
              "value": "="
            },
            {
              "key": "Two or More Races or Ethnicities",
              "value": "Not provided"
            },
            {
              "key": "LGBTQ+",
              "value": "Not provided"
            },
            {
              "key": "Did Not Disclose Demographic Background",
              "value": "Not provided"
            },
            {
              "key": "Summary",
              "value": "This matrix, as of March 21, 2023, shows the demographic composition of the board of directors with a noted presence of 1 female director. Some fields display placeholder symbols indicating missing or unclear data."
            },
            {
              "key": "Governance Committee Commentary",
              "value": "The Nominating and Corporate Governance Committee annually reviews board composition factors such as diversity in background, expertise, age, gender, race, and other specialized experiences."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 44,
          "title": "Board Qualifications, Governance, and Risk Oversight",
          "data": [
            {
              "key": "Board Qualifications",
              "value": "The document outlines that each board member, whether an incumbent or a candidate, is evaluated based on qualifications, judgment, attributes, background, experiences, perspectives and skills. The goal is to form a board that can best sustain the company's success and represent shareholder interests."
            },
            {
              "key": "Diversity and Inclusion",
              "value": "Diversity criteria such as gender and geographical background are considered. For instance, the proxy statement notes that as of the statement date, the board includes one (17%) woman and two (33%) racially or ethnically diverse individuals. Similarly, executive diversity is highlighted with percentages provided."
            },
            {
              "key": "Language and Background Skills",
              "value": "The document highlights individual qualifications, for example, Mr. Pilnik, who was born in São Paulo, Brazil, and is fluent in both Portuguese and Spanish."
            },
            {
              "key": "Risk Oversight Responsibilities",
              "value": "The document describes the board’s role in risk oversight. It acknowledges that risks (regulatory, compliance, legal, competitive, financial, operational, political, strategic and reputational) are inherent and outlines how the board, through its committees, oversees the risk management processes designed and implemented by management."
            },
            {
              "key": "Committee Roles",
              "value": "Multiple committees are mentioned: the Nominating and Corporate Governance Committee ensures that directors and officers meet a broad range of skills and diversity criteria, the Audit Committee focuses on financial reporting and risk review, and the Compensation Committee oversees risks associated with executive and director compensation as well as succession planning."
            }
          ],
          "currency": "N/A"
        }
      ]
    }
  },
  "currency": {
    "USD": 62,
    "EUR": 4,
    "AUD": 93,
    "CAD": 10,
    "RUB": 1
  },
  "sha1": "6e36d57320ec525da93b3ce2c7269580c746475b"
}